# **Interim Financial Information**

Rede D'Or São Luiz S.A.

March 31, 2023 with Independent Auditor's Review Report

# Interim financial information

March 31, 2023

## Contents

Independent auditor's review report on interim financial information	1
Interim financial information	
Statements of financial position	3
Statements of profit or loss	
Statements of comprehensive income	
Statements of changes in equity	
Statements of cash flows	8
Statements of value added	
Notes to interim financial information	10



Centro Empresarial PB 370 Praia de Botafogo, 370 6° ao 10° andar - Botafogo 22250-040 - Rio de Janeiro - RJ - Brasil

Tel: +55 21 3263-7000

A free translation from Portuguese into English of Independent Auditor's Review Report on interim financial information prepared in Brazilian currency in accordance the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR)

### Independent auditor's review report on interim financial information

To the Shareholders, Board of Directors and Officers of **Rede D'Or São Luiz S.A.** Rio de Janeiro - RJ, Brazil

#### Introduction

We have reviewed the accompanying individual and consolidated interim financial information, contained in the Quarterly Information Form (ITR) of Rede D'Or São Luiz (the "Company") for the quarter ended March 31, 2023, comprising the statement of financial position as of March 31, 2023 and the related statements of profit or loss, of comprehensive income, of changes in equity and of cash flows for the three-month period then ended, including material accounting practices and other explanatory information.

The executive board is responsible for the preparation of the individual and consolidated interim financial information in accordance with Accounting Pronouncement NBC TG 21 - Interim Financial Reporting, and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in conformity with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information Form (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

#### Scope of review

We conducted our review in accordance with Brazilian and international standards on review engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### Conclusion on the individual interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with NBC TG 21 and IAS 34 applicable to the preparation of Quarterly Information Form (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).



#### Conclusion on the consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with NBC TG 21 and IAS 34 applicable to the preparation of Quarterly Information Form (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).

#### **Emphasis - Restatement of Interim Financial Information**

We draw attention to explanatory note 2.1, the interim financial information as of March 31, 2023, which has been amended and is being restated to reflect the accounting policy modification described at the mentioned explanatory note. On May 15, 2023, we issued an unqualified review report on the Company interim financial statements, which are now being restated. Our conclusion remains unqualified, as these interim financial statements and their corresponding values for the previous period have been adjusted retrospectively.

#### Other matters

#### Statements of value added

The abovementioned quarterly information includes the individual and consolidated statement of value added (SVA) for the three-month period ended March 31, 2023, prepared under the Company management's responsibility and presented as supplementary information under IAS 34. These statements have been subject to review procedures performed together with the review of the quarterly information with the objective to conclude whether they are reconciled to the interim financial information and the accounting records, as applicable, and if their format and content are in accordance with the criteria set forth by NBC TG 09 – Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that they were not prepared, in all material respects, in accordance with the criteria set forth by this Standard and consistently with the overall individual and consolidated interim financial information.

Rio de Janeiro, March 26, 2024.

**ERNST & YOUNG** 

Auditores Independentes S/S Ltda.

CRC SP-015199/F

Diogo Afonso da Silva

Accountant CRC RJ-114783/O-8

A free translation from Portuguese into English of Interim Financial Information prepared in Brazilian currency in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR)

## Rede D'Or São Luiz S.A.

Statements of financial position March 31, 2023 and December 31, 2022 (In thousands of reais)

		Individual		Conso	lidated
	Note	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Assets		(Restated)	(Restated)	(Restated)	(Restated)
Current assets					
Cash and cash equivalents	4	109,032	96,360	2,077,753	1,109,796
Marketable securities	4	10,439,420	11,165,890	28,225,144	29,236,645
Accounts receivable	5	4,198,675	3,966,046	8,418,171	7,911,452
Inventories	6	362,677	414,005	727,528	808,688
Taxes recoverable		492,301	433,513	798,249	656,696
Insurance contract assets	12	-	-	25,130	70,012
Reinsurance contract assets		-	-	44,804	44,741
Derivative financial instruments	24	197,628	203,730	245,604	251,740
Transactions with related parties	7	161,091	167,578	8,786	7,753
Dividends receivable		170,384	75,277	5,370	1,769
Other		189,557	137,450	560,871	524,607
Total current assets		16,320,765	16,659,849	41,137,410	40,623,899
Noncurrent assets					
Transactions with related parties	7	1,767,896	1,659,658	119,113	75,899
Marketable securities	4	-	-	1,758,805	1,806,334
Accounts receivable	5	-	-	1,659,197	1,659,489
Taxes recoverable		8,677	8,677	470,760	469,970
Insurance contract assets	12	-	-	28,534	79,496
Reinsurance contract assets		-	-	2,307	527
Judicial deposits	14	301,487	294,653	2,620,363	2,862,274
Deferred taxes	17	-	-	3,348,841	3,366,280
Derivative financial instruments	24	367,620	334,186	2,392,545	2,487,765
Investments in subsidiaries, associates and joint					
ventures	8	26,986,356	26,271,987	2,537,939	2,553,401
Property and equipment	9	4,484,801	4,212,807	11,660,328	11,106,286
Intangible assets	10	6,845,345	6,880,944	16,421,748	16,477,631
Rights of use – leases	11	2,246,062	2,263,454	2,754,140	2,834,600
Other		83,522	86,098	265,275	274,476
Total noncurrent assets		43,091,766	42,012,464	46,039,895	46,054,428

Total assets **59,412,531** 58,672,313 **87,177,305** 86,678,327

Statements of financial position March 31, 2023 and December 31, 2022 (In thousands of reais)

		Individual		Conso	lidated
	Note	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Liabilities and equity		(Restated)	(Restated)	(Restated)	(Restated)
Current liabilities					
Trade accounts payable		675,777	532,476	1,397,012	1,256,601
Derivative financial instruments	24	647,473	682,825	793,659	827,908
Loans, financing and debentures	13	4,074,680	4,707,009	4,392,958	4,973,066
Salaries, accruals and social charges		502,534	445,623	1,108,816	982,150
Tax obligations	4.0	261,115	266,602	781,344	787,887
Dividends and interest on equity payable	16	23,882	137,640	36,390	145,085
Insurance contract liabilities	12	404.050	470.704	4,566,088	3,913,312
Leases	15	464,850	476,704	677,384	621,751
Other		76,386	120,586	1,264,007	1,243,567
Total current liabilities		6,726,697	7,369,465	15,017,658	14,751,327
Noncurrent liabilities					
Derivative financial instruments	24	1,037,421	1,131,108	1,037,421	1,131,108
Loans, financing and debentures	13	25,366,987	24,310,593	28,683,554	27,910,159
Transactions with related parties	7	-	-	2,397	4,207
Tax obligations		44,274	45,990	218,014	240,550
Insurance contract liabilities	12	´ <b>-</b>	· -	10,753,857	11,229,028
Deferred taxes	17	310,248	307,259	410,732	398,414
Provision for contingencies	14	1,112,604	1,208,942	3,489,539	3,792,172
Provision for losses on investments	8	532,126	509,044	-	-
Leases	15	2,127,978	2,116,624	2,609,574	2,710,651
Other		242,298	230,485	1,769,300	1,802,977
Total noncurrent liabilities		30,773,936	29,860,045	48,974,388	49,219,266
Equity	16				
Capital	10	15,711,360	15,711,360	15,711,360	15,711,360
Share issue costs		(253,031)	(253,031)	(253,031)	(253,031)
Capital reserves		4,884,269	4,914,500	4,884,269	4,914,500
Treasury shares		(519,417)	(544,610)	(519,417)	(544,610)
Income reserves		1,300,278	1,300,278	1,300,278	1,300,278
Retained earnings		298,692		298,692	
Future capital contribution		4,224	4,224	4,224	4,224
Other comprehensive income		485,523	310,082	485,523	310,082
Total equity attributable to the Company's		•	•	·	<u>,                                      </u>
shareholders		21,911,898	21,442,803	21,911,898	21,442,803
Noncontrolling interests				1,273,361	1,264,931
Total equity		21,911,898	21,442,803	23,185,259	22,707,734
i otai equity		21,311,030	£1,442,0U3	23,103,239	22,101,134
				A 1 1	
Total liabilities and equity		59,412,531	58,672,313	87,177,305	86,678,327

Statements of profit or loss Three-month periods ended March 31, 2023 and 2022 (In thousands of reais, unless otherwise stated)

		Individual		Consolidated		
_	Note	01/01/2023 to 03/31/2023	01/01/2022 to 03/31/2022	01/01/2023 to 03/31/2023	01/01/2022 to 03/31/2022	
		(Restated)		(Restated)		
Net operating revenues	18	3,208,976	2,667,682	11,249,972	5,373,283	
Costs of hospital services	19	(2,231,956)	(1,893,409)	(9,657,407)	(4,275,921)	
Gross profit		977,020	774,273	1,592,565	1,097,362	
General and administrative expenses Selling expenses Equity pickup	20 8	(159,252) (4,833) 262,767	(218,385) (1,764) 102,646	(339,862) (12,235) (18,666)	(212,321) (5,555) 9,078	
Other operating expenses	21	(14,455)	(38,514)	(98,197)	(95,028)	
Income before finance income (costs) and income and social contribution taxes		1,061,247	618,256	1,123,605	793,536	
Finance income Finance costs	22 22	798,355 (1,543,852)	631,183 (1,091,553)	2,071,766 (2,855,440)	1,740,010 (2,299,095)	
Income before income taxes		315,750	157,886	339,931	234,451	
Income taxes	17	(17,058)	52,684	(24,864)	(9,295)	
Net income for the period		298,692	210,570	315,067	225,156	
Income attributable to controlling interests Income attributable to noncontrolling interests		298,692 -	210,570 -	298,692 16,375	210,570 14,586	
Basic earnings per share Diluted earnings per share	23 23	0.1325 0.1322	0.1067 0.1064	0.1325 0.1322	0.1067 0.1064	

Statements of comprehensive income Three-month periods ended March 31, 2023 and 2022 (In thousands of reais)

	Individual		Conso	olidated	
	03/31/2023	03/31/2022	03/31/2023	03/31/2022	
	(Restated)		(Restated)		
Net income for the period	298,692	210,570	315,067	225,156	
Other comprehensive income					
Cash flow hedge	(41,378)	35,674	(45,218)	31,833	
Gain/(loss) on insurance assets and liabilities	•	-	400,271	-	
Unrealized gains/(losses) on financial assets available for sale	-	-	10,738	-	
Tax effects	14,069	(12,129)	(148,047)	(10,823)	
Gains/(losses) on changes in shareholding interest	(2,282)	-	-	-	
Other comprehensive income of associates and subsidiaries, by equity pickup	205,032	(2,535)	(42,303)	-	
	175,441	21,010	175,441	21,010	
Total comprehensive income	474,133	231,580	490,508	246,166	
Attributable to					
Controlling interests	474,133	231,580	474,133	231,580	
Noncontrolling interests	-	-	16,375	14,586	

Statements of changes in equity Three-month periods ended March 31, 2023 and 2022 (In thousands of reais)

							Controlling	interests						
		_	С	apital reserves	3	_	Income	reserves	_					
Description	Capital	Share issue costs	Premium reserve (issue of shares)	Goodwill on capital transactions	Share- based payment reserve	Treasury shares	Legal reserve	Investment reserve	Other comprehensiv e income	Future capital contribution	Retained earnings	Total equity	Noncontrolling interests	Total
Balances at December 31, 2021	7,575,516	(253,031)	5,727,122	(1,251,618)	-	(139,282)	8,666	1,591,514	320,267	4,224	-	13,583,378	1,094,561	14,677,939
Capital transactions in subsidiaries and														
acquisition of noncontrolling interests	_	_	_	(7,629)	_	_	_	_	_	_	_	(7,629)	22,740	15.111
Acquisition of subsidiary	-	-	-	-	-	-	-	-	-	-	-	-	54,975	54,975
Share-based payment (Note 16)	-	-	-	-	17,167	-	-	_	-	_	-	17,167	-	17,167
Changes - RSU	-	-	(36,933)	-	(17, 167)	9,284	-	-	-	-	-	(44,816)	-	(44,816)
Net income for the period	-	-	-	-	-	-	-	-	-	-	210,570	210,570	14,586	225,156
Dividends and interest on equity (Note 16)	-	-	-	-	-	-	-	(194,376)	-	-	-	(194,376)	(9,511)	(203,887)
Cash flow hedge	-	-	-	-	-	-	-	-	21,010	-	-	21,010	-	21,010
Balance at March 31, 2022	7,575,516	(253,031)	5,690,189	(1,259,247)	-	(129,998)	8,666	1,397,138	341,277	4,224	210,570	13,585,304	1,177,351	14,762,655
Balances at December 31, 2022 (Restated)	15,711,360	(253,031)	6,166,296	(1,251,796)	-	(544,610)	8,666	1,291,612	310,082	4,224	-	21,442,803	1,264,931	22,707,734
Acquisitions of subsidiaries (Note 3) Capital transactions in subsidiaries and	-	-	-	-	-	-	-	-	-	-	-	-	(65)	(65)
acquisition of noncontrolling interests	_	_		1.358	_	_			_			1,358	5.228	6.586
Changes - RSU (Note 16)			(31,589)		(11,035)	25,193						(17,431)	3,226	(17,431)
Share-based payment (Note 16)	_	_	(31,303)	_	11,035	23,133	_	_	_	_	_	11,035	_	11,035
Net income for the year					11,000		_		_		298.692	298,692	16,375	315,067
Dividends and interest on equity											200,002	_00,00_	.0,0.0	0.0,00.
(Note 16)	_	_	_	_	-	_	_		_	-	_	_	(20,608)	(20,608)
Cash flow hedge (Note 16)	_	_	_	_	-	_	_		(29,844)	-	_	(29,844)	(=0,000)	(29,844)
Gain/loss on insurance and reinsurance liabilities	-	_	_	_	-	_	_	_	240.183			240.183	-	240.183
Equity adjustments	-	_	_	-	-	_	_	-	(34,898)	-	-	(34,898)	_	(34,898)
Future capital contribution	-	-	-	-	-	-	-	-	(= 1,000)	-	-	-	7,500	7,500
Balances at March 31, 2023 2 (Restated)	15,711,360	(253,031)	6,134,707	(1,250,438)	-	(519,417)	8,666	1,291,612	485,523	4,224	298,692	22,911,898	1,273,361	23,185,259

Statements of cash flows Three-month periods ended March 31, 2023 and 2022 (In thousands of reais)

	Individual		Cons	solidated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
Cash flows from operating activities	(Restated)		(Restated)	
Income before income and social contribution taxes  Adjustments to reconcile income to cash from operating activities	315,750	157,886	339,931	234,451
Depreciation and amortization	218,673	184,721	399,074	347,461
Gain on property sales	(980)	(980)	(980)	(980)
Fair value of debt	63,198	(224,398)	73,634	(492,120)
Interest, monetary variations and foreign exchange differences, net	661,058	634,348	264,476	975,977
Share-based payment	11,035	17,167	11,035	17,167
Provision for contingencies	(99,402)	(21,380)	(28,473)	(32,793)
Equity pickup	(262,767)	(102,646)	18,666	(9,078)
Income from (loss on) insurance services	-	-	1,180,924	-
Allowance for expected credit losses	169,677	119,800	283,292	272,587
(Increase) decrease in assets and increase (decrease) in liabilities				
Accounts receivable	(402,305)	(184,643)	(789,718)	(495,507)
Inventories	51,328	4,501	81,160	(32,517)
Taxes recoverable	(58,788)	(93,715)	(142,343)	(125,927)
Judicial deposits	(6,834)	(13,513)	(11,730)	(17,430)
Other assets	132,020	(45,544)	56,991	(5,053)
Trade accounts payable	143,301	41,943	140,411	74,402
Salaries and social charges	48,808	(73,135)	118,563	(26,577)
Tax obligations	(7,202)	72,352	(50,786)	36,501
Transactions with related parties	(184,073)	(273,039)	(46,057)	(6,549)
Provision for contingencies	(454)	(215)	(55,996)	(1,989)
Insurance and reinsurance contract assets (liabilities)	(04.000)	40.004	(497,515)	
Other liabilities	(24,898) 767,145	19,031 218,541	19,763 1,364,322	8,995 721,021
Payment of interest	(894,959)	(336,427)	(879,957)	(622,091)
Payment of incerest Payment of income and social contribution taxes	(694,939)	(3,123)	(130.355)	(159,863)
Net cash flows from operating activities	(127,814)	(121,009)	354,010	(60,933)
Cash flows from investing activities				
Investment and business acquisitions, net of cash acquired	-	-	-	(828,075)
Future capital contribution	(225,967)	(1,327,074)	(4,750)	(19,350)
Additions to property and equipment	(317,591)	(234,102)	(716,217)	(644,834)
Additions to intangible assets	(13,239)	(29,222)	(40,279)	(42,527)
Acquisitions of marketable securities	(5,108,002)	(26,366,447)	(7,181,242)	(29,389,048)
Redemption of marketable securities	6,078,655	28,295,477	9,015,862	31,452,434
Dividends and interest on equity received	(81,533)	72,387	(3,900)	1,500
Net cash flows used in investing activities	332,323	411,019	1,069,474	530,100
Cash flows from financing activities				
Distribution of dividends and interest on equity	(113,758)	(33,242)	(136,438)	(41,928)
Treasury shares	-	117,711	-	117,711
Loans, financing and debentures raised	1,100,000	<b>-</b>	1,100,000	-
Payment of debentures, loans, financing and leases	(984,089)	(343,547)	(1,139,311)	(328,050)
Settlement (receipt) of swap	(193,990)	2,331	(277,576)	(69,914)
Accounts payable for acquisitions	-	(9,132)	(2,202)	(19,547)
Cash from (used in) financing activities	(191,837)	(265,879)	(455,527)	(341,728)
Increase in cash and cash equivalents	12,672	24.131	967.957	127,439
Cash and cash equivalents at beginning of period	96,360	43,910	1,109,796	124,621
Cash and cash equivalents at end of period	109,032	68,041	2,077,753	252,060
Table 3000 oquitations at one of portor	,	55,511	_,,	,000

Statements of value added Three-month periods ended March 31, 2023 and 2022 (In thousands of reais, unless otherwise stated)

	Indiv	ridual	Consolidated			
	03/31/2023	03/31/2022	03/31/2023	03/31/2022		
	(Restated)		(Restated)			
Revenue	3,409,451	2,821,577	11,682,823	5,708,181		
Sales of goods, products and services	3,578,148	2,940,397	5,564,633	5,979,788		
Revenues from insurance operations	-	-	6,370,262	-		
Provision for disallowances and allowance for expected credit losses	(169,677)	(119,800)	(283,292)	(272,587)		
Other revenues	980	980	31,220	980		
Benefits and claims			(4,843,908)	-		
Expenses with benefits and redemptions	-	-	(4,843,908)	-		
Bought-in inputs	(1,181,051)	(1,037,183)	(2,747,172)	(2,341,318)		
Costs of sales	(1,222,972)	(985,440)	(2,571,994)	(2,240,683)		
Materials, energy, third-party services and other	(57,481)	(73,123)	(203,651)	(133,428)		
Loss/recovery of assets	99,402	21,380	28,473	32,793		
Gross value added	2,228,400	1,784,394	4,091,743	3,366,863		
Depreciation and amortization	(218,672)	(184,721)	(399,073)	(347,461)		
Net value added	2,009,728	1,599,673	3,692,670	3,019,402		
Value added received in transfer	1,061,122	733,829	1,601,401	1,749,088		
Equity pickup	262,767	102,646	(18,666)	9,078		
Finance income (costs)	798,355	631,183	2,071,766	1,740,010		
Finance income insurance of contracts	-	-	(451,699)	-		
Total value added	3,070,850	2,333,502	5,294,071	4,768,490		
Value added distributed	(3,070,850)	(2,333,502)	(5,294,071)	(4,768,490)		
Personnel and charges	(955,881)	(876,343)	(2,012,797)	(1,762,424)		
Taxes, charges and contributions	(216,553)	(100,231)	(434.425)	(343,213)		
Interest, rents and other operating expenses	(1,599,724)	(1,146,358)	(2,531,781)	(2,437,697)		
Dividends and interest on equity	-	(194,376)	(20,608)	(203,887)		
Retained profits	(298,692)	(16,194)	(294,460)	(21,269)		
	•		•			

Notes to interim financial information March 31, 2023 (In thousands of reais, unless otherwise stated)

## 1. Operations

Rede D'Or São Luiz S.A. (the "Company" or "Parent Company" and jointly with its subsidiaries "Rede D'Or" or "Group"), headquartered at Rua Francisco Marengo, 1312, in the city and state of São Paulo, is engaged in the rendering of hospital services, offering assistance and hospitality concepts, creating medical and diagnostic excellence centers and generating medical knowledge and experience that ensure security to customers, either doctors, patients or healthcare plans. Through its subsidiaries and associates, the Company operates in the health (health and dental insurance, administrative services only (ASO) health and dental plans, and health and wellness solutions), life insurance, private pension, and asset management segments.

Rede D'Or operates in the states of Rio de Janeiro, São Paulo, Pernambuco, Maranhão, Bahia, Sergipe, Paraná, Ceará, Minas Gerais, Mato Grosso do Sul, Paraíba, Alagoas and the Federal District, with 68 own hospitals in operation and over 50 projects under development, in addition to oncology and radiotherapy clinics and laboratories. Currently, the Group has 9,462 hospital beds in total.

The first hospital unit, Hospital Barra D'Or, was opened in 1998, and Hospital Copa D'Or and Hospital Quinta D'Or were opened in 2000 and 2001, respectively. Since 2004, strategic partnerships have been made with other hospitals, thus increasing its range of expertise and reaching other areas in Rio de Janeiro. Also through partnerships and acquisitions, Rede D'Or started operations in the state of Pernambuco in 2007; in the states of Maranhão and Bahia in 2018; in the state of Sergipe in 2019; in the states of Paraná and Ceará in 2020; in the states of Minas Gerais, Mato Gross do Sul and Paraíba in 2021; and in the state of Alagoas in 2022.

In December 2022, the business combination between the Company and SulAmérica S.A. was completed through the merger of SulAmérica S.A. into Rede D'Or. As a result of the merger, Sul América S.A. was dissolved and succeeded by Rede D'Or as regards all its assets, rights and obligations, and Rede D'Or became the parent company of Sul América Group ("SASA" or "Sul América" - comprising the subsidiaries, associates and investment funds remaining from the merger of Sul América S.A.). Thus, since December 23, 2022, the shares of Sul América S.A. are no longer traded on B3 and the former shareholders of Sul América S.A. have become shareholders of the Company. For more details, see Note 3 - Business Combination.

The business combination includes two health market leaders in Brazil and joins the largest hospital chain to one of the main independent insurers in the country. Additionally, the business combination is based on a strategy for expanding and aligning their health ecosystems, including the health, dental, life, pension and investment businesses, favoring all customers, beneficiaries and business partners.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 1. Operations (Continued)

#### Seasonality

There are no significant seasonal effects on the Company's operations; however, a smaller volume of customers and, consequently, of claims in the insurance and health insurance businesses, is generally observed in December, January and February due to year-end celebrations and vacation period, and a larger volume of customers is observed in Winter.

## 2. Accounting policies

The Company's individual and consolidated quarterly information was prepared in accordance with the Technical Pronouncement CPC 21 (R1) – Interim Financial Reporting, issued by the Accounting Pronouncements Committee (CPC), equivalent to the international accounting standard IAS 34, issued by the International Accounting Standards Board (IASB) and presented in accordance with the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of the Quarterly Information (ITR).

Following Board Meeting 17 of the Brazilian Securities and Exchange Commission (CVM), which took place on May 9, 2023, under process 19957.015087/2022-62, the Company adhered to the option of disclosing the 2023 Quarterly Information (ITRs) in accordance with CPC 11 - Insurance Contracts and the simultaneous filing of the restated versions of the ITRs on the same date as the Financial Statements for the 2023 fiscal year. The notes not affected by CPC 50 - Insurance Contracts remain unchanged from their original form, including the subsequent events previously reported.

According to IAS 34/CPC 21 and Circular Letter CVM/SNC/SEP 003/2011, this quarterly information is presented in line with the concept of selected notes without the repetition of certain previously disclosed notes, but with an indication of the changes that occurred in the period and, therefore, must be read together with the annual financial information for the year ended December 31, 2022, disclosed to the CVM on March 15, 2023.

In addition, the quarterly information prepared from fiscal year 2023 onwards is being disclosed in accordance with IFRS 17/CPC 50. Changes related to accounting policies are described in Note 2.2.

The financial statements were approved and authorized for publication together with the annual financial statements by the Board of Directors on March 26, 2024.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

### 2.1. Restatement of the quarterly information (ITR) and corresponding value

In May 2017, the IASB published IFRS 17 - Insurance Contracts (CPC 50), replacing IFRS 4 (CPC 11), which established principles for the recognition, measurement, presentation and disclosure of insurance and reinsurance contracts.

The effectiveness of the standard was established from approval by the regulators. In this regard, the Brazilian SEC issued CVM Resolution No. 42 of July 22, 2021, approving CPC 50 and making it mandatory for publicly-held companies as of January 1, 2023, therefore it must be adopted by the Company.

Accordingly, in compliance with the procedures set forth in CPC 23 - Accounting Policies, Change in Accounting Estimates and Errors, the new accounting practice was applied retrospectively, recomposing the comparative balances for the purposes of presentation in these financial statements matched against equity. It should be noticed that the application of this standard had no impact on the statements of profit or loss, statements of comprehensive income, statements of cash flows as well as statements of value added for the year ended December 31, 2022, since the balances impacted by IFRS 17 come from the business combination related to the acquisition of Sul América S.A. that occurred at the end of that year. These adjustments are presented in the tables below.

In addition, as part of the process of continuous review and quality improvement of its accounting practices, management has eliminated certain lease agreements involving group companies matched against Right of use in the amounts corresponding to the consolidated financial statements. This adjustment impacts the statement of financial position only and is intended to reflect a more accurate presentation and improve the understanding of these operations in the Company's consolidated financial statements.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

# 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

			Individual	
		12/31/2022		12/31/2022
	Reference	(Original)	Adjustment	(Restated)
Assets				
Total current assets		16,659,849	-	16,659,849
Noncurrent assets Investments in subsidiaries, associates				
and joint ventures	(a)	26,549,365	(277,378)	26,271,987
Intangible assets	(a)	9,126,029	(2,245,085)	6,880,944
Other		8,859,533	-	8,859,533
Total noncurrent assets		44,534,927	(2,522,463)	42,012,464
Total assets		61,194,776	(2,522,463)	58,672,313
	Reference	12/31/2022 (Original)	Individual Adjustment	12/31/2022 (Restated)
Liabilities and equity Total current liabilities		7,369,465	-	7,369,465
Noncurrent liabilities			(	
Insurance contract liabilities	(a)	2,105,907	(2,105,907)	-
Deferred taxes	(b)	354,579	(47,320)	307,259
Others		29,552,786	(0.450.007)	29,552,786
Total noncurrent liabilities		32,013,272	(2,153,227)	29,860,045
Equity				
Total equity	(e)	21,812,039	(369,236)	21,442,803
Total liabilities and equity		61,194,776	(2,522,463)	58,672,313

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

## 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

Consolidated statement of financial position

<del>-</del>		12/31/2022		12/31/2022
	Reference	(Original)	Adjustment	(Restated)
Assets			•	,
Current assets				
Cash and cash equivalents		1,109,796	-	1,109,796
Marketable securities		29,236,645	-	29,236,645
Accounts receivable - hospital				
services	(a)	8,522,503	(611,051)	7,911,452
Inventories	. ,	808,688	•	808,688
Taxes recoverable		656,696	-	656,696
Insurance contract assets	(a)	-	70,012	70,012
Reinsurance assets		106,882	(62,141)	44,741
Derivative financial instruments		251,740	•	251,740
Transactions with related parties		7,753	-	7,753
Dividends receivable		1,769	-	1,769
Deferred acquisition costs	(a)	450,610	(450,610)	-
Other	(a)	524,607	-	524,607
Total current assets	<del>-</del>	41,677,689	(1,053,790)	40,623,899
Noncurrent assets				
Transactions with related parties		75,899	_	75,899
Marketable securities		1,806,334	_	1,806,334
Accounts receivable - insurance and		, ,		, ,
healthcare plans		1,659,489	_	1,659,489
Taxes recoverable		469,970	-	469,970
Insurance contract assets	(a)	-	79,496	79,496
Reinsurance assets	()	4.874	(4,347)	527
Judicial deposits		2,862,274	-	2,862,274
Deferred income and social		, ,		, ,
contribution taxes	(b)	3,818,728	(452,448)	3,366,280
Derivative financial instruments	(-)	2,487,765	-	2,487,765
Investments in subsidiaries,		, - ,		, - ,
associates and joint ventures		2,553,401	_	2,553,401
Property and equipment		11,106,286	_	11,106,286
Intangible assets	(a)	18,831,039	(2,353,408)	16,477,631
Rights of use – leases	(c)	3,864,560	(1,029,960)	2,834,600
Deferred acquisition costs	(a)	997,897	(997,897)	_,,
Other	(a)	274,476	-	274,476
Total noncurrent assets	(-/ _	50,812,992	(4,758,564)	46,054,428
Total assets	_	92,490,681	(5,812,354)	86,678,327

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

## 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

## Consolidated statement of financial position (Continued)

	Reference	12/31/2022 (Original)	Adjustment	12/31/2022 (Restated)
Current liabilities	Reference	(Original)	Aujustinient	(Nestateu)
Trade accounts payable		1,256,601	-	1,256,601
Derivative financial instruments		827,908	-	827,908
Loans, financing and debentures		4,973,066	-	4,973,066
Salaries, accruals and social charges		982,150	-	982,150
Tax obligations	(b)	800,950	(13,063)	787,887
Dividends and interest on equity	, ,		, ,	
payable		145,085	-	145,085
Insurance contract liabilities	(a)	5,974,995	(2,061,683)	3,913,312
Leases	(c)	813,919	(192,168)	621,751
Other	(a)	969,128	274,439	1,243,567
Total current liabilities	( )	16,743,802	(1,992,475)	14,751,327
Noncurrent liabilities				
Derivative financial instruments		1,131,108		1,131,108
Loans, financing and debentures		27,910,159	-	27,910,159
			-	
Transactions with related parties		4,207 240.550	-	4,207 240.550
Tax obligations Insurance contract liabilities	(a)	13,421,690	(2,192,662)	11,229,028
	` '		,	
Deferred taxes	(b)	1,064,336	(665,922)	398,414
Provision for contingencies	(d)	3,558,744	233,428	3,792,172
Leases Other	(c)	3,548,443	(837,792)	2,710,651
Total noncurrent liabilities	(a)	1,790,672 <b>52,669,909</b>	12,305 (3,450,643)	1,802,977 <b>49,219,266</b>
Equity		02,000,000	(0,400,040)	43,213,200
Capital		15,711,360	_	15,711,360
Share issue costs		(253,031)	-	(253,031)
Capital reserves		4,914,500	-	4,914,500
Treasury shares		(544,610)	-	(544,610)
Income reserves	(e)	1,669,514	(369,236)	1,300,278
Future capital contribution	(-/	4,224		4,224
Other comprehensive income		310,082	-	310,082
Total equity attributable to the				2.2,202
Company's shareholders		21,812,039	(369,236)	21,442,803
Noncontrolling interests		1,264,931	-	1,264,931
Total equity		23,076,970	(369,236)	22,707,734
Total liabilities and equity		92,490,681	(5,812,354)	86,678,327

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

# **2.1.** Restatement of the quarterly information (ITR) and corresponding value (Continued) Statement of financial position (Continued)

			Controladora			Consolidado	
	Referência	31/03/2023 (Original)	adjustment	31/03/2023 (restated)	31/03/2023 (Original)	adjustment	31/03/2023 (restatement)
Assets							
Current assets							
Cash and cash equivalents		109,032	-	109,032	2,077,753	-	2,077,753
Marketable securities		10,439,420	-	10,439,420	28,225,144	-	28,225,144
Accounts receivable - hospital services	(a)	4,198,675	-	4,198,675	9,008,459	(590,288)	8,418,171
Inventories		362,677	-	362,677	727,528	· -	727,528
Taxes recoverable		492,301	-	492,301	798,249	-	798,249
Insurance contract assets		-	-	-	-	25,130	25,130
Reinsurance contract assets		-	-	-	125,428	(80,624)	44,804
Derivative financial instruments		197,628	-	197,628	245,604	-	245,604
Transactions with related parties		161,091	-	161,091	8,786	-	8,786
Dividends receivable		170,384	-	170,384	5,370	-	5,370
Deferred acquisition costs	(a)	-	-	-	483,692	(483,692)	-
Other		189,425	132	189,557	560,871		560,871
Total current assets		16,320,633	132	16,320,765	42,266,884	(1,129,474)	41,137,410
Noncurrent assets							
Transactions with related parties		1,767,896	-	1,767,896	119,113	-	119,113
Marketable securities		-	-	-	1,758,805	-	1,758,805
Accounts receivable	(a)	-	-	-	1,659,426	(229)	1,659,197
Taxes recoverable		8,677	-	8,677	470,760	·	470,760
Insurance contract assets		-	-	-	-	28,534	28,534
Reinsurance contract assets		-	-	-	12,079	(9,772)	2,307
Judicial deposits		301,487	-	301,487	2,620,363	<u> </u>	2,620,363
Deferred income and social contribution taxes	(b)	-	-	-	4,116,502	(767,661)	3,348,841
Derivative financial instruments		367,620	-	367,620	2,392,545	<u>-</u>	2,392,545
Investments in subsidiaries, associates and joint ventures		27,054,200	(67,844)	26,986,356	2,537,939	-	2,537,939
Property and equipment		4,484,801	· · · · · · · · ·	4,484,801	11,660,328	-	11,660,328
Intangible assets	(a)	8,979,150	(2,133,805)	6,845,345	18,662,673	(2,240,925)	16,421,748
Rights of use - leases	(c)	2,246,062	-	2,246,062	3,798,363	(1,044,223)	2,754,140
Deferred acquisition costs	(a)	-	-	-	988,399	(988,399)	-
Other	` '	83,522	-	83,522	265,275	` ' <u>'</u>	265,275
Total noncurrent assets		45,293,415	(2,201,649)	43,091,766	51,062,570	(5,022,675)	46,039,895
Total assets		61,614,048	(2,201,517)	59,412,531	93,329,454	(6,152,149)	87,177,305

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

# **2.1.** Restatement of the quarterly information (ITR) and corresponding value (Continued) Statement of financial position (Continued)

<u> </u>		<u></u>	Individual		Consolidated				
Passivo	Referência	31/03/2023 (original)	Adjustment	31/03/2023 (Restated)	31/03/2023 (Original)	Adjustment	03/31/2023 (Restated)		
Liabilities and equity Current liabilities									
<del></del>		675,777	-	675,777	1,397,012	_	1,397,012		
Trade accounts payable		675,777	-	675,777	1,397,012	_	1,397,012		
Derivative financial instruments		647,473	-	647,473	793,659	-	793,659		
Loans, financing and debentures		4,074,680	-	4,074,680	4,392,958	-	4,392,958		
Salaries, accruals and social charges		502,534	-	502,534	1,108,816	-	1,108,816		
Tax obligations	( )	261,115	-	261,115	793,977	(12,633)	781,344		
Dividends and interest on equity payable	(a)	23,882	-	23,882	36,390	(4.000.040)	36,390		
Insurance contract liabilities Leases	(c)	464,850	-	464,850	6,366,304 892,579	(1,800,216) (215,195)	4,566,088 677,384		
Other		76,386	-	76,386	1,024,558	239,449	1,264,007		
Total current liabilities		6,726,697	<u>_</u>	6,726,697	16,806,253	(1,788,595)	15,017,658		
Total current habilities	-	0,120,031		0,720,037	10,000,233	(1,700,333)	13,017,030		
Noncurrent liabilities									
Derivative financial instruments		1,037,421	-	1,037,421	1,037,421	-	1,037,421		
Loans, financing and debentures		25,366,987	-	25,366,987	28,683,554	-	28,683,554		
Transactions with related parties		-	-	-	2,397	-	2,397		
Tax obligations	(-)	44,274	(0.050.500)	44,274	218,014 13,586,486	(0.000.000)	218,014 10,753,857		
Insurance contract liabilities  Deferred income and social contribution taxes	(a)	2,058,530 335,841	(2,058,530)	310,248	1,240,892	(2,832,629) (830,160)	410,732		
Provision for contingencies	(b) (d)	1,112,604	(25,593)	1,112,604	3,256,111	(830,160)	3,489,539		
Provision for losses on investments	(u)	532,126		532,126	5,230,111	200,420	5,403,553		
Leases	(c)	2,127,978	-	2,127,978	3,438,602	(829,028)	2,609,574		
Other	(-)	242,298	-	242,298	1,757,071	12,229	1,769,300		
Total noncurrent liabilities		32,858,059	(2,084,123)	30,773,936	53,220,548	(4,246,160)	48,974,388		
Equity									
Capital		15,711,360	-	15,711,360	15,711,360	-	15,711,360		
Share issue costs		(253,031)	-	(253,031)	(253,031)	-	(253,031)		
Capital reserves	(e)	4,883,623	646	4,884,269	4,883,623	646	4,884,269		
Treasury shares Income reserves	(a)	(519,417) 1,669,514	(369,236)	(519,417) 1,300,278	(519,417) 1,669,514	(369,236)	(519,417) 1,300,278		
Retained earnings	(e)	287,433	11,259	298,692	287,433	(369,236)	298,692		
Future capital contribution		4.224	-	4,224	4,224	11,235	4.224		
Other comprehensive income		245,586	239,937	485,523	245,586	239,937	485,523		
Total equity attributable to the Company's shareholders		22,029,292	(117,394)	21,911,898	22,029,292	(117,394)	21,911,898		
Noncontrolling interests		-		-	1,273,361	-	1,273,361		
Total equity		22,029,292	(117,394)	21,911,898	23,302,653	(117,394)	23,185,259		
Total liabilities and equity	_	61,614,048	(2,201,517)	59,412,531	93,329,454	(6,152,149)	87,177,305		

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

## 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

Statement of profit or loss position (Continued)

	Controladora				Consolidated				
	Reference	03/31/2023 (Original)	Adjustment	03/31/2023 (Restated)	03/31/2023 (originallly)	Adjustment	03/31/2023 (Restated)		
Net operating revenues from hospital services	(a)	3,208,976	-	3,208,976	11,315,224	(65,252)	11,249,972		
Changes in premium reserves	(a)	-	-	-	(135,398)	135,398	-		
Costs of hospital services	(a)	(2,295,860)	63,904	(2,231,956)	(9,558,160)	(99,247)	(9,657,407)		
Gross profit	_	913,116	63,904	977,020	1,621,666	(29,101)	1,592,565		
General and administrative expenses Selling expenses Equity pickup Other operating expenses	(a) (a) (a), (c)	(159,252) (4,833) 293,685 (14,455)	(30,918)	(159,252) (4,833) 262,767 (14,455)	(581,872) (18,764) (18,666) (136,055)	242,010 6,529 - 37,858	(339,862) (12,235) (18,666) (98,197)		
Income before finance income (costs) and income and social contribution taxes	(a)	1,028,261	32,986	1,061,247	866,309	257,296	1,123,605		
Finance income Finance costs	(a) (a)	798,355 (1,543,852)	-	798,355 (1,543,852)	2,068,292 (2,607,072)	3,474 (248,368)	2,071,766 (2,855,440)		
Income before income taxes	_	282,764	32,986	315,750	327,529	12,402	339,931		
Income taxes	(b)	4,669	(21,727)	(17,058)	(23,721)	(1,143)	(24,864)		
Net income for the period	<u>-</u>	287,433	11,259	298,692	303,808	11,259	315,067		
Income attributable to controlling interests Income attributable to noncontrolling interests		287,433 -	11,259 -	298,692 -	287,433 16,375	11,259 -	298,692 16,375		
Diluted earnings per share (in reais) Diluted earnings per share (in reais)		0,1275 0,1272	0,005 0,005	0,1325 0,1322	0,1275 0,1272	0,005 0,005	0,1325 0,1322		

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

# 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

## Statement of comprehensive income

		Individual			Consolidated	
	03/31/2023 (Original)	Adjustment	31/03/2023 (Restated)	03/31/2023 (Original)	Adjustment	03/31/2023 (Restated)
Net income for the period	287,433	11,259	298,692	303,808	11,259	315,067
Other comprehensive income						
Cash flow hedge	(41,378)	-	(41,378)	(45,218)	-	(45,218)
Gain/(loss) on insurance assets and liabilities	-	-	-	-	400,271	400,271
Unrealized gains/(losses) on financial assets available for sale	-	-	-	(52,503)	63,241	10,738
Tax effects	14,069	-	14,069	33,225	(181,272)	(148,047)
Gains/(losses) on changes in shareholding interest	(2,282)	-	(2,282)	-	-	-
Other comprehensive income of associates and subsidiaries, by equity pickup	(34,905)	239,937	205,032	-	(42,303)	(42,303)
Other comprehensive moonie of associates and subsidiaries, by equity pickup	(64,496)	239,937	175,441	(64,496)	239,937	175,441
Total comprehensive income	222,937	251,196	474,133	239,312	251,196	490,508
Attributable to						
Controlling interests	222,937	251,196	474,133	222,937	251,196	474,133
Noncontrolling interests	-	-	-	16,375	-	16,375

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

# 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

## Statements of cash flows

Page		Individual			Consolidated			
Cash flows from operating activities   282,764   32,866   315,750   327,529   12,402   339,931   32,031   32,		01/01/2	2023 to 03/31/20	23	01/	01/2023 to 03/31/2	023	
Name   Part		(Original)	Adjustment	(Restated)	(Original)	Adjustment	(Restated)	
Adjustments to reconcile income before taxes to cash flows from operating activities Depreciation and amortization Depreciation and amortization Depreciation and amortization Interest, monetary variations and foreign exchange differences, net differences, net differences, net differences, net rows (99,402) C99,402) C99,402) C99,402 C9,446 C77 C82,473 C82,4	Cash flows from operating activities							
Interest, monetary variations and foreign exchange differences, net differences, net differences, net differences, net (99,402)	Adjustments to reconcile income before taxes to cash flows from	•	32,986	315,750	327,529	12,402	339,931	
differences, net         601,095         - 601,095         (24,165)         286,699         269,476           Provision for/(reversal of) contingencies         (99,402)         - (99,402)         (28,446)         (27)         (28,473)           Equity pickup         (293,685)         30,918         (262,767)         18,666         - 18,666           Income from (loss on) insurance services         - 169,677         - 169,677         335,908         (52,616)         283,292           (Increase) decrease in assets and increase (decrease) in liabilities         - (402,305)         - (402,305)         (52,1801)         32,083         (789,718)           Accounts receivable         (402,305)         - (402,305)         (821,801)         32,083         (789,718)           Other assets         133,002         - 133,002         (99,403         42,412         56,991           Tax obligations         (7,202)         - (7,202)         (19,777)         (31,009)         (50,786)           Provision for contingencies         (454)         - (454)         (56,023)         27         (55,996)           Insurance and reinsurance assets (liabilities)         - (24,877)         (1) (24,898)         (28,955)         48,688         19,763           Other liabilities         (24,877)         (1)	Depreciation and amortization	282,576	(63,903)	218,673	480,571	(81,497)	399,074	
Equity pickup   Cay3,685   30,918   Cay3,676   18,666   18,0666		661,058	-	661,058	(24,163)	288,639	264,476	
Income from (loss on) insurance services	Provision for/(reversal of) contingencies	(99,402)	-	(99,402)	(28,446)	(27)	(28,473)	
Allowance for expected credit loss 169,677 - 169,677 335,908 (52,616) 283,292 (Increase) decrease in assets and increase (decrease) in liabilities Accounts receivable (402,305) - (402,305) (821,801) 32,083 (789,718) Other assets 132,020 - 132,020 99,403 (42,412) 56,991 Tax obligations (7,202) - (7,202) (19,777) (31,009) (50,786) Provision for contingencies (454) - (454) (56,023) 27 (55,996) Insurance and reinsurance assets (liabilities) (497,515) (497,515) Insurance technical reserve (497,515) (621,551) - Other liabilities (24,897) (1) (24,898) (28,925) 48,688 19,763 (76,145) (76,14	Equity pickup	(293,685)	30,918	(262,767)	18,666	-	18,666	
(Increase) decrease in assets and increase (decrease) in liabilities Accounts receivable (402,305) - (402,305) (821,801) 32,083 (789,718) Other assets 132,020 - 132,020 99,403 (42,412) 56,991 Tax obligations (7,202) - (7,202) (19,777) (31,009) (50,786) Provision for contingencies (454) - (454) (56,023) 27 (55,996) Insurance and reinsurance assets (liabilities) - (497,515) (497,515) Insurance technical reserve 621,551 (621,551) (497,515) Insurance technical reserve 621,551 (621,551) (497,515) Other liabilities (24,897) (1) (24,898) (28,925) 48,688 19,763 Other liabilities (66,995) - 66,995 223,693 - 223,693 Payment of interest (894,959) - (894,959) (879,957) - (879,957) Payment of income and social contribution taxes (894,959) - (894,959) (879,957) - (879,957) Payment of income and social contribution taxes (94,959) - (130,355) - (130,355) Net cash from (used in) operating activities (127,814) - (127,814) 117,874 236,136 354,010  Cash flows from investing activities Acquisitions of marketable securities (5,108,002) - (5,108,002) (6,892,603) (288,639) (7,181,242) Redemption of marketable securities (638,330) - (638,330) (765,146) - (56,146) Net cash flows from financing activities (19,837) - (191,837) (455,527) - (455,527)  Increase in cash and cash equivalents 12,672 - 12,672 967,957 - 967,957 Cash and cash equivalents at beginning of period 96,360 - 96,360 1,109,796 - 1,109,796	Income from (loss on) insurance services	-	-	-	-	1,180,924	1,180,924	
Accounts receivable         (402,305)         - (402,305)         (821,801)         32,083         (789,718)           Other assets         132,020         - 132,020         99,403         (42,412)         56,991           Tax obligations         (7,202)         - (7,202)         (19,777)         (31,009)         (50,786)           Provision for contingencies         (454)         - (454)         (56,023)         27         (55,996)           Insurance and reinsurance assets (liabilities)         - (454)         - (454)         (56,023)         27         (55,996)           Insurance technical reserve         - (24,897)         (1)         (24,898)         (28,925)         48,688         19,763           Other liabilities         (24,897)         (1)         (24,898)         (28,925)         48,688         19,763           Other liabilities         (66,995)         - (66,995)         223,693         - (223,693)         223,693         - (223,693)         - (223,693)         - (223,693)         - (223,693)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)         - (243,697)<	Allowance for expected credit loss	169,677	-	169,677	335,908	(52,616)	283,292	
Other assets         132,020         - 132,020         99,403         (42,412)         56,991           Tax obligations         (7,202)         - (7,202)         (19,777)         (31,009)         (50,786)           Provision for contingencies         (454)         - (454)         (56,023)         27         (55,996)           Insurance and reinsurance assets (liabilities)         (497,515)         (497,515)         (497,515)         (497,515)         (497,515)         (497,515)         (1,976)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,977)         (1,978)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979)         (1,979) <t< td=""><td>(Increase) decrease in assets and increase (decrease) in liabilities</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	(Increase) decrease in assets and increase (decrease) in liabilities							
Tax obligations   (7,202)   - (7,202)   (19,777)   (31,009)   (50,786)     Provision for contingencies   (454)   - (454)   (56,023)   27   (55,996)     Insurance and reinsurance assets (liabilities)   -   -   -   -   -   (497,515)   (497,515)     Insurance technical reserve   -   -   -   -   621,551   (621,551)   -     Other liabilities   (24,897)   (1)   (24,898)   (28,925)   48,688   19,763     Other liabilities   (66,995   - 66,995   223,693   -   223,693     Other liabilities   (894,959)   -   (694,959)   (879,957)   -   (879,957)     Payment of interest   (894,959)   -   (694,959)   (879,957)   -   (879,957)     Payment of income and social contribution taxes   -   -   -   -   (130,355)     Net cash from (used in) operating activities   (127,814)   -   (127,814)   117,874   236,136   354,010     Cash flows from investing activities   (5,108,002)   -   (5,108,002)   (6,892,603)   (288,639)   (7,181,242)     Redemption of marketable securities   (5,108,002)   -   (5,108,002)   (6,892,603)   (288,639)   (7,181,242)     Redemption of marketable securities   (6,078,655   - 6,078,655   8,963,359   52,503   9,015,862     Other   (638,330)   -   (638,330)   (765,146)   -   (765,146)     Net cash flows from financing activities   (191,837)   -   (191,837)   (455,527)   -   (455,527)     Increase in cash and cash equivalents   12,672   -   12,672   967,957   -   967,957     Cash and cash equivalents at beginning of period   96,360   -   96,360   1,109,796   -   1,109,796	Accounts receivable	(402,305)	-	(402,305)	(821,801)	32,083	(789,718)	
Provision for contingencies         (454)         - (454)         (56,023)         27         (55,996)           Insurance and reinsurance assets (liabilities)         -         -         -         -         (497,515)         (497,515)         (497,515)         (197,515)         (197,515)         (197,515)         (497,515)         (497,515)         (197,615)         (197,615)         (197,615)         (197,6145) <t< td=""><td>Other assets</td><td>132,020</td><td>-</td><td>132,020</td><td>99,403</td><td>(42,412)</td><td>56,991</td></t<>	Other assets	132,020	-	132,020	99,403	(42,412)	56,991	
Insurance and reinsurance assets (liabilities)	Tax obligations	(7,202)	-	(7,202)	(19,777)	(31,009)	(50,786)	
Insurance technical reserve	Provision for contingencies	(454)	-	(454)	(56,023)	27	(55,996)	
Other liabilities         (24,897)         (1)         (24,898)         (28,925)         48,688         19,763           Other liabilities         66,995         -         66,995         223,693         -         223,693           767,145         -         767,145         1,128,186         236,136         1,364,322           Payment of interest         (894,959)         -         (894,959)         (879,957)         -         (879,957)           Payment of income and social contribution taxes         -         -         -         -         (130,355)         -         (130,355)           Net cash from (used in) operating activities         (127,814)         -         (127,814)         117,874         236,136         354,010           Cash flows from investing activities         (5,108,002)         -         (5,108,002)         (6,892,603)         (288,639)         (7,181,242)           Redemption of marketable securities         6,078,655         -         6,078,655         8,963,359         52,503         9,015,862           Other         (638,330)         -         (638,330)         (765,146)         -         -         (765,146)           Net cash flows from financing activities         (191,837)         -         (191,837)         (455,	Insurance and reinsurance assets (liabilities)	-	-	-	-	(497,515)	(497,515)	
Other liabilities         66,995         - 66,995         223,693         - 223,693           Payment of interest         (894,959)         - 767,145         1,128,186         236,136         1,364,322           Payment of interest         (894,959)         - 894,959)         (879,957)         - (879,957)           Payment of income and social contribution taxes         (130,355)         - (130,355)         - (130,355)           Net cash from (used in) operating activities         (127,814)         - (127,814)         117,874         236,136         354,010           Cash flows from investing activities         (5,108,002)         - (5,108,002)         (6,892,603)         (288,639)         (7,181,242)           Redemption of marketable securities         (6,078,655)         - 6,078,655         8,963,359         52,503         9,015,862           Other         (638,330)         - (638,330)         (638,330)         (765,146)         - (765,146)           Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796	Insurance technical reserve	-	-	-	621,551	(621,551)	-	
Payment of interest         767,145         - 767,145         1,128,186         236,136         1,364,322           Payment of interest         (894,959)         - (894,959)         (879,957)         - (879,957)           Payment of income and social contribution taxes         (130,355)         - (130,355)         - (130,355)           Net cash from (used in) operating activities         (127,814)         - (127,814)         117,874         236,136         354,010           Cash flows from investing activities         (5,108,002)         - (5,108,002)         (6,892,603)         (288,639)         (7,181,242)           Redemption of marketable securities         (5,078,655)         - 6,078,655         8,963,359         52,503         9,015,862           Other         (638,330)         - (638,330)         (765,146)         - (765,146)           Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796<	Other liabilities	(24,897)	(1)	(24,898)	(28,925)	48,688	19,763	
Payment of interest (894,959) - (894,959) (879,957) - (879,957)  Payment of income and social contribution taxes (130,355) - (130,355)  Net cash from (used in) operating activities (127,814) - (127,814) 117,874 236,136 354,010  Cash flows from investing activities  Acquisitions of marketable securities (5,108,002) - (5,108,002) (6,892,603) (288,639) (7,181,242)  Redemption of marketable securities (6,078,655 - 6,078,655 8,963,359 52,503 9,015,862)  Other (638,330) - (638,330) (765,146) - (765,146)  Net cash flows from financing activities 332,323 - 332,323 1,305,610 (236,136) 1,069,474  Net cash flows from financing activities (191,837) - (191,837) (455,527) - (455,527)  Increase in cash and cash equivalents 12,672 - 12,672 967,957 - 967,957  Cash and cash equivalents at beginning of period 96,360 - 96,360 1,109,796 - 1,109,796	Other liabilities	66,995	-	66,995	223,693	-	223,693	
Payment of income and social contribution taxes Net cash from (used in) operating activities  (127,814) - (127,814) 117,874 236,136 354,010  Cash flows from investing activities  Acquisitions of marketable securities (5,108,002) - (5,108,002) (6,892,603) (288,639) (7,181,242)  Redemption of marketable securities 6,078,655 - 6,078,655 8,963,359 52,503 9,015,862  Other (638,330) - (638,330) (765,146) - (765,146)  Net cash flows from financing activities 332,323 - 332,323 1,305,610 (236,136) 1,069,474  Net cash flows from financing activities (191,837) - (191,837) (455,527) - (455,527)  Increase in cash and cash equivalents 12,672 - 12,672 967,957 - 967,957  Cash and cash equivalents at beginning of period		767,145	-	767,145	1,128,186	236,136	1,364,322	
Net cash from (used in) operating activities         (127,814)         - (127,814)         117,874         236,136         354,010           Cash flows from investing activities         (5,108,002)         - (5,108,002)         (6,892,603)         (288,639)         (7,181,242)           Redemption of marketable securities         6,078,655         - 6,078,655         8,963,359         52,503         9,015,862           Other         (638,330)         - (638,330)         (765,146)         - (765,146)           Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796         - 1,109,796	Payment of interest	(894,959)	-	(894,959)	(879,957)	-	(879,957)	
Cash flows from investing activities         Acquisitions of marketable securities       (5,108,002)       - (5,108,002)       (6,892,603)       (288,639)       (7,181,242)         Redemption of marketable securities       6,078,655       - 6,078,655       8,963,359       52,503       9,015,862         Other       (638,330)       - (638,330)       (765,146)       - (765,146)         Net cash flows from financing activities       332,323       - 332,323       1,305,610       (236,136)       1,069,474         Net cash flows from financing activities       (191,837)       - (191,837)       (455,527)       - (455,527)         Increase in cash and cash equivalents       12,672       - 12,672       967,957       - 967,957         Cash and cash equivalents at beginning of period       96,360       - 96,360       1,109,796       - 1,109,796	Payment of income and social contribution taxes	-	-	-	(130,355)	-	(130,355)	
Acquisitions of marketable securities         (5,108,002)         - (5,108,002)         (6,892,603)         (288,639)         (7,181,242)           Redemption of marketable securities         6,078,655         - 6,078,655         8,963,359         52,503         9,015,862           Other         (638,330)         - (638,330)         (765,146)         - (765,146)           Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796         - 1,109,796	Net cash from (used in) operating activities	(127,814)	-	(127,814)	117,874	236,136	354,010	
Redemption of marketable securities         6,078,655         - 6,078,655         8,963,359         52,503         9,015,862           Other         (638,330)         - (638,330)         (765,146)         - (765,146)           Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796         - 1,109,796	Cash flows from investing activities							
Other         (638,330)         - (638,330)         (765,146)         - (765,146)           Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796         - 1,109,796	Acquisitions of marketable securities	(5,108,002)	-	(5,108,002)	(6,892,603)	(288,639)	(7,181,242)	
Net cash flows from financing activities         332,323         - 332,323         1,305,610         (236,136)         1,069,474           Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796         - 1,109,796	Redemption of marketable securities	6,078,655	-	6,078,655	8,963,359	52,503	9,015,862	
Net cash flows from financing activities         (191,837)         - (191,837)         (455,527)         - (455,527)           Increase in cash and cash equivalents         12,672         - 12,672         967,957         - 967,957           Cash and cash equivalents at beginning of period         96,360         - 96,360         1,109,796         - 1,109,796			-		, ,	-		
Increase in cash and cash equivalents 12,672 - 12,672 967,957 - 967,957 Cash and cash equivalents at beginning of period 96,360 - 96,360 1,109,796 - 1,109,796	Net cash flows from financing activities	332,323	-	332,323	1,305,610	(236,136)	1,069,474	
Cash and cash equivalents at beginning of period 96,360 - 96,360 1,109,796 - 1,109,796	Net cash flows from financing activities	(191,837)	-	(191,837)	(455,527)	-	(455,527)	
	Increase in cash and cash equivalents	12,672	-	12,672	967,957	-	967,957	
Cash and cash equivalents at end of period 109,032 - 109,032 2,077,753 - 2,077,753	Cash and cash equivalents at beginning of period	96,360	-	96,360	1,109,796	-	1,109,796	
	Cash and cash equivalents at end of period	109,032	-	109,032	2,077,753	-	2,077,753	

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies (Continued)

## 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

## Consolidated Statements of value added

		Individual 03/30/2023			Consolidado 31/03/2023	
	Original	Adjustment	Restated	Original	Adjustment	Restated
Revenue	3,409,451	-	3,409,451	11,831,745	(148,922)	11,682,823
Sales of goods, products and services	3,578,148	-	3,578,148	5,564,633	-	5,564,633
Revenues from insurance operations	-	-	-	6,361,691	8,571	6,370,262
Allowance for expected credit loss	-	-	-	168,335	(168,335)	-
Provision for disallowances and doubtful debts	(169,677)	-	(169,677)	(336,142)	52,850	(283,292)
Other revenues	980	-	980	73,228	(42,008)	31,220
Changes in premium reserves				(135,398)	135,398	-
Net operacional revenuel	3,409,452	-	3,409,452	11,696,347	(13,524)	11,682,823
Benefits and claims	-	-	_	(4,497,628)	(346,280)	(4,843,908)
Expenses with benefits and redemptions		-		(4,497,628)	(346,280)	(4,843,908)
<del></del>				( , - ,,	(,,	( ,,,
Bought-in inputs	(1,181,051)	-	(1,181,051)	(3,176,218)	429,046	(2,747,172)
Costs of sales	(1,222,972)	-	(1,222,972)	(3,149,691)	577.697	(2,571,994)
Materials, energy, third-party services and other	(57,481)	_	(57,481)	(147,102)	(56,549)	(203,651)
Loss/recovery of assets	99,402	_	99,402	99,140	(70,667)	28,473
Bought-in inputs		-	-	21,435	(21,435)	· -
Gross value added	2.228.400		2,228,400	4,022,501	69.242	4,091,743
Cross value added	2,220,400		2,220,400	4,022,001	00,242	4,001,140
Depreciation and amortization	(282,575)	63,903	(218,672)	(480,571)	81,498	(399,073)
Net value added	1,945,825	63,903	2,009,728	3,541,930	150,740	3,692,670
Value added received in transfer	1,092,040	(30,918)	1,061,122	1,528,512	72.889	1,601,401
-	293,685	(30,918)	262,767	(18,666)	12,000	(18,666)
Equity pickup Finance income (costs)	798,355	(30,910)	798,355	1,683,151	388,615	2,071,766
Insurance contract finance income	-	_	700,000	- 1,000,101	(451,699)	(451,699)
Income from ceded reinsurance and coinsurance operations	_	_	_	(27,925)	27,925	(101,000)
Monetary and exchange rate variations - insurance and pension plans	_	_	-	(210,281)	210,281	-
Other	-	-	-	102,233	(102,233)	-
Total value added	3,037,865	32,985	3,070,850	5,070,442	223,629	5,294,071
	5,00.,000	02,000	3,0.0,000	0,0.0,		5,25 .,5
Value added distributed	(3,037,865)	(32,985)	(3,070,850)	(5,070,442)	(223,629)	(5,294,071)
Personnel and charges	(955,881)	(02,000)	(955,881)	(2,009,933)	(2,864)	(2,012,797)
Taxes, charges and contributions	(194,827)	(21,726)	(216,553)	(537,681)	103,256	(434,425)
Interest, rents and other operating expenses	(1,599,724)	(= :,: =0)	(1,599,724)	(2,219,020)	(312,761)	(2,531,781)
Dividends and interest on equity	( . , , )	-	( . , , , -	(20,608)		(20,608)
Retained profits	(287,433)	(11,259)	(298,692)	(283,200)	(11,260)	(294,460)

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

## 2.1. Restatement of the quarterly information (ITR) and corresponding value (Continued)

- a) This refers to the accounting practice changes between IFRS 4 and IFRS 17, which accounting policies based on that new practice are described on the explanatory notes n° 2.20.
- b) Impacts on current and deferred taxes on the adjustments mentioned above and on deferred tax from the adoption of CPC 50 / IFRS 17, since for tax purposes such practice is not adopted, therefore there is a temporary difference between tax and accounting records. The referred to tax impacts were calculated at the rates in effect and matched against equity at transition date.
- c) This refers to the elimination of certain lease agreements matched against the Right of use line, in order to reflect a better understanding of the consolidated financial statements. This adjustment impacts the statement of financial position only.
- d) This refers to the change in accounting policy for measurement of certain civil lawsuits involving adjustments in premiums of health portfolios, in order to reconcile the accounting practice of the new management as well as the respective tax effects.
- e) Net effect from adjustments mentioned above and from the adoption of CPC 50 / IFRS 17.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### 2.2. Insurance contracts

In the ordinary course of its business, the Company issues insurance contracts, and accepts significant insurance risk relating to policyholders under such contracts. In general, the Company determines if insurance risk is significant by comparing the benefits to be paid after an insured event with the benefits to be paid if the insured event does not occur. Insurance contracts may also transfer financial risk. The Company issues health care, dental, life, travel and private pension insurance.

Separating components of insurance and reinsurance contracts

The Company analyzes its products to determine whether they contain distinct components that should be accounted for under a CPC/IFRS other than CPC 50/IFRS 17. After separating any distinct components, the Company applies CPC 50/IFRS 17 to all remaining components of the issued insurance or reinsurance contract. Currently, the Company's insurance contracts do not include any distinct component that requires such separation.

Level of aggregation of insurance and reinsurance contracts

CPC 50/IFRS 17 requires that management determine the level of aggregation of the Company's insurance and reinsurance contracts in order to apply CPC 50/IFRS 17 requirements. The Company previously applied aggregation levels in accordance with CPC11/IFRS 4, which were significantly higher than the level of aggregation required by CPC 50/IFRS 17. The level of aggregation for the Company is primarily determined by the grouping of the Company's contracts into portfolios. The portfolios, comprised of groups of contracts with similar risks managed together, are Group healthcare plans, individual healthcare plans, dental plans (group and individual), life (group, individual and long-term life, credit life insurance (monthly and lump-sum payment) and pension risks), travel insurance and private pension plans (traditional and PGBL/VGBL).

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### **2.2. Insurance contracts** (Continued)

Level of aggregation of insurance and reinsurance contracts (Continued)

The portfolios are subdivided (groups) based on estimated profitability upon initial recognition into three categories, as follows:

- Onerous group of onerous contracts upon initial recognition, which is: Individual health;
- Low risk of onerous contracts groups of contracts which, upon initial recognition, have no significant possibility of becoming onerous subsequently and are: Group health plans, group and individual dental plans, private pension plans (VGBL/PGBL) and travel insurance;
- Other group that contains the other contracts, such as: Life (individual and group), credit life insurance (monthly and lump-sum payment), pension risks and traditional pension plans.

All reinsurance contracts were classified as cost, that is, contracts which, upon initial recognition, have a low possibility of generating net gains after initial recognition.

CPC 50/IFRS 17 also requires that no group contain contracts issued more than one year apart and the Company opted to aggregate in annual cohorts.

The profitability of contract groups is evaluated by actuarial valuation models that take into consideration existing and new businesses.

#### Contract limits

The Company includes in the measurement of a group of insurance contracts all future cash flows within the limit of each contract in the group. These cash flows are within the limits of an insurance contract if they arise from substantive rights and obligations that exist during the reporting period in which the Company can obligate the policyholder to pay premiums, or in which the Company has a substantive obligation to provide the policyholder with insurance contract services.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### **2.2. Insurance contracts** (Continued)

Premium Allocation Approach (PAA) - subsequent measurement (Continued)

For contracts in which the Company expects the period between providing each part of the coverage and the respective premium maturity date not to exceed one year, the Company chose not to adjust the carrying amount of the liability for remaining coverage to reflect the time value of money and the effect of financial risk. Subsequent measurement of reinsurance contracts held follows the same principles as insurance contracts and was adapted to reflect the specific characteristics of reinsurance.

General Approach (Building Block Approach - BBA)

Measurement upon initial recognition: the Company applies BBA to the following groups: Individual health, Individual dental, Traditional pension and Long-term life (Long-term life, Credit life insurance (lump-sum payment), and pension risks). BBA measures a group of insurance contracts as the total of:

- Fulfillment cash flows (inflow and outflow cash flows necessary for the fulfillment of the Company's contractual rights to receive funds from contractors and the Company's contractual obligations to the policyholders/beneficiaries); and
- CSM, which is the component of assets or liabilities for the contract group that
  represents unearned profit that the entity should recognize based on the provision of
  insurance coverage in the future.

Fulfillment cash flows comprise unbiased, probability-weighted estimates of future cash flows, discounted to present value to reflect the time value of money and financial risks, plus a risk adjustment for non-financial risk. The Company's objective in estimating future cash flows is to determine the expected amount, or probability-weighted average, of the full range of possible outcomes, given all reasonable and supportable information available at the reporting date, without undue cost or effort.

CSM at the end of the reporting period represents profit in the group of contracts that has not yet been recognized in profit or loss, since it refers to services still to be provided. For a group of contracts, the CSM carrying amount of the group at the end of the reporting period equals the carrying amount at the beginning of the reporting period, adjusted as follows: the effect of any new contracts added to the group; accumulated interest on the CSM carrying amount over the reporting period, measured at the discount rates upon initial recognition; changes in fulfillment cash flows relating to future services unless: these increases in

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### **2.2. Insurance contracts** (Continued)

General Approach (Building Block Approach - BBA) (Continued)

fulfillment cash flows exceed the CSM carrying amount, giving rise to a loss; or these reductions in fulfillment cash flows are allocated to the loss component of the liability for remaining coverage; the amount recognized as insurance revenue due to the transfer of contract services in the period, determined by allocating the remaining CSM at the end of the reporting period (before any allocation) over the current and remaining coverage period. The locked-in discount rate is the rate applicable on the date of initial recognition of contracts. The discount rate used for adding interest in CSM is calculated using the bottom up approach at the beginning.

Changes in fulfillment cash flows relating to future services that adjust CSM include:

- Experience adjustments that arise from the difference between premium received (and any related cash flows, such as insurance acquisition cash flows and taxes on insurance premiums) and the estimated amounts at the beginning of the period. Differences relating to premiums received (or payable) referring to current or past services are recognized immediately in profit or loss, whereas differences relating to premiums received (or payable) for future services are adjusted against CSM;
- Changes in estimated present value of future cash flows in the liability for remaining coverage, except changes relating to the time value of money and changes in financial risk (recognized in P&L (Pension) and other comprehensive income (other portfolios) rather than adjusting CSM);
- Differences between any investment component that is expected to be due in the period and the actual investment component that becomes due in the period.
- Changes to the risk adjustment for non-financial risk relating to future services.

Except for the changes in risk adjustment, CSM adjustments mentioned above are measured at discount rates that reflect the characteristics of the group of contracts' cash flows upon initial recognition.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### **2.2. Insurance contracts** (Continued)

General Approach (Building Block Approach - BBA) (Continued)

The Company measures the carrying amount of a group of contracts at the end of each reporting period as the sum of the liability for remaining coverage, comprising fulfillment cash flows relating to future services allocated to the group at that date and the group's CSM at that date and the incurred claim liability, comprising fulfillment cash flows relating to past services allocated to the group at that date.

Variable Fee Approach (VFA)

<u>Measurement upon initial recognition:</u> The Company applies the VFA to contracts with direct participation features: Private Pension (PGBL/VGBL), similar to BBA, except for the fact that the fulfillment cash flows take into consideration the participation of the beneficiaries and of the Company in the fair value of underlying assets. Similarly to BBA, CSM at the end of the reporting period represents profit in the group of contracts that has not yet been recognized in profit or loss, since it refers to services still to be provided. For a group of contracts, the CSM carrying amount of the group at the end of the reporting period equals the carrying amount at the beginning of the reporting period, adjusted as follows:

- the effect of any new contracts added to the group;
- the change in the entity's participation upon change in fair value of the underlying items, except to the extent that:
  - the reduction in the amount of the entity's participation in the decrease in fair value of the underlying items exceeds the carrying amount of CSM, giving rise to the loss; or
  - the increase in the entity's participation in the increase in fair value of the underlying items reverses the amount described in the previous item;
- The changes in fulfillment cash flows relating to future insurance coverage, except to the extent that:
  - these increases in fulfillment cash flows exceed the CSM carrying amount, giving rise to the loss; or
  - these reductions in fulfillment cash flows are allocated to the loss component of the liability for remaining coverage; and
- the amount recognized as insurance revenue due to the provision of coverage under contracts in the period, determined by allocating the remaining CSM at the end of the reporting period (before any allocation) over the current and remaining coverage period.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### 2.2. Insurance contracts (Continued)

#### Loss components

The Company grouped contracts that are onerous upon initial recognition separately from contracts in the same portfolio that are not onerous upon initial recognition. Groups that were not onerous upon initial recognition may also become onerous subsequently if assumptions and experience change. The Company established a loss component for the liability for remaining coverage for any onerous group representing future losses. A loss component represents an amount of losses attributable to each group of onerous contracts (or initially profitable contracts that became onerous). The loss component is released based on a systematic allocation of subsequent changes relating to future services in fulfillment cash flows to: the loss component; and the liability for remaining coverage less the loss component.

The loss component is also updated for subsequent changes relating to future services in the estimated fulfillment cash flows and to the risk adjustment for non-financial risk. The systematic allocation of subsequent changes in the loss component results in the total amounts allocated to the loss component equal to zero at the end of the coverage period of a group of contracts (since the loss component will have materialized in the form of claims and other costs that may be allocated to such group of contracts). The Company uses the ratio upon initial recognition to determine the systematic allocation of subsequent changes in future cash flows between the loss component and the liability for remaining coverage less the loss component.

### Loss recovery components

When the Company recognizes a loss on initial recognition of an onerous group of underlying insurance contracts or when other onerous underlying insurance contracts are added to a group, the Company establishes a loss recovery component for the asset for remaining coverage of a group of reinsurance contracts held that represent the recovery of losses. When a loss component has been established after initial recognition of a group of underlying insurance contracts, the portion of revenue that was recognized from the related reinsurance contracts is disclosed as a loss recovery component. When a loss recovery component was established on initial recognition or subsequently, the Company adjusts the loss recovery component to reflect changes in the loss component of an onerous group of

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### **2.2.** Insurance contracts (Continued)

Loss recovery components (Contonued)

underlying insurance contracts. The carrying amount of the loss recovery component should not exceed the portion of the carrying amount of the loss component of the onerous group of underlying insurance contracts that the Company expects to recover from the group of reinsurance contracts held.

Accordingly, the loss recovery component recognized upon initial recognition is reduced to zero in line with reductions in the onerous group of underlying insurance contracts and is nil when the loss component of the onerous group of underlying insurance contracts is nil.

#### Liabilities for claims incurred

For all measurement approaches (PAA, BBA or VFA), the Company estimates liabilities for claims incurred based on the best estimates available, which take into consideration the historical experience observed, realistic assumptions and reasonable information that reflect the Company's current perspective and include an adjustment for non-financial risk (risk adjustment).

## Insurance acquisition cash flows

Insurance acquisition cash flows result from the costs of selling, underwriting and initiating a group of contracts (issued or expected to be issued) that are directly attributable to the portfolio of contracts to which the group belongs. Insurance acquisition cash flows are allocated on a straight-line basis over time (through insurance revenue) or based on the portfolio's permanence curve. At the end of each reporting period, the Company assesses the recoverability of assets for the acquisition of insurance cash flows. If facts and circumstances indicate that the asset may be impaired, and if an impairment loss is identified, the Company adjusts the carrying amount of the asset and recognizes the impairment loss in P&L.

### Insurance and reinsurance contracts acquired in business combinations

As mentioned before, the Company acquired all of its insurance and reinsurance contract portfolios by acquiring 100% control over SulAmérica S.A. at the end of 2022, therefore by means of a business combination.

In conjunction with the practices described above, the Company used the consideration received (groups of contracts whose fair value determined a liability) or paid (groups of contracts whose fair value determined an asset) for the contracts as a replacement for

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### 2.2. Insurance contracts (Continued)

Insurance and reinsurance contracts acquired in business combinations—Continuação

premiums received. The consideration received or paid for the contracts excluded the consideration received or paid for any other assets and liabilities acquired in the same transaction, and no differences between fair value and book value of the reinsurance contracts were identified.

In business combinations within the scope of application of CPC 15, the consideration paid or received is the fair value of the contracts on that date.

For groups of contracts where PAA was the measurement approach determined for measuring the liability for remaining coverage, the consideration received or paid was allocated in the same manner as described for acquisition cash flows.

For groups of contracts measured using the BBA or VFA, the CSM was calculated based on the initial measurement of such approaches using the consideration received or paid for the contracts as a replacement for the premiums received or paid on the date of initial recognition.

For onerous contracts acquired, the Company recognized the excess of fulfillment cash flows over the consideration paid or received against equity, as required by CPC 23 when a new accounting policy is adopted.

The Company established the loss component of the liability for remaining coverage for this excess, and applied the previously described accounting practice for loss components to allocate subsequent changes in fulfillment cash flows to that loss component.

#### Net income or expense from reinsurance contracts

The Company presents separately in the statement of profit or loss and in other comprehensive income, the amounts expected to be recovered from reinsurers and the allocation of reinsurance premiums paid. The Company treats reinsurance cash flows that depend on claims in the underlying contracts as part of the claims expected to be reimbursed under the executed contract and excludes investment components and commissions from the allocation of reinsurance premiums presented in the statement of profit or loss and in other comprehensive income.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### **2.2.** Insurance contracts (Continued)

Net income or expense from reinsurance contracts--Continuação

Finance income and costs from insurance

Finance income or costs arising from insurance comprise changes in the carrying amount of the group of contracts derived from:

- The effect of the time value of money and changes in the time value of money;
- The effect of financial risk and changes in financial risk.

The Company disaggregates finance income or costs arising from insurance and reinsurance contracts into profit or loss and other comprehensive income. The impact of changes in market interest rates on insurance amounts and respective reinsurance assets and liabilities, when applicable, are reflected in P&L (pension) and in other comprehensive income (other portfolios) in order to minimize accounting mismatches between the recording of financial assets and insurance assets and liabilities. The Company's financial assets that back the insurance portfolios are predominantly measured at fair value through profit or loss or fair value through other comprehensive income, except for a portion of the assets that back traditional pension contracts, which are measured at amortized cost.

The Company systematically allocates expected total finance income or cost from insurance or reinsurance over the life of the group of contracts to P&L using the discount rates determined upon initial recognition of the group of contracts

For groups of insurance contracts (traditional pension plans) for which changes in assumptions referring to financial risk have a substantial effect on the amounts paid to policyholders, the Company systematically allocates to finance income or costs resulting from estimated future cash flows using the rate that allocates the remaining revised expected finance income or costs over the remaining term of the group of contracts at the constant rate.

Finance income or costs deriving from insurance contracts with direct participation features (VFA)

For contracts with direct participation features, for which the entity maintains the underlying items, the accounting policy chosen by the entity was to disaggregate insurance finance income or costs for the period to include in P&L the amount that eliminates accounting mismatches with income or costs included in P&L in the underlying items held, including in

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 2. Accounting policies (Continued)

#### 2.2. Insurance contracts (Continued)

Significant accounting judgments, estimates and assumptions to the insurance and reinsurance contracts (Continued)

P&L income or costs that exactly match income or cost amounts included in P&L for the underlying items, and therefore the items' net amount presented separately equaled zero.

For BBA and VFA measurement models, the Company mainly uses deterministic projections to estimate the present value of future cash flows and for some groups, management uses stochastic modeling techniques. A stochastic model is a tool for estimating probability distributions of potential outcomes, allowing for random variation in one or more assumptions over time. Random variation is usually based on fluctuations observed in historical data for a selected period using standard time series techniques. The assumptions used for estimating future cash flows were as follows:

Mortality rates (Life, Long-term life - portion of reinsurance and private pension risks)

Mortality assumptions are based on standard domestic industry tables, according to the type of contract entered into. These assumptions reflect recent historical experience and are adjusted where appropriate to reflect the Company's experiences and future prospects. The assumptions are differentiated by gender of the policyholder, underwriting class and type of contract.

An increase in expected mortality rates will increase the expected cost of the claim, which will reduce the Company's expected future earnings.

Tables used	2023	2022
Pension risks	BR-EMS (Sob) / Winklevoss / Álvaro Vindas	BR-EMS (Sob) / Winklevoss / Álvaro Vindas
Private pension	BR-EMS (Sob)	BR-EMS (Sob)
Long-term life	BR-EMS (Mor)	BR-EMS (Mor)
Individual health	BR-EMS (Mor)	BR-EMS (Mor)

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Basis of preparation and presentation and significant accounting policies (Continued)

#### 2.2. Insurance contracts (Continued)

Significant accounting judgments, estimates and assumptions to the insurance and reinsurance contracts (Continued)

Expenses allocated to groups of contracts

The assumptions for operating expenses reflect the projected costs of maintaining and meeting the Company's obligations under current insurance contracts and associated indirect expenses. The current level of expenses is considered as an appropriate expense base, adjusted for expected inflation, if appropriate. Variations in the expected expense level will change the Company's expected future earnings.

Cancellation fees for death, delinquency and withdrawal

Contract termination (cancellation) assumptions are determined using statistical measures based on the Company's experience and vary according to product type, contract duration and sales trends. An increase in default rates at the beginning of the contract term would tend to reduce the Company's profits, but subsequent increases have a largely neutral effect.

Discount rates (BBA, VFA and Claims liability)

Insurance contract liabilities are calculated by discounting expected future cash flows at a risk-free rate, plus an illiquidity premium, when applicable. Risk-free rates are determined by reference to yields provided by highly liquid sovereign bond in the currency of the insurance contract liabilities (Brazilian reais).

The illiquidity premium is determined based on observable market rates, based on a reference private credit portfolio, indexed by CDI and CDI+, whose issuers have a Brazil rating equal to or greater than A. The spread over DI is reduced by premiums for credit risk, based on the probability of default for each issuer, and the difference results in the premium for liquidity risk.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Basis of preparation and presentation and significant accounting policies (Continued)

#### **2.2.** Insurance contracts (Continued)

Significant accounting judgments, estimates and assumptions to the insurance and reinsurance contracts (Continued)

Discount rates applied for discounting future cash flows are as follows:

		1 Ano		2 anos		5 anos		10 anos	
	Ajuste de liquidez	2022	2023	2022	2023	2022	2023	2022	2023
Saúde individual	100,00%	12.85%	12.84%	12.23%	12.12%	11.31%	11.74%	11.14%	12.00%
Saúde/Odonto Coletivo									
Clube									
Prestamista BBA									
Previdência Riscos	75,00%	12.54%	12.40%	11.89%	11.65%	10.95%	11.22%	10.75%	11.44%
VG+VI+AR/Viagem									
Tradicional									
Resseguro									
Odonto individual	50,00%	12.23%	11.96%	11.56%	11.17%	10.58%	10.70%	10.36%	10.88%
PGBL/VGBL		12.23%	11.90%	11.30%	11.1770	10.56%	10.70%	10.30%	10.00%

The risk adjustment for non-financial risks represents the compensation that the Company requires to bear the uncertainty about the amount and timing of cash flows from groups of insurance contracts and covers insurance risk, cancellation risk and expense risk. The risk adjustment reflects an amount that an insurer would rationally pay to remove the uncertainty that future cash flows would exceed the best estimate amount.

The Company estimated the risk adjustment using a cost of capital technique for all contract groups, except for pension contracts (traditional and VGBL/PGBL) for which management used a chosen percentile of confidence interval.

The cost of capital represents the return required by the Company to offset the exposure to non-financial risk. The confidence interval technique used for pension contracts (traditional and VGBL/PGBL) is based on the calculation of an interval, associated with a probability (the confidence level), which represents the confidence that the interval contains the parameter.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Basis of preparation and presentation and significant accounting policies (Continued)

#### **2.2.** Insurance contracts (Continued)

Significant accounting judgments, estimates and assumptions to the insurance and reinsurance contracts (Continued)

Risk adjustment for non-financial risk (risk adjustment)

The risk adjustment calculated in future durations is discounted up to the statement of financial position date at the risk-free rate, to be maintained as part of the total insurance contract liability.

The risk adjustment of insurance contracts corresponds to levels greater than or equal to 60%.

#### CSM amortization

CSM amount for a group of insurance contracts is recognized in profit or loss as insurance revenue in each period to reflect the insurance contract services provided under the group of insurance contracts in that period, by determining the group's coverage units. The number of a group's coverage units is the amount of insurance contract services provided by the group's contracts, calculated considering the amount of benefits offered and the expected period of coverage. For reinsurance contracts held, CSM amortization is similar to insurance contracts issued and reflects the expected underwriting pattern of the underlying contracts since the level of service provided depends on the number of underlying contracts in force.

Assets for insurance acquisition cash flows

The Company applies judgment in determining the assumptions used in the methodology to systematically and rationally allocate insurance acquisition cash flows to groups of insurance contracts. This includes judgments about whether insurance contracts are expected to arise from renewals of existing insurance contracts and, where applicable, the amount to be allocated to groups including future renewals and the volume of expected renewals of new contracts issued in the period.

In the current and prior years, the Company allocated insurance acquisition cash flow to groups of future insurance contracts, as management expected renewals arising from new contracts issued in the period.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 2. Basis of preparation and presentation and significant accounting policies (Continued)

#### **2.2.** Insurance contracts (Continued)

Significant accounting judgments, estimates and assumptions to the insurance and reinsurance contracts (Continued)

Assets for insurance acquisition cash flows

In the current and prior year, the Company identified no facts and circumstances that indicate that the assets could be impaired.

#### 2.3. Adoption of IFRS 9, Financial Instruments, for hedge accounting

For hedging transactions, the Company adopted IFRS 9 on January 1, 2023, replacing IAS 39, Financial Instruments (CPC 38), which the Company had elected to keep in force for hedge accounting purposes at the time of initial adoption of IFRS 9 (CPC 48) on January 1, 2018. The transition to IFRS 9 was carried out prospectively and the pre-existing hedging relationships were treated as continuous hedging relationships, with no loss of effectiveness or designation in the transition. Adoption of IFRS 9 had no significant effect on the financial statements.

#### 3. Business combinations

On February 23, 2022, the Company and Sul América S.A. entered into (i) an Association Agreement, Voting Commitment and Other Covenants ("Association Agreement"); and (ii) the Private Instrument of Rationale for the Merger of Sul América S.A. (SASA) into Rede D'Or ("Rationale for the Merger" and, together with the Association Agreement, the "Purchase and Sale Agreements"), through which the parties agreed to the terms and conditions of a business combination between the two Companies, with unification of their shareholding bases, through the merger of SASA into Rede D'Or (the "Transaction"). The consummation of the Transaction was conditioned on the approvals of the General Meetings of the two companies and of the relevant regulatory agencies ("conditions precedent").

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 3. Business combination (Continued)

On April 14, 2022, the shareholders of Rede D'Or and Sul América S.A. approved the Rationale for the Merger at their respective Special General Meetings and, on that date, the approvals of the relevant regulatory agencies for the implementation of the Transaction as part of the conditions precedent were still pending.

On December 20, 2022, in view of the fulfillment of the conditions precedent, the Boards of Directors of both companies authorized the immediate consummation of the Transaction, through the issue of 308,304,834 new common shares of Rede D'Or, which replaced the shares of Sul América S.A. In this resolution, December 23, 2022 was determined as the date of consummation of the Transaction pursuant to the terms of the Rationale for the Merger and, consequently, the date on which Rede D'Or assumed the control of the management and guidelines of SASA's business for all purposes (date of acquisition for purposes of applying IFRS 3 and CPC 15 (R1)). It should be noted that on December 23, 2022, after the market closed, the shares of Sul América S.A. ceased to be traded on B3 and the former shareholders of Sul América S.A. became shareholders of the Company.

In addition, on the date of consummation of the Transaction, the portion invested in shares of Sul América S.A. that were until then held by Rede D'Or, Original acquired at the acquisition cost of R\$1,214,850, was measured at the fair value of R\$854,238. As such, of the 308,304,834 new shares issued by Rede D'Or, as mentioned above, 29,379,399 shares were used to replace the shares of Sul América S.A. held by Rede D'Or on the date of consummation of the Transaction and, consequently, were allocated to the treasury shares line item of Rede D'Or, as provided for in the terms of the Rationale for the Merger.

It should be noticed that the adoption of IFRS 17/CPC 50, although retrospective to the year ended December 31, 2022, had no impact on the measurement of the assets acquired and liabilities assumed in the business combination related to the acquisition of Sul América S.A., since at the time of the acquisition the referred to standard was not yet in force. Therefore, any impacts brought about by IFRS 17/CPC 50 were matched against equity as required by the respective standard, and their effects are duly presented in Note 2.2

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 3. Business combination (Continued)

	In millions of R\$, except number of shares
Consideration transferred	8,998,860
Fair value of assets acquired:	
Cash and cash equivalents and marketable securities	18,867,230
Trade accounts receivable	3,373,425
Taxes recoverable	722,199
Reinsurance assets	111,756
Judicial deposits	2,443,586
Deferred income and social contribution taxes – assets	2,218,443
Investments	88,841
Property and equipment	116,519
Intangible assets	5,687,486
Rights of use – leases	92,801
acquisition costs	1,448,507
Other assets	66,258
Fair value of liabilities assumed:	,
Trade accounts payable	(11,527)
Loans and financing	(2,783,914)
Salaries, accruals and social charges	(160,110)
Tax obligations	(262,114)
Insurance liabilities	(20,782,988)
Administrative services only health plan	(430,665)
Provision for contingencies	(3,223,475)
Leases	(99,924)
Other liabilities	(300,757)
Total net identifiable assets at fair value	7,181,577
Noncontrolling interests	3,342
Goodwill from acquisition of SASA	1,820,625

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 3. Business combination (Continued)

The main allocations of fair values of assets acquired and liabilities assumed are summarized as follows:

Description	Adjustment to fair value	Remaining useful life (years)	Valuation method
Intangible assets - "Sul América" brand (i)	2,068,575	Indefinite	Royalty Relief
Intangible assets - Customer relationship portfolio (ii)	2,452,720	3-9 years	MPEEM
Insurance liabilities (iii)	(2,105,907)	12-13 years	MPEEM
Provision for contingencies - Contingent liabilities (ii)	(1,070,642)	n/a	Fair value
Loans and financing	(21,625)	n/a	Fair value
Marketable securities	111,246	n/a	Fair value
Tax effects - deferred tax liabilities, net (iii)	(487,685)	-	-

- (i) This represents the fair value of the brand "SulAmérica". The royalty relief method was applied considering a reference to similar royalty transactions (Note 10).
- (ii) The fair values (consideration received or paid) of the customer relationship portfolio in the business combination, which encompass the following portfolios: Dental, SME Small and Medium Enterprises, Business, Affinity, Life and Pension (VGBL/PGBL), estimated by using the Multi-Period Excess Earnings Method, for long-term portfolios, measured by the BBA or VFA, were considered as a substitute for the earned premiums in the initial measurement of such portfolios based on CPC 50/IFRS 17, while for short-term portfolios, measured by the PAA, such fair value was allocated in the same manner as described for acquisition cash flows.
- (iii) The revaluation deficit at fair value (consideration received or paid), arising from the Individual Health and Traditional Pension portfolios, assumed in the business combination, estimated through the Multi-Period Excess Earning Method, as they are considered long-term portfolios, measured by the BBA or VFA, such revaluation surplus was considered as a substitute for the earned premiums in the initial measurement of such portfolios based on CPC 50/IFRS 17.Contingent liabilities not previously recognized in the acquiree were valued and recognized at fair value, when they are classified as a present obligation and are reliably measurable, as required by CPC 15/IFRS 3 (Note 17).
- (iv) Refers to the temporary differences generated on the identified assets and liabilities assumed at fair value in the business combination process, as required by CPC15//IFRS3, having goodwill as contra entry.

It should be noted that the amounts related to the revaluation surplus presented in the table above, as well as the goodwill of R\$1,860,625, will not be deductible for income and social contribution tax purposes. The goodwill represents the expected future profitability, based on the benefits expected from the synergy of the Company's and its subsidiaries' operations.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 3. Business combination (Continued)

		2022	
	Aeroporto	Santa Isabel	Arthur Ramos
Acquisition date	03/15/2022	02/24/2022	01/27/2022
Location	BA	SP	AL
Equity interest acquired (%)	100.00	100.00	100.00
Total consideration	218,138	280,000	356,257
Payment on acquisition date	186,827	280,000	284,817
Accounts payable for acquisitions	31,311		71,440
Assets			
Cash and cash equivalents	2,669	-	6,246
Trade accounts receivable	23,383	35,961	52,095
Inventories	1,562	1,339	3,557
Taxes recoverable	185	-	4,928
Judicial deposits	780	-	153
Deferred income and social contribution taxes	5,771	-	6,604
Property and equipment	41,289	10,414	68,795
Intangible assets	29	-	504
Rights of use – leases	-	81,323	-
Other	5,466	197	5,744
	81,134	129,234	148,626
Liabilities		_	
Trade accounts payable	(8,814)	-	(18,600)
Loans and financing	(8,642)	-	(4,123)
Salaries, accruals and social charges	(3,765)	(9,756)	(6,490)
Tax obligations	(5,692)	(1,284)	(20,580)
Deferred income and social contribution taxes	(1,634)	-	(1,413)
Provision for contingencies	(5,452)	-	(4,156)
Leases	-	(81,437)	-
Other	(508)	(44)	(9,693)
	(34,507)	(92,521)	(65,055)
Total indemnifiable assets, net	46,627	36,713	83,571
Goodwill on acquisition (Note 10)	171,511	243,287	272,686
Contribution for the Group with revenues since the acquisition date Contribution for the Group with income (loss) before taxes since the	92,799	122,965	252,058
acquisition date	(859)	(7,825)	43,137
Revenues from acquiree since the beginning of year	109,698	122,965	331,127
Income (loss) from acquiree before taxes since the beginning of year	562	(7,825)	75,856

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 3. Business combination (Continued)

The outstanding payables are guarantees for certain liabilities assumed by the sellers (e.g. materialization of contingencies), and will be paid within six years on average after their execution dates, restated based on the Interbank Deposit Certificate (CDI), the Extended Consumer Price Index (IPCA) and the Central Bank benchmark rate (SELIC) included in the balance of "Accounts payable for acquisitions".

### 4. Cash and cash equivalents and marketable securities

#### 4.1. Cash and cash equivalents

	Indiv	ridual	Consolidated		
	03/31/2023	12/31/2022	03/31/2023	12/31/2022	
Cash and cash equivalents					
Cash and banks	17,708	8,866	135,910	92,262	
Short-term investments	91,324	87,494	1,941,843	1,017,534	
Cash and cash equivalents	109,032	96,360	2,077,753	1,109,796	

Short-term investments classified as cash equivalents mature within three months from the investment date, and the amounts classified as marketable securities refer to securities maturing after three months, with substantially immediate liquidity.

#### 4.2. Marketable securities

Short-term investments are broken down in the table below, which shows their respective classifications, curve value and market value, as well as the contractual average rates:

	Fair value through profit or loss		Individual - 03/31/2023
Description	Market value/carrying amount	Average interest rate	Total
Fixed income securities - corporate Bank deposit certificates	10,390,043	-	10,390,043
Floating rate CDI %	10,390,043	104.27%	10,390,043
Financial bills			
Fixed income securities - government	49,199	-	49,199
Financial treasury bills	49,199	SELIC	49,199
Investment fund shares	178	-	178
Investment fund shares - other than funds of one	178	-	178
		_	10,439,420
		Current	10,439,420
		Noncurrent	

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 4. Cash and cash equivalents and marketable securities (Continued)

### 4.2. Marketable securities (Continued)

	Fair value through profit or loss		Individual 12/31/2022
Description	Market value/carrying amount	Average interest rate	Total
Fixed income securities - corporate Bank deposit certificates	11,024,270	-	11,024,270
Floating rate CDI %	11,024,270	104.30% of CDI	11,024,270
Financial bills			, ,
Fixed income securities - government	30,201	-	30,201
Financial treasury bills	30,201	SELIC	30,201
Investment fund shares	173	-	173
Investment fund shares - other than funds of one	173	-	173
Outros (1)	111.246	-	111.246
		_	11,165,890
		Current =	11,165,890
		Noncurrent	-

<sup>(1)</sup> Revaluation surplus of assets classified as amortized cost recognized in December 2022 as a result of the acquisition of SulAmérica and measurement of assets at fair value. Amount recorded in books in the parent, Rede D'Or, due to the calculation of goodwill on acquisition.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 4. Cash and cash equivalents and marketable securities (Continued)

### 4.2. Marketable securities (Continued)

	Fair value through profit or loss		rough other sive income	Amortiz	ed cost		Consolidated 03/31/2023
Description	Market value/ carrying amount	Curve value	Market value/ carrying amount	Curve value/carrying amount	Market value	Average interest rate (1)	Total
Fixed income securities - corporate	13,736,864	1,282,169	1,274,739	-	-	-	15,011,603
Bank deposit certificates							
Floating rate CDI +	6,905	4,941	4,957			CDI+0.82% p.a.	11,862
Floating rate CDI %	12,248,791	-	-	-	-	104.27% of CDI	12,248,791
Debentures							
Fixed rate	179	-	-	-	-	18.47% p.a.	179
Floating rate CDI +	552,717	177,146	176,094	-	-	CDI+2.93% p.a.	728,811
Floating rate CDI %	51,973	86,840	86,607	-	-	114.67% of CDI	138,580
Floating rate IPCA	425	-	-	-	-	IPCA+6.07% p.a.	425
Financial bills							
Fixed rate		1,214	1,193			5.92% p.a.	1,193
Floating rate CDI +	557,831	379,738	384,207			CDI+1.71% p.a.	942,038
Floating rate CDI %	282,582	598,802	588,175			119.25% CDI	870,757
Floating rate IPCA	2,049					IPCA+7.28% p.a.	2,049
Promissory notes	33,412	33,488	33,506	-	-	CDI+1.81%	66,918
Fixed income securities - government	5,886,531	1,762,367	1,691,856	1,813,520	1,805,675	-	9,391,907
Financial treasury bills	4,051,587	412,619	412,755	-	-	SELIC	4,464,342
Fixed rate	1,257,382	3,529	3,429	-	-	13.05%	1,260,811
National treasury notes							
Series F - Fixed rate	598	33,586	30,665	-		8.88% p.a.	31,263
Series B - Floating rate IPCA	576,964	1,166,282	1,103,383	64,096	63,712	IPCA+4.59% p.a.	1,744,443
Series C – Floating rate IGP-M	-	146,351	141,624	1,749,424	1,741,963	IGPM+5.79% p.a.	1,891,048
Variable income securities	232,372	-	-	-	-	-	232,372
Shares	232,372	209	209	-	-	-	232,581
Impairment	-	(209)	(209)	-	-	-	(209)
Investment fund shares	5,335,623	-	-	-	-	-	5,335,623
Fixed income, equity and multi-market investment fund shares	5,249,757	-	-	-	-	-	5,249,757
Equity fund shares	85,866	-	-	-	-	-	85,866
Other investments	12,444	-	-	-	-		12,444 29,983,949
						Current	28,225,144
						Noncurrent	1,758,805
						Noncurrent	1,730,005

<sup>(1)</sup> Market rates for assets classified at fair value through profit or loss, and purchase rate for assets classified at fair value through other comprehensive income and amortized cost.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 4. Cash and cash equivalents and marketable securities (Continued)

### 4.2. Marketable securities (Continued)

	Fair value through profit or loss	Fair value thro		Amortized cost		net.	
	Market value/	Comprehensiv	Market value/ carrying	Curve value/carrying	Market	Average	12/31/2022
Description	carrying amount	Curve value	amount	amount	value	interest rate <sup>(1)</sup>	Total
Fixed income securities - corporate	14,490,699	1,276,859	1,269,354	-	-	-	15,760,053
Bank deposit certificates							
Floating rate CDI +	11,610	4	4	-	-	CDI + 0.88% p.a.	11,614
Floating rate CDI % Debentures	12,999,797	4,768	4,786	-	-	104.10% of CDI	13,004,583
Fixed rate	182	_	_	_	_	18.47% p.a.	182
Floating rate CDI +	545,602	177,719	178,350	-	-	CDI + 1.68% p.a.	723,952
Floating rate CDI %	50,825	92,423	93,001	-	-	109.75% of CDI	143,826
Floating rate IPCA	423	32,423	33,001			IPCA + 5.47% p.a.	423
Other	1,747	_	_	_	_	11 OA + 3.41 /0 p.a.	1,747
Financial bills	1,747	_	_	_	_	_	1,777
Fixed rate	545	615	609			5.92% p.a.	1,154
Floating rate CDI +	423,382	477,365	473.048	-	-	CDI + 1.71%	896,430
Floating rate CDI %	433,001	488,210	483,796	-	-	119.8% of CDI	916,797
Floating rate IPCA	1.324	1.493	1.480	-	-	IPCA+7.15% p.a.	2.804
Promissory notes	22,261	34.262	34,280	-	-	CDI + 1.54%	56,541
Fixed income securities - government	5,672,342	1,451,932	1,370,998	1,857,545	1,857,545	CDI + 1.54%	8,900,885
Financial treasury bills	4,055,855	117,151	117,078	1,037,343	1,037,343	SELIC	4,172,933
National treasury bills	4,055,655	117,131	117,070	-	-	SLLIC	4,172,555
Fixed rate	1,050,131	4.004	4,717			42 270/	4.054.040
National treasury notes	1,050,131	4,864	4,717	-	-	13.37% p.a.	1,054,848
Series F - Fixed rate	649	123,438	120,035			5.47% p.a.	120,684
	565,707	1,146,885	1,073,966	63.646	63.646	IPCA + 4.50% p.a.	1,703,319
Series B - Floating rate IPCA Series C - Floating rate IGP-M	565,707	1,146,885 59,594	55,202	1,793,899	1,793,899	IGP-M + 5.78% p.a.	1,703,319
Variable income securities	282.647	59,594	55,202	1,793,899	1,793,899	IGP-IVI + 5.78% p.a.	1,849,101 <b>282.647</b>
Shares		-	- 59	-	-	-	
	282,647	-		-	-	-	282,706
Impairment		-	(59)	-	-	-	(59)
Investment fund shares Fixed income, equity and multi-market investment fund	6,086,845	-	-	-	•	-	6,086,845
shares	6,023,946	-	-	-	-	-	6,023,946
Equity fund shares	62,899	-	-	-	-	-	62,899
Other investments	12,549	_	-		_		12,549
	,					-	31,042,979
						Current Noncurrent	29,236,645 1,806,334
						Noncurrent	1,806,3

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 5. Accounts receivable

		Individ	ıal	Consolidated		
Description	Note 2		2022	2023	2022	
Accounts receivable for hospital services	5.1	4,198,675	3,966,046	7,550,142	7,055,383	
Others accounts receivable	5.2	-	-	2,527,226	2,515,558	
	_	4,198,675	3,966,046	10,077,368	9.570,941	
Current		4,198,675	3,966,046	8,418,171	7,911,452	
Noncurrent		· · · · · •		1.659.197	1,659,489	

### 5.1. Hospital services

Trade accounts receivable comprise receivables from healthcare companies and individuals, as follows:

	Indiv	ridual	Consolidated		
	03/31/2023	12/31/2022	03/31/2023	12/31/2022	
			(Restated)	(Restated)	
Accounts receivable from health insurance and	4,930,558		8,793,338		
health plans		4,715,501		8,352,866	
Accounts receivable from individuals	163,062	94,315	299,805	179,685	
Allowance for expected credit losses and					
provision for disallowances	(894,945)	(843,770)	(1,543,001)	(1,477,168)	
	4,198,675	3,966,046	7,550,142	7,055,383	

### Changes in provision for disallowances and allowance for expected credit losses

	Indiv	idual	Consolidated		
	03/31/2023	03/31/2022	03/31/2023	03/31/2022	
			(Restated)		
Balance at beginning of period	(843,770)	(670,526)	(1,477,168)	(1,709,766)	
Recognition of provision	(169,677)	(119,800)	(275,361)	(272,587)	
Write-offs (a)	118,502	126,577	209,528	239,614	
Provision arising from acquisitions	-	=	-	(10,275)	
Balance at end of period	(894,945)	(663,749)	(1,543,001)	(1,753,014)	

<sup>(</sup>a) Write-offs include the derecognition of uncollectible amounts and elimination of the provision for disallowances of the Group companies.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

#### **5. Accounts receivable** (Continued)

### 5.1. Hospital services (Continued)

At March 31, 2023 and December 31, 2022, the aging list of trade accounts receivable was as follows:

				ı	ndividual				
	Overdue								
		_	1 -	31 -	61 -	91 -	121 -	181 -	360 -
	Total	Falling due	30 days	60 days	90 days	120 days	180 days	360 days	720 days
03/31/2023	5,093,620	3,448,764	37,274	143,671	101,118	71,932	181,713	438,959	670,189
12/31/2022	4,809,816	3,107,521	161,678	116,745	100,414	89,378	168,662	404,581	660,837
				С	onsolidated	ı			
						Overdue			
			1 -	31 -	61 -	91 -	121 -	181 -	360 -
	Total	Falling due	30 days	60 days	90 days	120 days	180 days	360 days	720 days
03/31/2023	9,093,143	5,393,783	350,747	301,051	201,582	181,575	361,937	902,150	1,400,318
12/31/2022	8,532,551	5,201,719	361,508	254,613	193,728	168,868	306,350	762,581	1,283,184

The Company's revenues arise from the provision of hospital services, including the use of medicines and hospital materials. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, i.e. upon rendering of medical services at an amount that reflects the consideration to which an entity expects to be entitled in exchange for providing services to a customer.

#### Changes in provision for disallowances and allowance for expected credit losses

The provision for disallowances and allowance for expected credit losses is presented reducing the balance of accounts receivable and recognized at an amount deemed sufficient by management to cover any expected losses on the realization of amounts billed.

The Company's criterion to recognize a provision for disallowances is to annually analyze the performance of notes overdue between 360 to 720 days, a period deemed sufficient for exhausting the collection process. The percentage reached is applied to the gross revenue recorded and recognized as a provision in current profit or loss, reflecting management's best expectation based on the analyzed history. The analysis is made individually by cashgenerating unit, as well as the percentage recorded as a provision for disallowances in the year.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 5. Accounts receivable (Continued)

#### **5.1.** Hospital services (Continued)

As a criterion for the recognition of an allowance for expected credit losses, an individual analysis of receivables is performed to identify specific counterparty risks. If necessary, an allowance for expected credit losses is recorded for the full balance of receivables outstanding of these customers.

#### 5.2. Other accounts receivable

The receivables as at March 31, 2023 and 2022 presented in the consolidated financial statements are as follows:

		Consolidated	Consolidated
	Note	03/31/2023	12/31/2022
		(Restated)	(Restated)
Other operating receivables	5.2.1	1,868,220	1,825,912
Consideration receivable - pension plan administrator	5.2.2	467,348	501,777
Other (a)		191,658	187,869
		2,527,226	2,515,558
Current		868,029	856,069
Noncurrent		1.659.197	1.659.489

<sup>(</sup>a) The "Other" balance is represented mainly by receivables related to recovery of the Supplementary Health Fees and security-related commitments.

#### 5.2.1. Other operating receivables

	Consolidated				
	03/31/2023	12/31/2022			
Receivables from FCVS – SFH	(Restated)	(Restated)			
Principal (Note 5.2.1.1)	1,938,404	1,921,639			
Impairment (Note 5.2.1.1)	(222,722)	(214,911)			
Frozen funds (a)	49,862	45,838			
Other (b)	102,676	73,346			
Total	1,868,220	1,825,912			
Current Noncurrent	212,616 1,655,604	170,184 1,655,728			

<sup>(</sup>a) These refer to funds frozen in bank accounts and investment funds due to lawsuits; and

<sup>(</sup>b) The balance of "Other" line item is mainly represented by advances to suppliers and payments related to the refund to the Unified Health System (SUS), managed by the regulatory authority and recorded as advance until the regulatory authority authorizes the write-off of liability.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 5. Accounts receivable (Continued)

### **5.2. Other accounts receivable** (Continued)

### 5.2.1. Other operating receivables (Continued)

### 5.2.1.1. Receivables from FCVS - SFH

Balance of receivables FCVS-SFH at 12/31/2022 Additions Write-offs Balance of receivables FCVS-SFH at 03/31/2023 Balance of impairment at 03/31/2023 Closing balance net of impairment at 03/31/2023	Consolidated 03/31/2023 (Restated) 1,921,639 48,749 (31,984) 1,938,404 (222,722) 1,715,682
Current Noncurrent	118,062 1,597,620 <u>Consolidated</u> 12/31/2022
Balance of receivables FCVS-SFH at 12/31/2021 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2022 Balance of impairment at 12/31/2022 Closing balance net of impairment at 12/31/2022 Current	1,842,315 246,368 (167,044) 1,921,639 (214,911) 1,706,728

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

#### **5. Accounts receivable** (Continued)

- **5.2.** Other accounts receivable (Continued)
  - 5.2.1. Other operating receivables (Continued)
    - 5.2.1.1. Receivables from FCVS SFH (Continued)

As at March 31, 2023, there are lawsuits related to the Housing Financial System (SH/SFH) in progress in which the Company has been summoned. Such lawsuits may give rise to future cash disbursement with the corresponding request for reimbursement to Caixa Econômica Federal (CAIXA), manager of the Wage Variation Compensation Fund (FCVS). In the cases in which the lawsuit is in the provisional enforcement phase to avoid early disbursement in cases whose decisions are not final and unappealable, the Company pledges in court surety bond policies. As at March 31, 2023, the total amount guaranteed through surety bond is R\$954,717 (R\$926,304 at December 31, 2022). The SH/SFH was created by article 14 of Law No. 4380/1964, and since 1967, has been guaranteed by the FCVS. Insurance companies have lawsuits filed against them because they are mischaracterized as representatives of the FCVS, which is the role of CAIXA, the manager of that Fund. In view of this role of FCVS representative in lawsuits, the insurance companies, which are the illegitimate parties, are entitled to receive reimbursements for all incurred expenditures. Law No. 12409/2011, amended by Law No. 13000/2014, as well as the CCFCVS Resolution No. 364, of March 28, 2014, expressly establish the responsibility of FCVS, through its manager CAIXA, for all lawsuits relating to the SH/SFH's public policy. Additionally, the Office of the Attorney-General of the National Treasury (PGFN) issued the Opinion SEI PGFN/CAF No. 489/2018, amended by Note SEI No. 158/2018, in which it recognizes the role of insurance companies as non-interested third parties of the SH/SFH. In September 2018, the Federal Supreme Court (STF) recognized the general repercussion of the appeal to the Supreme Court filed by the Company to analyze the jurisdiction of the Federal Court in lawsuits of this nature. In June 2020, the merits of that appeal were judged and accepted, by majority of votes, to consolidate the interest of CAIXA, the FCVS administrator, in the SH/SFH-related lawsuits, and, consequently, establish the Federal Court's jurisdiction for processing and judging lawsuits of this nature.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 5. Accounts receivable (Continued)

#### **5.2.** Other accounts receivable (Continued)

#### 5.2.1. Other operating receivables (Continued)

### 5.2.1.1. Receivables from FCVS - SFH (Continued)

In November 2022, when the motions for clarification presented within the scope of the lawsuit were judged, the Supreme Court did not change its understanding that the Federal Courts are responsible for processing and judging those lawsuits. Currently, insurance companies are reimbursed by the FCVS for payments made in connection with SH/SFH-related lawsuits based on the criteria established by Resolution CCFCVCS No. 448/2019.

#### 5.2.2. Consideration receivable - ASO health plans

Administrative service only (ASO) health plans are plans in which the Company administers medical and hospital expenses on behalf of its customers, and is fully reimbursed by the customers, recording only its administration fee as revenue. The amounts related to consideration receivable by maturity are as follows:

	Consolidated				
	03/31/2023	12/31/2022			
Falling due	(Restated)	(Restated)			
Falling due from 1 to 30 days	384,827	450,685			
Falling due from 31 to 60 days	50,541	30,949			
Falling due from 61 to 180 days	8,235	7,660			
Total falling due	443,603	489,294			
Overdue					
Overdue from 1 to 30 days	22,712	10,921			
Overdue from 31 to 60 days	473	1,426			
Overdue from 61 to 180 days	71	202			
Overdue from 181 to 365 days	7	14			
Overdue for more than 365 days	3,713	3,813			
Total	26,976	16,376			
Provision for impairment	(3,231)	(3,893)			
Total overdue	23,745	12,483			
Total unearned premiums	470,579	505,670			
Total provision for impairment	(3,231)	(3,893)			
Total	467,348	501,777			

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

#### 6. Inventories

	Indiv	idual	Consolidated			
	03/31/2023	03/31/2023 12/31/2022		12/31/2022		
Medicines	135,762	161,320	271,771	327,376		
Special materials	96,708	100,019	161,583	159,877		
Disposable materials	78,266	92,149	132,800	151,797		
Consumables	11,313	15,289	60,415	62,800		
Laboratory materials	3,938	3,913	16,319	17,177		
Surgical sutures	5,698	6,369	9,680	10,355		
Dressing room materials	2,839	2,540	9,256	8,883		
Food stuff	2,868	3,126	6,225	6,576		
Other	25,285	29,280	59,479	63,847		
	362,677	414,005	727,528	808,688		

### 7. Transactions with related parties

Significant related-party transactions

The nature of significant related-party transactions is summarized below:

- (i) Leases the Company leases properties owned by the controlling shareholders, namely: properties of the hospitals Copa D'Or and Quinta D'Or, and the property of the administrative unit. Leases are at market value and generated an expense in P&L for the period ended March 31, 2023 of R\$8,055 (R\$8,143 at March 31, 2022), referring to interest and amortization of rights of use. Leases are annually restated by reference to the Extended Consumer Price Index (IPCA).
- (ii) Transfers of funds between companies to enhance the operations of certain investees and provide funds for expansion and/or acquisitions, management transfers funds between Group companies, current account remittance agreements signed between the parties. These balances are substantially eliminated in the consolidated financial statements.
- (iii) Shared services these are centralized services rendered by the Parent Company, Rede D'Or, such as legal assistance, marketing, accounting, treasury, accounts payable and accounts receivable, which are shared among the other entities of the Group based on apportionment criteria that take into consideration the contribution of each entity to the consolidated gross revenue.
- (iv) *Debentures* certain subsidiaries issued nonconvertible debentures, which were acquired by the parent company. These debentures are intended to provide funds to the investees for investment in operations and expansion.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

Significant related-party transactions (Continued)

(v) Revenues and accounts receivable partially arise from commercial transactions conducted in the ordinary course of business relating to medical care provided to members of Sul América plans. These transactions have reference tables by type of service provided by the Company with Sul América and the maturities of these services are stipulated in a contract entered into between the parties.

In addition to the balances presented below, the Parent Company and subsidiary Rede D'Or Finance carried out two debenture issue and purchase transactions, as follows:

On January 17, 2018, subsidiary Rede D'Or Finance carried out the first issue of senior notes, totaling US\$500,000 thousand, and, at the same time the Parent Company issued debentures (10th issue), which were acquired by subsidiary Rede D'Or Finance (Note 13);

On January 22, 2020, subsidiary Rede D'Or Finance carried out the second issue of senior notes, totaling US\$850,000 thousand. On February 13, 2020, Rede D'Or Finance reopened the second issue of senior notes and issued an additional US\$350 thousand in notes with the same characteristics as the initial issue. In addition, on April 17, 2020, the Parent Company issued debentures (17th issue - 1st series), which were acquired by subsidiary Rede D'Or Finance.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 7. Transactions with related parties (Continued)

### Balances with related parties

Company         Current Assets         Assets         Current Assets         Assets         P&L					Individual			
Company			03/31/2023			12/31/2022		03/31/2022
Debentures Sao Lucas (b)   9,716   38,000   1,787   7,930   38,000   8,983   1,86   Debentures Hospital Nossa Senhora das Neves (f)   142,871   40,000   5,675   137,196   18,747   2,876   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   18,	Company			P&L			P&L	P&L
Debentures Sao Lucas (b)   9,716   38,000   1,787   7,930   38,000   8,983   1,86   Debentures Hospital Nossa Senhora das Neves (f)   142,871   40,000   5,675   137,196   18,747   2,876   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   2,876   18,747   18,	Dehentures Norte D'Or (a)	0 504	20.000	1.026	22.452	20,000	E 0.42	553
Debentures Hospital Nossa Senhora das Neves (f)   142,871   40,000   5,675   137,196   - 18,747   2,68   Shared services   Medise Medicina Diagnóstico e Serviços Ltda.   - 530   3,344   11,102   3,77   Hospital São Marcos S.A.   - 5,970   3,072   - 2,888   10,94   3,34   Hospital Sño Marcos S.A.   - 5,970   3,072   - 2,888   10,94   3,34   J. Badim S.A.   - 5,970   3,072   - 2,888   10,94   3,35   J. Badim S.A.   - 16,839   15,587   12,34   Hospital Fluminense S.A.   16,839   15,177   4,4   Clírica São Vicente   2,724   10,316   2,94   Hospital Huminense S.A.   893   10,316   2,94   URC   - 2,026	( )	-,			, -		-,	
Shared services         Medise Medicina Diagnóstico e Serviços Ltda.         530         3,344         11,102         3,74           Hospital Esperança S.A.         10,687         35,87         10,97           Hospital So Marcos S.A.         1,784         5,388         19,97           Hospital Norte D'Or de Cascadura S.A.         5,970         3,072         2,898         10,194         3,33           J. Badim S.A.         15,425         816         14,609         3,367         88           Concologia D'Or S.A.         15,425         816         14,609         3,367         88           Hospital Fluminense S.A.         1,527         4,755         15,177         4,4           Hospital Santa Helena S.A.         2         4,755         15,177         4,4           Hospital Spha-Med LTDA.         893         3,344         9         5,681         12,34           URC         2,026         2,026         2,026         16,988         5,34           Hospital JMpa-Med LTDA.         47,192         4,617         42,575         16,622         4,32           URC         2,026         2,026         2,026         16,838         5,34           Hospital Linga         47,192         4,617         4,2						36,000		
Medician Diagnóstico e Serviços Ltda.   530   3,344   - 11,102   3,74     Hospital São Marcos S.A.   - 10,887   3,072   2,888   1,98     Hospital São Marcos S.A.   - 5,970   3,072   - 2,888   1,98     Hospital Notre D'Or de Cascadura S.A.   - 15,425   816   - 14,609   3,367   88     Oncologia D'Or S.A.   - 15,425   816   - 14,609   3,367   88     Oncologia D'Or S.A.   - 15,425   816   - 14,609   3,367   88     Oncologia D'Or S.A.   - 16,839   - 5,5861   12,34     Clinica São Vicente   - 2,724   - 10,316   2,98     Hospital Alprimense S.A.   2,724   - 10,316   2,98     Hospital Alprimense S.A.   1,760   5,760   5,760     Hospital Alprimense S.A.   1,608   1,608     URC   - 2,026   1,608   1,608     URC   - 2,026   1,608   5,34     URC   - 4,7152   4,617   - 42,575   16,622   4,93     DF Star   - 1,708   - 5,577   1,939   4,27     São Lucas   - 5,177   - 1,234   16,551   4,55     São Rafael   - 12,620   1,723   14,723   40,737   12,53     Casa de Saúde Laranjeiras   - 12,620   1,723   1,4723   4,733   16,551   4,55     São Rafael   - 12,620   1,723   1,4723   4,733   1,2139   3,11     Hospital Alpinça   - 13,250   1,870   11,381   8,408   2,14     Hospital Alpinça   - 12,768   1,909   - 1,996   1,324     Hospital Alpinça   - 1,276   1,393   1,20     Hospital Babino   - 2,246   - 2,296   - 2,296     Hospital Homorar   - 3,932   - 15,193   3,193   1,00     Hospital Homorar   - 1,381   8,408   2,14     Hospital Morte D'Or de Cascadura S.A. (c)   1,381   8,88   3,193   3,193   1,00     Hospital Norte D'Or de Cascadura S.A. (c)   1,209   - 1,209   - 1,209     Hospital Norte D'Or de Cascadura S.A. (c)   1,209   - 1,209   - 1,209     Hospital Norte D'Or de Cascadura S.A. (c)   1,209   - 1,209   - 1,209     Hospital Norte D'Or de Cascadura S.A. (c)   1,209   - 1,209   - 1,209     Hospital Norte D'Or de Cascadura S.A. (c)   1,209   - 1,209   - 1,209     Hospital Norte D'Or de Cascadura S.A. (c)   1,209   - 1,209   - 1,209     Hospital Norte D'Or de Pesquisa e Ensino (c)   1,209   - 1,209		142,071	40,000	3,073	137,130	_	10,747	2,001
Hospital Esperanga S.A.   - 10,687   - 35,847   10,97     Hospital São Marros S.A.   - 1,784   - 5,388   1,98     Hospital Norte D'Or de Cascadura S.A.   5,970   3,072   2,888   1,194   3,33     Hospital Norte D'Or de Cascadura S.A.   15,425   816   14,609   3,367   81     Oncologia D'Or S.A.   - 16,839   - 55,861   12,34     Hospital Fluminense S.A.   - 4,755   - 15,177   4,4     Clinica São Vicente   - 2,774   - 10,316   2,98     Hospital Plaph-Med LTDA.   - 893   - 3,414   99     Hospital Japha-Med LTDA.   - 893   - 2,026   - 2,026     Hospital UDI   - 2,026   - 2,026   - 2,026     Hospital UDI   - 5,508   - 16,988   5,34     Onco Star SP   - 47,192   4,617   42,575   16,622   4,93     DF Star   - 5,177   - 1,937   4,25     Saner   - 7,108   - 4,753   16,551   4,55     Sanera   - 1,708   - 4,753   16,551   4,55     São Lucas   - 51,661   4,118   47,543   16,551   4,55     São Rafael   - 1,708   - 4,753   16,551   4,55     São Rafael   - 1,708   - 4,753   16,551   4,55     São Carlos   - 1,708   - 1,703   1,723   1,723   1,723   1,723     Hospital Jainena   - 5,616   - 2,696   - 2,096     São Carlos   - 1,3250   1,870   11,381   8,408   2,1     Hospital Jainena   - 5,616   - 2,696   - 2,096     São Carlos   - 1,3250   1,870   11,381   8,408   2,1     Hospital Babino   - 2,140   - 7,096     Cardio Pulmonar   - 1,248   1,278   1,013   1,013   1,013     Hospital Morta id (tormerly Hospital América)   - 3,393   - 10,864   2,2     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,483   1,524   37,368   12,77     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,483   1,524   37,368   12,77     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,483   1,524   37,368   12,77     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,483   1,524   37,368   12,77     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,483   1,524   37,368   12,77     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,483   1,524   37,368   12,77     Hospital Norte D'Or de Cascadura S.A. (c)   1,810   1,481   1,481   1,		_	530	3.344	_	_	11 102	3,761
Hospital Note D'Or de Cascadura S.A.   5,970   3,072   2,888   10,194   3,34   3,34   3,34   3,367   8,000   3,367   3,367   3,367		_	-		_	_	,	10.917
Hospital Notre D'Or de Cascadura S.A.   5,970   3,072   2,888   10,194   3,36   3,10   3,36		_	_	- ,	_	_	,	1,953
J. Badim S.A   - 15,425	•	_	5.970	,	_	2.898	,	3,308
Oncologia D'Or S.A.	•	_	,	,	_	,	,	894
Hospital Fluminense S.A.   -   -   4,755   -   15,177   4,44		_	-		_			12,340
Clinica São Vicente		_	_	•	_	_	,	4,482
Hospital Santa Helena S.A.	•	_	_	,	_	_	,	2,982
Hospital Alpha-Med LTDA.   -   -   -   -   -   -   -   -   -		_	_	_,	_	_	,	5,746
Diagno SM	•	_	_	893	_	_	,	961
URČ Hospital UDI Onco Star SP		_	_	-	_	_	-	33
Hospital UDI	•	_	2.026	_	_	2.026	_	-
Onco Star SP         - 47,192         4,617         - 42,575         16,622         4,93           DF Star         5,177         18,937         4,25           Samer         1,708         5,878         1,77           São Lucas         - 51,661         4,118         - 47,543         16,551         4,55           São Rafael         - 12,620         11,723         - 14,723         40,737         12,55           Casa de Saúde Laranjeiras         12,620         11,723         - 14,723         40,737         12,55           Casa de Saúde Laranjeiras         12,620         11,723         - 14,723         40,737         12,55           Casa de Saúde Laranjeiras         12,620         11,723         - 14,723         40,737         12,55           Casa de Saúde Laranjeiras         2,845         2,936         2,66         10,91         12,139         3,31         10,51         4,68         2,66         10,51         4,61         6,61         12,139         4,31         4,69         4,61         4,61         1,62         1,62         2,66         2,66         1,62         2,69         2,69         2,69         2,69         2,69         1,62         1,62         1,62		_	-,	5.008	_		16 988	5,345
DF Star Samer         -         -         5,177         -         18,937         4,20           Samer         -         1,708         -         -         5,878         1,77           São Lucas         -         51,661         4,118         -         47,543         16,551         4,55           São Rafael         -         12,620         11,723         -         14,723         40,737         12,58           Casa de Saúde Laranjeiras         -         -         3,414         -         -         12,139         3,11           Hospital Santa Cruz         -         -         2,845         -         -         9,236         2,6           Hospital Aliança         -         -         5,616         -         -         20,690         5,50           São Carlos         -         13,250         1,870         -         11,381         8,408         2,1           Glória D'Or         -         -         2,140         -         11,381         8,408         2,1           Hospital Balbino         Bliocor Hospital Mauá (formerly Hospital América)         -         -         3,932         -         -         1,33         1,3           Hospital Ross		_	47.192	,	_	42 575	,	4,936
Samer		_		,	_	-	,	4,204
São Lucas         -         51,661         4,118         -         47,543         16,551         4,555           São Rafael         -         12,620         11,723         -         14,723         40,737         12,51           Casa de Saúde Laranjeiras         -         -         3,414         -         -         12,139         3,11           Hospital Santa Cruz         -         -         2,845         -         -         9,236         2,63           Hospital Aliança         -         -         5,616         -         -         2,0690         5,55           São Carlos         -         13,250         1,870         -         11,381         8,408         2,14           Glória D'Or         -         -         2,140         -         -         7,096           Cárdio Pulmonar         -         -         3,932         -         -         15,193         4,38           Hospital Balbino         -         -         927         -         -         2,991         1,38           Biocor Hospital Mauá (formerly Hospital América)         -         -         927         -         -         2,991         1,34           Hospital Balbino		_	_	,	_	_	,	1,751
São Rafael         -         12,620         11,723         -         14,723         40,737         12,526           Casa de Saúde Laranjeiras         -         -         3,414         -         -         12,139         3,13           Hospital Santa Cruz         -         -         2,845         -         -         9,236         2,65           Hospital Aliança         -         -         5,616         -         -         20,690         5,55           São Carlos         -         13,250         1,870         -         11,381         8,408         2,14           Glória D'Or         -         -         2,140         -         -         7,096           Cárdio Pulmonar         -         -         3,932         -         -         15,193         4,34           Hospital Brasil Mauá (formerly Hospital América)         -         -         3,093         -         -         2,991         1,38           Hospital Balbino         -         -         927         -         -         2,991         1,38           Hospital Moso Altibaia         -         12,781         2,768         -         10,013         3,02           Hospital Nosa Senhora das Neves		_	51,661	•	_	47 543	,	4,556
Casa de Saúde Laranjeiras Hospital Santa Cruz Casa de Saúde Laranjeiras Casa Carlos Ca		_		•	_			12,589
Hospital Santa Cruz		_	,00	,	_	- 1,1.20	-, -	3,139
Hospital Aliança	•	_	_	,	_	_		2,637
São Carlos       -       13,250       1,870       -       11,381       8,408       2,14         Glória D'Or       -       -       2,140       -       -       7,096         Cárdio Pulmonar       -       -       3,932       -       -       15,193       4,36         Hospital Brasil Mauá (formerly Hospital América)       -       -       3,093       -       -       10,864       2,25         Hospital Balbino       -       -       927       -       -       2,991       1,35         Biocor Hospital de Doenças Cardiovasculares       -       12,781       2,768       -       10,013       10,013       3,2°         Proncor Unidade Intensiva Cardiorespiratória       -       4,081       888       -       10,013       10,013       3,2°         Proncor Unidade Intensiva Cardiorespiratória       -       4,081       888       -       3,193       3,193       1,0°         Hospital Nossa Senhora das Neves       -       2,690       2,690       -       -       -       -       -       2,838       -       -       -       -       -       -       -       -       -       -       -       -       -       - <t< td=""><td>•</td><td>_</td><td>_</td><td>,</td><td>_</td><td>_</td><td>,</td><td>5,502</td></t<>	•	_	_	,	_	_	,	5,502
Glória D'Or   2,140   7,096   Cárdio Pulmonar   3,932   15,193   4,36   4,		_	13.250	,	_	11 381	,	2,144
Cárdio Pulmonar       -       -       3,932       -       -       15,193       4,36         Hospital Brasil Mauá (formerly Hospital América)       -       -       3,093       -       -       10,864       2,28         Hospital Balbino       -       -       927       -       -       2,991       1,33         Biocor Hospital de Doenças Cardiovasculares       -       12,781       2,768       -       10,013       10,013       3,27         Proncor Unidade Intensiva Cardiorespiratória       -       4,081       888       -       3,193       3,193       1,02         Hospital Nossa Senhora das Neves       -       2,690       2,690       -       -       -       -         Hospital Novo Atibaia       -       -       2,838       -       -       -       -         Hospital Memorial Arthur Ramos       -       -       1,810       12,483       -       1,524       37,368       12,72         Hospital Norte D'Or de Cascadura S.A. (c)       -       4,615       -       -       2,286       -       -       12,72         Hospital Norte D'Or de Cascadura S.A. (c)       -       13,881       -       -       12,000       -       -       2		_	-	,	_	-	,	_,
Hospital Brasil Mauá (formerly Hospital América)   -   -   3,093   -   -   10,864   2,255     Hospital Balbino   -   -   927   -   -   2,991   1,355     Biocor Hospital de Doenças Cardiovasculares   -   12,781   2,768   -   10,013   10,013   3,227     Proncor Unidade Intensiva Cardiorespiratória   -   4,081   888   -   3,193   3,193   1,027     Hospital Nossa Senhora das Neves   -   2,690   2,690   -   -   -     Hospital Novo Atibaia   -   -   2,338   -   -   -     Hospital Memorial Arthur Ramos   -   2,709   -   -   -     Other   -   1,810   12,483   -   1,524   37,368   12,727     Hospital Norte D'Or de Cascadura S.A. (c)   -   4,615   -   -   2,286   -     Unidade de Radiologia Clínica Ltda. (c)   -   13,881   -   -   13,814   -     Jenner S.A. (c)   -   2,000   -   -   2,000   -     JMJB Diagnósticos e Serviços Hospitalares S.A. (c)   -   12,019   -   -   12,019   -     J. Badim S.A.   -   8,512   -   -   8,369   -     Instituto D'Or de Pesquisa e Ensino (c)   -   8,711   -   -   12,995   -     JM&M Empreendimentos Imobiliários S.A. (d)   -   370   8,031   -   370   32,713   8,12     Onco Star SP (e)   -   921,582   -   -   914,201   -     JTO Holding S.A. (c)   -   78,567   -   -   71,840   -     Rede D'Or Finance   -   263,891   -   -   263,891   -		_	_	,	_	_	,	4,362
Hospital Balbino		_	_	,	_	_	-,	2,293
Biocor Hospital de Doenças Cardiovasculares   12,781   2,768   - 10,013   10,013   3,27     Proncor Unidade Intensiva Cardiorespiratória   - 4,081   888   - 3,193   3,193   1,02     Hospital Nosa Senhora das Neves   - 2,690   2,690       Hospital Novo Atibaia   2,838       Hospital Memorial Arthur Ramos   2,709       Other   - 1,810   12,483   - 1,524   37,368   12,72     Hospital Norte D'Or de Cascadura S.A. (c)   - 4,615   2,286   -     Unidade de Radiologia Clínica Ltda. (c)   - 13,881   -   - 13,814   -     Jenner S.A. (c)   - 2,000   -   - 2,000   -     JMJB Diagnósticos e Serviços Hospitalares S.A. (c)   - 12,019   -   12,019   -     J. Badim S.A.   - 8,512   -   - 8,369   -     Instituto D'Or de Pesquisa e Ensino (c)   - 8,711   -   - 12,995   -     JM&M Empreendimentos Imobiliários S.A. (d)   - 370   8,031   - 370   32,713   8,12     Onco Star SP (e)   - 921,582   -   914,201   -     JTO Holding S.A. (c)   - 78,567   -   71,840   -     Rede D'Or Finance   - 263,891   -   263,891   -     Other   - 175,712   -   139,388   -		_	_	•	_	_	,	1,358
Proncor Unidade Intensiva Cardiorespiratória		_	12.781		_	10.013		3,212
Hospital Nossa Senhora das Neves		_	,	,	_	,	,	1,022
Hospital Novo Atibaia	•	_			_	-,	-,	-,
Hospital Memorial Arthur Ramos		_	-,	,	-	-	-	-
Other         -         1,810         12,483         -         1,524         37,368         12,72           Hospital Norte D'Or de Cascadura S.A. (c)         -         4,615         -         -         2,286         -         -         13,814         -         -         13,814         -         -         13,814         -         -         13,814         -         -         13,814         -         -         13,814         -         -         13,814         -         -         13,814         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,000         -         -         2,019         -         -         2,019         -         -         2,019         -         -         2,019         -         -         2,019         -         -         2,000         -         -         3,699         -         -         12,995         -	•	_	_	•	_	_	_	_
Hospital Norte D'Or de Cascadura S.A. (c) - 4,615 2,286 - Unidade de Radiologia Clínica Ltda. (c) - 13,881 13,814 - 2,000 2,000 -	•	_	1.810	,	_	1.524	37.368	12,726
Unidade de Radiologia Clínica Ltda. (c) - 13,881 13,814 - 2,000 -		_	,	-,	_	,	-	,
Jenner S.A. (c)     -     2,000     -     -     2,000     -       JMJB Diagnósticos e Serviços Hospitalares S.A. (c)     -     12,019     -     -     12,019     -       J. Badim S.A.     -     8,512     -     -     8,369     -       Instituto D'Or de Pesquisa e Ensino (c)     -     8,711     -     -     12,995     -       JM&AM Empreendimentos Imobiliários S.A. (d)     -     370     8,031     -     370     32,713     8,12       Onco Star SP (e)     -     921,582     -     -     914,201     -       JTO Holding S.A. (c)     -     78,567     -     -     71,840     -       Rede D'Or Finance     -     263,891     -     -     263,891     -       Other     -     175,712     -     139,388     -		_		_	_		_	_
JMJB Diagnósticos e Serviços Hospitalares S.A. (c)     -     12,019     -     -     12,019     -       J. Badim S.A.     -     8,512     -     -     8,369     -       Instituto D'Or de Pesquisa e Ensino (c)     -     8,711     -     -     12,995     -       JM&AM Empreendimentos Imobiliários S.A. (d)     -     370     8,031     -     370     32,713     8,12       Onco Star SP (e)     -     921,582     -     -     914,201     -       JTO Holding S.A. (c)     -     78,567     -     -     71,840     -       Rede D'Or Finance     -     263,891     -     -     263,891     -       Other     -     175,712     -     139,388     -		_		_	_	,	_	_
J. Badim Š.A.     -     8,512     -     -     8,369     -       Instituto D'Or de Pesquisa e Ensino (c)     -     8,711     -     -     12,995     -       JM&AM Empreendimentos Imobiliários S.A. (d)     -     370     8,031     -     370     32,713     8,12       Onco Star SP (e)     -     921,582     -     -     914,201     -       JTO Holding S.A. (c)     -     78,567     -     -     71,840     -       Rede D'Or Finance     -     263,891     -     -     263,891     -       Other     -     175,712     -     -     139,388     -	· ,	_	•	_	_	,	_	_
Instituto D'Or de Pesquisa e Ensino (c)     -     8,711     -     -     12,995     -       JM&AM Empreendimentos Imobiliários S.A. (d)     -     370     8,031     -     370     32,713     8,12       Onco Star SP (e)     -     921,582     -     -     914,201     -       JTO Holding S.A. (c)     -     78,567     -     -     71,840     -       Rede D'Or Finance     -     263,891     -     -     263,891     -       Other     -     175,712     -     -     139,388     -		_		_	_		_	_
JM&AM Empreendimentos Imobiliários S.A. (d)     -     370     8,031     -     370     32,713     8,12       Onco Star SP (e)     -     921,582     -     -     914,201     -       JTO Holding S.A. (c)     -     78,567     -     -     71,840     -       Rede D'Or Finance     -     263,891     -     -     263,891     -       Other     -     175,712     -     139,388     -		_		_	_		_	_
Onco Star SP (e)       -       921,582       -       -       914,201       -         JTO Holding S.A. (c)       -       78,567       -       -       71,840       -         Rede D'Or Finance       -       263,891       -       -       263,891       -         Other       -       175,712       -       -       139,388       -		_		8.031	_		32 713	8,120
JTO Holding S.A. (c)     - 78,567     - 71,840     -       Rede D'Or Finance     - 263,891     - 263,891     -       Other     - 175,712     - 139,388     -		_		-	_		-	
Rede D'Or Finance     -     263,891     -     -     263,891     -       Other     -     175,712     -     -     139,388     -	· ,	_	•	_	_	,	_	_
Other - 175,712 139,388 -		_		_			_	_
		_		_	_		_	_
	<del></del>	161,091	1,767,896	142,897	167,578	1,659,658	477,464	132,292

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

Balances with related parties (Continued)

	Consolidated								
		03/3	1/2023			12/3	1/2022		03/31/2022
	Current	Noncurrer	n Noncurren		Current	Noncurre	Noncurren		
Company	assets	t assets	t liabilities	P&L	assets	t assets	t liabilities	P&L	P&L
Debentures Mederi (g)	8,786	53,135	-	1,033	7,753	13,135	-	550	-
Shared services									
J Badim S.A.	-	15,425	-	816	-	14,609	-	3,367	894
JMJB Diagnósticos e Serviços		•							
Hospitalares S.A.	_	12,020	-	-	-	12,020	-	-	-
Instituto D'Or de Pesquisa e		•							
Ensino (c)	_	12,539	-	-	-	13,232	-	-	-
J Badim S.A. (c)	_	8,906	-	-	-	8,749	-	-	-
JM&AM Empreendimentos		•				•			
Imobiliários S.A. (d)	_	370	-	8,055	_	370	_	32,811	8,143
Other	_	16,718	2,397	-,,,	_	13,784	4,207	-,	-7
	8,786	119,113	2,397	9,904	7,753	75,899	4,207	36,728	9,037

- (a) On March 25, 2019, Norte D'Or conducted the third private issue of nonconvertible, single-series, registered debentures amounting to R\$10,000, maturing on March 25, 2023, which were acquired by Rede D'Or. The debentures earn interest on a *pro rata* basis equivalent to 100% of the DI (Interbank Deposits) plus 2.25% p.a. Interest is paid semiannually, and the nominal value will be paid semiannually from the 24th (twenty-fourth) month from the issue date. There are no guarantees for the debentures.
  - On August 26, 2019, Norte D'Or conducted the fourth private issue of nonconvertible, single-series, registered debentures amounting to R\$15,000, maturing on August 26, 2023, which were acquired by Rede D'Or. The debentures eam interest on a pro rata basis equivalent to 100% of the DI (Interbank Deposits) plus 2.25% p.a. Interest is paid semiannually, and the nominal value will be paid semiannually from the 24th (twenty-fourth) month from the issue date. There are no guarantees for the debentures.
  - On April 25, 2022, Norte D'Or conducted the fifth private issue of nonconvertible, single-series, registered debentures amounting to R\$30 million, maturing on April 1, 2025, which were acquired by Rede D'Or. The debentures earn interest on a *pro rata* basis equivalent to 100% of the DI (Interbank Deposits) plus 3.00% p.a. Interest is paid semiannually, and the nominal value will be paid in full on the maturity date. There are no guarantees for the debentures.
- (b) On May 28, 2019, Hospital São Lucas privately issued nonconvertible, single-series, registered debentures amounting to R\$38,000, maturing on May 28, 2024, with Rede D'Or as the debenture holder. The debentures earn interest on a pro rata basis equivalent to 100% of the DI (Interbank Deposits) plus 2.5% p.a. Interest is paid annually, and the nominal value will be paid in full on the maturity date. There are no guarantees for the debentures.
  - On December 5, 2020, Hospital São Lucas conducted the 2nd private issue of nonconvertible, single-series, registered debentures amounting to R\$ 20,000, maturing on December 5, 2022, with Rede D'Or as the debenture holder. The debentures earn interest on a pro rata basis equivalent to 100% of the DI (Interbank Deposits) plus 3.2% p.a. Interest is paid quarterly, and the nominal value will be paid in full on the maturity date. There are no guarantees for the debentures.
- (c) Transfers of funds for acquisition of companies, properties, expansion of operations, among others. These balances are substantially eliminated in the consolidated financial statements. There is no maturity or monetary restatement on these balances.
- (d) Lease of properties owned by the controlling shareholders of Rede D'Or.
- (e) Onco Star SP was created in 2017 and, throughout the subsequent years, Rede D'Or provided funds for the acquisition of machinery and equipment, as part of the Company's operational routine.
- (f) On December 17, 2021, Hospital Nossa Senhora das Neves conducted a private issue of nonconvertible, single-series, registered debentures amounting to R\$185,000, maturing on December 18, 2023. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest is paid semiannually, and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.
  - On March 15, 2023, Hospital Nossa Senhora das Neves conducted the 2nd private issue of nonconvertible, single-series, registered debentures amounting to R\$158,200, maturing on March 15, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.
- (g) On December 17, 2021, Mederi Distribuidora e Importadora de Produtos para Saúde conducted a private issue of nonconvertible, single-series, registered debentures amounting to R\$7,530, maturing on December 18, 2023. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest is paid semiannually, and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On March 15, 2023, Mederi Distribuidora e Importadora de Produtos para Saúde conducted the 3rd private issue of nonconvertible, single-series, registered debentures amounting to R\$158,200, maturing on March 15, 2025. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

### Key management personnel compensation

The Company considers "Key management personnel" only the members of its Statutory Board and Board of Directors. At March 31, 2023 and 2022, key management personnel compensation is summarized as follows:

	03/31/2023	03/31/2022
Salaries and bonuses	25,857	30,516
Benefits	51	31
Share-based payment	10,751	10,402
	36,659	40,949

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 8. Investments

#### Breakdown and changes in investments - Individual

Company						Capital increase/				Merger of subsidiary	
Medise Medicina Diagnostico e Serviços S.A.   244,620   7,597   -   -   -   -   -   -   1   101   -   252,116   105,114   10		12/31/2022	Equity		Acquisition of		Canital				03/31/2023
Medise Medicina Diagnóstico e Serviços S.A.	Company			Dividends				Transfer	Other		
Hospital Esperança S.A.   4,277,885   55,448   (92,725)   60,770   (2,535)   4,292,843   806,8582   Note DO'r Participações S.A. (including goodwill)   137,298   4,908   (9,585)   11,090   -		,									
PMJ Empreendimentols   mobiliários   S.A.   842,601   6,891				-	-	-	-	-		-	
Note DO P Participações S.A. (Including goodwill)			55,448	(92,725)	-		-	-	(2,535)	-	
Deno D'O Chosologia S.A.   726.351   50.460				-	-	11,090	-	-	-	-	
Jenner S.A. (including goodwill)				(9,585)	-	-	-	-	-	-	
JMJB Diagnósticos e Serviços Hospitalares   40,861   217		726,351	50,460	-	-	-	-	-	-	-	776,811
Rodin Empreendimentos e Participações S.A.   123,313   (220)   -   34,667   -   -   157,760     157,				-	-	-	-	-	-	-	
Counta Empreendimentos Imobiliários Ltda.		40,861		-	-	-	-	-	-	-	41,078
Hospital Fluminense S.A. (including goodwill)	Rodin Empreendimentos e Participações S.A.	123,313	(220)	-	-	34,667	-	-	-	-	157,760
Cardial Serviços Médicos (including goodwill)  101/247 8,637  TJK Empreendimentos Hospitalares  18,323 486  18,7920 4,115 (12,398)  Villa Lobos Empreendimentos Imobiliários Ltda.  187,920 4,115 (12,398)  Villa Lobos Empreendimentos Imobiliários Ltda.  187,920 4,115 (12,398)  Villa Lobos Empreendimentos Imobiliários Ltda.  187,920 4,115 (12,398)  Villa Lobos Empreendimentos Imobiliários Ltda.  18,809  Villa Lobos Empreendimentos Imobiliários Ltda.  18,404  18,404  18,404  18,404  18,404  18,404  18,404  18,404  18,404  18,404  18,404  18,404  18,405  19,404  19,405  19,404  19,405  19,404  19,406  19,404  19,406  19,404  19,406  19,404  10,406  10				(11,014)	-	-	-	-	-	-	
TJK Empreendimentos Hospitalares				(26,495)	-	4,885	-	-	-	-	
Villa Lobos Empreendimentos Imobiliários Ltda.	Cardial Serviços Médicos (including goodwill)	101,247	8,637	-	-	-	-	-	-	-	109,884
Santa Luzia II Empreendimentos Imobiliários Ltda. 59,785 (124) - 1,226 60,887 Campinas Empreendimentos Imobiliários Ltda. 311,087 (1,806) - 25,236 331,917 Sator Empreendimentos e Participações Ltda 3,135,185 18,494 - 38,619 3,192,298 Rede D'or São Luiz Serviços Médicos S.A. 300,885 25,924 2,15 326,809 Climpia Projeto Rua do Rocio 86 SPE S.A. 599,424 4,625 - 2,115				-	-	-	-	-	-	-	
Campinas Empreedimentos Imobiliários Ltda         311,087         (1,806)         -         25,236         -         -         -         334,517           Sator Empreendimentos e Participações Ltda         31,5185         18,494         -         -         38,619         -         -         -         -         3,192,298           Red D Or São Luiz Serviços Médicos S.A.         300,885         25,924         -         -         -         -         -         -         326,809           Olimpia Projeto Rua do Rocio 86 SPE S.A.         599,424         4,625         -         -         2,115         -         -         -         606,164           Proncordis Protto Atendimento Cardiológico Ltda.         464         (3)         -         -         -         -         -         606,164           Laboratórios Richet         305,929         (3,582)         -         -         9,104         -         -         -         311,451           California Investimentos Imbiliários Ltda.         142,389         891         -         -         11,536         -         -         -         159,940           Hospital Aviceena S.A.         142,389         891         -         -         11,536         -         -	Villa Lobos Empreendimentos Imobiliários Ltda.		4,115	(12,398)	-	-	-	-	-	-	179,637
Sato   Empreendimentos e Participações Ltda   3,135,185   18,494   -   38,619   -   -   -   3,192,298   Rede D'or São Luiz Serviços Médicos S.A.   300,885   25,924   -   -   -   -   -   -   -   -   -	Santa Luzia II Empreendimentos Imobiliários Ltda.	59,785	(124)	-	-	1,226	-	-	-	-	60,887
Rede D'or São Luiz Serviços Médicos S.A. 300,885 25,924 326,809 Olimpia Projeto Rua do Rocio 86 SPE S.A. 599,424 4,625 2,1115 606,164 Proncordis Pronto Atendimento Cardiológico Ltda. 464 (3) 606,164 Proncordis Pronto Atendimento Cardiológico Ltda. 464 (3)	Campinas Empreendimentos Imobiliários Ltda.	311,087	(1,806)	-	-		-	-	-	-	334,517
Olimpia Projeto Rua do Rocio 86 SPE S.A.   599,424   4,625   -   2,115   -   -   -   -   606,164     Pronocrdis Pronto Atendimento Cardiológico Ltda.   464   (3)   -   -   -   -   -   -   -   -   -		3,135,185	18,494	-	-	38,619	-	-	-	-	3,192,298
Pronordis Pronto Atendimento Cardiológico Ltda.	Rede D'or São Luiz Serviços Médicos S.A.	300,885	25,924	-	-	-	-	-	-	-	326,809
Laboratórios Richet 305,929 (3,582) 9,104 311,451 California Investimentos Imobiliários Ltda. 59,940 59,940 Hospital Aviccena S.A. 142,389 891 111,536 59,940 Santa Luzia III 310,107 4,398	Olimpia Projeto Rua do Rocio 86 SPE S.A.	599,424	4,625	-	-	2,115	-	-	-	-	606,164
California Investimentos Imobiliários Ltda.  59,940 Hospital Aviccena S.A. 142,389 891 - 115,566 - 154,398 - 154,816 Santa Luzia III 310,107 4,398	Proncordis Pronto Atendimento Cardiológico Ltda.	464	(3)	-	-	-	-	-	-	-	461
Hospital Aviccena S.A.	Laboratórios Richet	305,929	(3,582)	-	-	9,104	-	-	-	-	311,451
Santa Luzia III Qualicorp Consultoria e Corretora de Seguros S.A. (a) 2,125,919 (5,941) (1,323)	California Investimentos Imobiliários Ltda.	59,940	-	-	-	-	-	-	-	-	59,940
Qualicorp Consultoria e Corretora de Seguros S.A. (a)         2,125,919         (5,941)         (1,323)         -         -         -         (1,632,305)         72         -         486,422           Clinica Médica São Remo         43,504         (1,813)         -         -         3,096         -         -         -         -         44,787           Casa de Saúde Laranjeiras S.A (Perinatal) (including goodwill)         926,298         8,151         -         3,535         -         -         -         -         937,984           Hospital Santa Cruz         400,555         6,215         (22,048)         -         10,390         -         -         -         -         395,112           Advance Plano de Saúde S.A.         42,397         1,977         -         -         -         -         -         -         44,374           Prisma Capital (a)         2         (19,686)         -         -         587         -         1,632,305         -         -         1,613,208           Traditio Companhia de Seguros (b)         4,006,589         57,567         -         -         -         -         -         152,001         -         4,216,157           Cia Saúde – SulAmérica (b)         3,020,712	Hospital Aviccena S.A.	142,389	891	-	-	11,536	-	-	-	-	154,816
Clínica Médica São Remo 43,504 (1,813) 3,096 44,787 Casa de Saúde Laranjeiras S.A (Perinatal) (including godwill) 926,298 8,151 3,535 937,984 Hospital Santa Cruz 400,555 6,215 (22,048) - 10,390 44,374 Advance Plano de Saúde S.A. 42,397 1,977 44,374 Prisma Capital (a) 2 (19,686) 587 - 1,632,305 1,613,208 Traditio Companhia de Seguros (b) 4,006,589 57,567 152,001 - 4,216,157 Cia Saúde – SulAmérica (b) 3,020,712 356 (9,024) 57,099 - 1,623,319 Other 1,655,999 2,965 (1,106) - 90,136 (10,205) - 1,737,789		310,107	4,398	-	-	-	(5,149)	-	-	-	309,356
Casa de Saúde Laranjeiras S.A (Perinatal) (including goodwill)  926,298  Hospital Santa Cruz  400,555  6,215  (22,048)  1,977  Prisma Capital (a)  7 2 (19,686)  7 3,535  7 7 7 7 1,632,305  7 3,535  7 7 7 7 1,632,305  7 1,632,3	Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,125,919	(5,941)	(1,323)	-	-	-	(1,632,305)	72	-	486,422
goodwill)  Hospital Santa Cruz  400,555  6,215  (22,048)  10,390  3957,944  Advance Plano de Saúde S.A.  Prisma Capital (a)  2 (19,686)  587  - 16,32,305  16,43,208  Traditio Companhia de Seguros (b)  4,006,589  57,567  152,001  7,006,589  57,567  152,001  5AEPAR Serv. E Partic (b)  5AEPAR Serv. E Partic (b)  7,546,682  1,556,999  2,965  1,106)  - 90,136  (10,205)  - 1,737,789	Clínica Médica São Remo	43,504	(1,813)	-	-	3,096	-	•	-	-	44,787
Same	Casa de Saúde Laranjeiras S.A (Perinatal) (including		0.454			2 525		-		-	027.004
Advance Plano de Saúde S.A. 42,397 1,977 44,374 Prisma Capital (a) 2 (19,686) 587 - 1,632,305 1,613,208 Traditio Companhia de Seguros (b) 4,006,589 57,567 152,001 - 4,216,157 Cia Saúde - SulAmérica (b) 3,020,712 356 (9,024) 116,875 - 3,128,919 SAEPAR Serv. E Partic (b) 1,546,682 19,538 57,099 - 1,623,319 Other 1,655,999 2,965 (1,106) - 90,136 (10,205) - 1,737,789	goodwill)	926,298	0,131	-	-	3,333	-		-		937,904
Prisma Capital (a)     2     (19,686)     -     -     587     -     1,632,305     -     -     1,613,208       Traditio Companhia de Seguros (b)     4,006,589     57,567     -     -     -     -     -     152,001     -     4,216,157       Cia Saúde - SulAmérica (b)     3,020,712     356     (9,024)     -     -     -     -     116,875     -     3,128,919       SAEPAR Serv. E Partic (b)     1,546,682     19,538     -     -     -     -     57,099     -     1,623,319       Other     1,655,999     2,965     (1,106)     -     90,136     -     -     (10,205)     -     1,737,789	Hospital Santa Cruz	400,555	6,215	(22,048)	-	10,390	-	-	-	-	395,112
Traditio Companhia de Seguros (b)     4,006,589     57,567     -     -     -     -     -     152,001     -     4,216,157       Cia Saúde – SulAmérica (b)     3,020,712     356     (9,024)     -     -     -     -     116,875     -     3,128,919       SAEPAR Serv. E Partic (b)     1,546,682     19,538     -     -     -     -     57,099     -     1,623,319       Other     1,655,999     2,965     (1,106)     -     90,136     -     -     (10,205)     -     1,737,789	Advance Plano de Saúde S.A.	42,397	1,977	•	-	-	-	-	-	-	44,374
Cia Saúde – SulAmérica (Ď)       3,020,712       356       (9,024)       -       -       -       -       -       116,875       -       3,128,919         SAEPAR Serv. E Partic (b)       1,546,682       19,538       -       -       -       -       -       57,099       -       1,623,319         Other       1,655,999       2,965       (1,106)       -       90,136       -       -       (10,205)       -       1,737,789	Prisma Capital (a)	2	(19,686)	-	-	587	-	1,632,305	-	-	1,613,208
SAEPAR Serv. E Partic (b)     1,546,682     19,538     -     -     -     -     -     57,099     -     1,623,319       Other     1,655,999     2,965     (1,106)     -     90,136     -     -     (10,205)     -     1,737,789	Traditio Companhia de Seguros (b)	4,006,589	57,567	-	-	-	-	-	152,001	-	4,216,157
Other	Cia Saúde – SulAmérica (b)	3,020,712	356	(9,024)	-	-	-	-	116,875	-	3,128,919
Other	SAEPAR Serv. E Partic (b)	1,546,682	19,538	-	-	-	-	-	57,099	-	1,623,319
		1,655,999	2,965	(1,106)	-	90,136	-	-	(10,205)	-	1,737,789
		26,271,987			-	306,992	(5,149)	-		-	26,986,356

<sup>(</sup>a) On January 2, 2023, Rede D'Or entered into an agreement under which it transferred the management of shares representing 19.85% of the voting and total capital of Qualicorp Consultoria e Corretora de Seguros S.A. ("Qualicorp") that it held to Prisma Capital ("Prisma"). Rede D'Or transferred the shares representing 19.85% interest in Qualicorp to a new company 100% owned by Rede D'Or called "PrismaQuali Gestão Ativa de Participações S.A." ("PrismaQuali Gestão Ativa").

<sup>(</sup>b) Restated due to change in accounting practice, as described in Notes 2.2. and 2.3.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2022	Equity pickup	Dividends	Acquisition of equity interest	Capital increase/ Future capital contribution	Capital reduction	Transfer	Other	Merger	03/31/2023
Onco Star	(259,546)	(16,377)	_	-	-		_	(4,480)	_	(280,403)
Centro Hospitalar São Marcos S.A.	(13,662)	(14)	-	-	-	-	-	1,507	-	(12,169)
Hospital São Marcos (including goodwill)	(83,865)	(2,175)	-	-	1,297	-	-	· -	-	(84,743)
Rede D'or Finance	(151,106)	(3,705)	-	-	· -	-	-	-	-	(154,811)
Other	(865)	•	-	-	-	-	-	865	-	•
	(509,044)	(22,271)	-	-	1,297	-	-	(2,108)	-	(532,126)
Equity pickup		262,767						•		

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2021	Equity pickup	Dividends	Capital increase/ Future capital contribution	Capital reduction	Transfer	Other	03/31/2022
Medise Medicina Diagnóstico e Serviços S.A.	232,371	4,686	-	-	-	-	-	237,057
Hospital Esperança S.A.	2,880,695	72,305	-	655,517	-	-	(2,535)	3,605,982
Hospital São Marcos (including goodwill)	(88,543)	(2,898)		1,979	<del>.</del>	70,663	18,799	<del>-</del>
PMJ Empreendimentos Imobiliários S.A.	796,223	5,642	(7,636)	8,006	(1,826)	-	2	800,411
Norte D'Or Participações S.A. (including goodwill)	134,796	2,207	(11,484)	-	=	-	-	125,519
Onco D'Or Oncologia S.A.	592,405	23,248	-	-	-	-	-	615,653
Jenner S.A. (including goodwill)	173,729	8,436	-	-	-	-	-	182,165
JMJB Diagnósticos e Serviços Hospitalares	42,235	(1,091)	-	-	-	-	-	41,144
Rodin Empreendimentos e Participações S.A.	75,431	(23)	-	2,030	-	-	-	77,438
Quinta Empreendimentos Imobiliários Ltda.	58,993	2,853	-	-	-	-	-	61,846
Hospital Fluminense S.A. (including goodwill)	268,506	(5,478)	(7,355)	4,597	-	-	-	260,270
Cardial Serviços Médicos (including goodwill)	84,595	6,952	-	-	-	-	-	91,547
Hospital Santa Helena S.A. (including goodwill)	494,493	1,386	(11,366)	6,035	-	-	-	490,548
TJK Empreendimentos Hospitalares	18,235	369	-	-	(1,598)	-	-	17,006
Villa Lobos Empreendimentos Imobiliários Ltda.	187,216	3,432	(7,434)	-	(7,205)	-	-	176,009
Santa Luzia II Empreendimentos Imobiliários Ltda.	56,252	(78)	-	878	-	-	-	57,052
Campinas Empreendimentos Imobiliários Ltda.	115,290	(2,142)	-	26,781	-	-	-	139,929
Sator Empreendimentos e Participações Ltda	2,377,506	(12,470)	-	448,596	-	-	-	2,813,632
Rede D'or Finance	(129,440)	(17,112)	-	-	-	146,552	-	-
Rede D'or São Luiz Serviços Médicos S.A.	236,110	10,661	-	5,142	-	-	-	251,913
Olimpia Projeto Rua do Rocio 86 SPE S.A.	447,447	(77)	-	23,494	-	-	-	470,864
Proncordis Pronto Atendimento Cardiológico Ltda.	261	(5)	-	219	-	-	-	475
Maximagem - Diagnóstico por Imagem Ltda. (including goodwill)	2,611	-	-	-	-	-	(2,611)	-
Laboratórios Richet	270,566	579	-	8,042	-	-	-	279,187
California Investimentos Imobiliários Ltda.	59,940	-	-	· -	-	-	-	59,940
Hospital Aviccena S.A.	133,592	2,721	(13,836)	4,039	-	-	-	126,516
Santa Luzia III	305,087	2,194	`	· -	(10,561)	-	-	296,720
Qualicorp Consultoria e Corretora de Seguros S.A.	2,129,020	6.032	-	-		-	(34,713)	2,100,339
Clínica Médica São Remo	37.538	(1,987)	-	4,599	-	-	-	40.150
Casa de Saúde Laranjeiras S.A (Perinatal) (including goodwill)	895,544	3,959	(10,233)	25,289	-	-	-	914,559
Hospital Santa Cruz	356,751	3,845	`	19,693	-	_	_	380,289
Advance Plano de Saúde S.A.	35,458	1,046	_	2,805	-	_	_	39,309
Other	1.305.496	(1.137)	(3,043)	126.111	(684)	-	9,941	1.436.684
	14,586,409	118,055	(72,387)	1,373,852	(21,874)	217,215	(11,117)	16,190,153

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2021	Equity pickup	Dividends	Acquisition of equity interest	Capital increase/ Future capital contribution	Transfer	Other	Merger	03/31/2022
Onco Star	(200,323)	(15,276)	-	-	-	-	-	-	(215,599)
Centro Hospitalar São Marcos S.A.	(13,380)	(21)	-	-	-	-	-	-	(13,401)
Hospital São Marcos	-	-	-	-	-	(70,663)	-	-	(70,663)
Rede D'or Finance	-	-	-	-	-	(146,552)	-	-	(146,552)
Other	(412)	(112)	-	-	-	-	-	-	(524)
	(214,115)	(15,409)	-	-	-	(217,215)	-	-	(446,739)
Equity pickup		102,646							<del>.</del>

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 8. Investments (Continued)

### Breakdown of and changes in investments - Consolidated

		Equity	Acquisition of		Capital increase/ Future capital			
Company	12/31/2022	pickup	equity interest	Dividends	contribution	Transfer	Other	03/31/2023
JMJB Diagnósticos e Serviços Hospitalares S.A.	40,861	217	_	-	-	-	-	41,078
Instituto de Radioterapia do Vale do Paraíba Ltda.	43,689	1,499	-	-	-	-	(408)	44,780
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,125,919	(25,589)	-	(1,323)	-	-	74	2,099,081
Eldorado do Sul Participações Ltda.	22,616	1,892	-	-	-	-	490	24,998
Sharecare Brasil Serviços de Consult. Ltda.	9,662	(1,778)	-	-	-	-	-	7,884
Sul América Investimentos Distribuidora de Títulos e								
Valores Mobiliários S.A. (SAMI)	78,242	2,457	-	-	-	-	-	80,699
Other	232,412	2,636	-	(3,900)	12,250	-	(3,979)	239,419
	2,553,401	(18,666)	-	(5,223)	12,250	-	(3,823)	2,537,939

Company	12/31/2021	Equity pickup	Dividends	Capital increase/ Future capital contribution	Other	03/31/2022
IMID Diagnásticas a Caminas Haspitalares C A	42.225	(4,004)				44 4 4 4
JMJB Diagnósticos e Serviços Hospitalares S.A.	42,235	(1,091)	-	-	-	41,144
Instituto de Radioterapia do Vale do Paraíba Ltda.	43,076	804	(1,500)	-	(132)	42,248
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,129,020	6,032	-	-	(34,713)	2,100,339
Eldorado do Sul Participações Ltda.	19,005	703	-	-	-	19,708
Other	92,503	2,630	-	19,350	14,900	129,383
_	2,325,839	9,078	(1,500)	19,350	(19,945)	2,332,822

<sup>(</sup>a) Based on the shareholders' agreement entered into in November 2019, considering the nominations to the Executive Board and Board of Directors that the Company is entitled to, it was concluded that Rede D'Or has significant influence over Qualicorp; therefore, it records the investment using the equity method. Considering that Qualicorp's financial information as of March 31, 2023 is not yet available, the Company recognized the equity pickup until December 31, 2022.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

Summary of information of main subsidiaries

				03/31/20	23			03/31/2022
	%	% Voting				Operating income	P&L for the	P&L for the
	Total	capital	Assets	Liabilities	Equity	(expenses)	year	year
Direct and indirect subsidiaries								
Medise Medicina Diagnóstico e Serviços S.A. ("Medise")	98.00	98.00	366,252	96,804	269,448	12,545	8,478	26,248
Hospital Esperança S.A. ("Esperança")	100.00	100.00	7,407,554	2,996,539	4,411,015	87,907	21,435	136,681
PMJ Empreendimentos Imobiliários S.A.	100.00	100.00	902,622	41,012	861,610	7,761	6,898	64
Norte D'Or Participações S.A.	100.00	100.00	111,700	7,433	104,267	4,573	4,913	6,763
Onco D'Or Oncologia S.A.	98.87	98.87	619,477	173,985	445,492	72,959	49,266	34,394
Jenner S.A.	91.24	91.24	393,503	2,000	391,503	45,456	39,774	27,764
Rodin Empreendimentos e Participações S.A.	100.00	100.00	165,233	7,498	157,735	(218)	(221)	(329)
Quinta Empreendimentos Imobiliários Ltda.	100.00	100.00	65,725	1,543	64,182	3,619	3,498	17,073
Hospital Fluminense S.A.	100.00	100.00	407,595	145,234	262,361	2,413	2,133	942
Cardial Serviços Médicos Ltda.	89.44	89.44	107,944	31,048	76,896	14,119	8,637	17,209
Hospital Santa Helena S.A.	100.00	100.00	-	-	-	-	-	4,774
TJK Empreendimentos Imobiliários Ltda.	100.00	100.00	19,829	1,008	18,821	472	487	774
Villa Lobos Empreendimentos Imobiliários S.A.	100.00	100.00	180,965	1,109	179,856	4,314	4,119	19,085
Santa Luzia II Émp. Imobiliários Ltda.	100.00	100.00	65,428	4,491	60,937	(124)	(124)	(320)
Campinas Empreendimentos Imob.	100.00	100.00	338,340	3,777	334,563	(1,775)	(1,807)	(232)
Sator Empreendimentos e Participações Ltda.	100.00	100.00	•	(676,630)	676,630	18,513	18,513	(33,228)
Rede D'Or Finance	100.00	100.00	6,877,140	7,031,950	(154,810)	•	(3,705)	22,285
Rede D'Or São Luiz Serviços Médicos S.A.	100.00	100.00	425,631	98,606	327,025	37,964	25,950	7,666
Olimpia Projeto Rua do Rocio 86 SPE S.A.	100.00	100.00	607,035	533	606,502	5,558	4,630	(28)
Proncordis Pronto Atendimento Cardiológico Ltda.	100.00	100.00	7,111	477	6,634	(202)	(202)	(1,110)
Laboratórios Richet	100.00	100.00	179,935	77,398	102,537	(7,185)	(5,950)	(4,298)
Onco Star SP Oncologia Ltda.	75.00	75.00	931,887	1,306,070	(374,183)	(27,985)	(16,377)	(69,574)
Centro Hospitalar São Marcos S.A.	100.00	100.00	20	5,877	(5,857)	(12)	(14)	(274)
Hospital Aviccena S.A.	100.00	100.00	146,029	50,642	95,387	1,887	892	11,517 <sup>′</sup>
Santa Luzia IIII Empreendimentos Imobiliários Ltda.	100.00	100.00	312,606	2,944	309,662	4,649	4,402	(2,244)
Café Verde	100.00	100.00	6,963	6,957	6	(110)	(594)	(7,117)
Hospital São Marcos	100.00	100.00	193,871	289,150	(95,279)	(1,334)	(2,175)	4,746
Clínica Médica São Remo	100.00	100.00	60,545	17,719	42,826	(1,466)	(1,814)	(5,726)
California Investimentos Imobiliários Ltda.	100.00	100.00	59,999	-	59,999	(.,,	(.,,	-
Casa de Saúde Laranjeiras S.A (Perinatal)	100.00	100.00	324,449	67,604	256,845	6,142	8,159	(681)
Hospital Santa Cruz	100.00	100.00	325,537	183,869	141,668	9,833	4,894	7,084
Advance Plano de Saúde S.A.	100.00	100.00	57,287	12,798	44,489	1,412	1,979	7,348
GSH Corp Participações S.A. (Lorem)	50.00	50.00	768,771	636,906	131,865	22,574	1,393	9,326
Traditio Companhia de Seguros (a)	100.00	100.00	6,213,636	474,805	5,738,831	(10,548)	78,934	-
Cia Saúde – SulAmérica (a)	100.00	100.00	16,381,895	9,681,847	6,700,048	37,465	4,876	_
SAEPAR Serviços e particpações (a)	100.00	100.00	1,619,544	7,828	1,611,716	18,682	19,538	_
.(a) Restated due to change in accounting practice Note 2,1.	.00.00	.00.00	.,0.0,0	.,020	7,011,710	10,002	.0,000	

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 8. Investments (Continued)

### Summary of the associates' and joint ventures' information

_				03/31/2023				03/31/2022
	%	%				Operating income	P&L for the	P&L for the
_	Total	Voting capital	Assets	Liabilities	Equity	(expenses)	year	year
Companies recognized by the equity method in the consolidated								
financial statements								
JMJB Diagnósticos e Serviços Hospitalares S.A.	50	50	92,125	9,785	82,340	(2,746)	(1,374)	(1,091)
Instituto de Radioterapia do Vale do Paraíba Ltda.	50	50	36,112	17,790	18,322	12,394	5,330	805
Eldorado do Sul Participações Ltda.	33.33	33.33	43,256	-	43,256	10,835	3,611	703
Qualicorp Consultoria e Corretora de Seguros S.A. (a)/(b)	25.85	25.85	4,512,028	3,155,434	1,356,594	(a)	(a)	(b)
Sharecare Brasil Serviços de Consult. Ltda.	49	49	24,606	10,773	13,833	(3,600)	(1,778)	-
Sul América Investimentos Distribuidora de Títulos e Valores								
Mobiliários S.A. (SAMI)	49	49	174,240	20,414	153,826	4,129	2,457	-

<sup>(</sup>a) The Company recognized equity pickup until December 31, 2022.

<sup>(</sup>b) Qualicorp's 2022 financial information was not available on the issue date of the financial information as at March 31, 2023; therefore, management used information publicly available at that time.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 9. Property and equipment

### Balance breakdown

		Individual						
			03/31/2023			12/31/2022		
	Depreciation		Accumulated	Net		Accumulated	Net	
Description	rate	Cost	depreciation	amount	Cost	depreciation	amount	
Hospital machinery and equipment	12% to 20%	1,542,925	(1,195,588)	347,337	1,485,605	(1,152,009)	333,596	
Surgical instruments	20%	124,789	(57,905)	66,884	122,273	(53,419)	68,854	
Machinery and equipment	20%	584,290	(471,302)	112,988	564,773	(453,248)	111,525	
Buildings	2.5% to 4%	843,248	(224,388)	618,860	827,109	(215,725)	611,384	
Improvements in own buildings	4%	335,104	(149,123)	185,981	328,716	(145,846)	182,870	
Leasehold improvements	3% to 4%	2,198,338	(571,161)	1,627,177	2,071,940	(550,296)	1,521,644	
Furniture and fixtures	10%	230,624	(161,885)	68,739	227,323	(156,051)	71,272	
Vehicles	20%	5,162	(4,245)	917	5,162	(4,200)	962	
Facilities	10%	141,541	(80,834)	60,707	138,789	(78,009)	60,780	
Land	-	150,699	•	150,699	150,699	-	150,699	
Construction in progress	-	1,236,629	-	1,236,629	1,091,391	-	1,091,391	
Other	5% to 10%	14,398	(6,515)	7,883	14,228	(6,398)	7,830	
		7,407,747	(2,922,946)	4,484,801	7,028,008	(2,815,201)	4,212,807	

		Consolidated						
	_		03/31/2023			12/31/2022	<u>.</u>	
De	preciation		Accumulated	Net		Accumulated	Net	
Description	rate	Cost	depreciation	amount	Cost	depreciation	amount	
Hospital machinery and equipment	2% to 20%	2,895,662	(1,903,196)	992,466	2,793,325	(1,796,052)	997,273	
Surgical instruments	20%	291,118	(133,619)	157,499	286,300	(124,560)	161,740	
Machinery and equipment	20%	1,075,132	(772,231)	302,901	1,047,737	(737,044)	310,694	
Buildings 2	.5% to 4%	3,217,754	(581,210)	2,636,544	3,184,273	(547,761)	2,636,512	
Improvements in own buildings	4%	585,054	(211,359)	373,695	577,485	(204,682)	372,803	
Leasehold improvements	3% to 4%	3,405,762	(818,640)	2,587,122	3,145,996	(803,341)	2,342,655	
Furniture and fixtures	10%	469,799	(291,352)	178,447	463,911	(279,331)	184,580	
Vehicles	20%	28,842	(25,195)	3,647	28,512	(24,350)	4,162	
Facilities	10%	287,813	(145,039)	142,774	273,788	(139,451)	134,337	
Land	-	1,178,000	•	1,178,000	1,168,390	-	1,168,390	
Construction in progress	-	3,055,992	-	3,055,992	2.742,104	-	2,742,104	
Other 5	5% to 10%	59,989	(8,748)	51,241	59,628	(8,592)	51,036	
	_	16,550,917	(4,890,589)	11,660,328	15,771,449	(4,665,163)	11,106,286	

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 9. Property and equipment (Continued)

### Changes - Individual

	12/31/2022	Additions	Transfers	03/31/2023
Cost	•			
Hospital machinery and equipment	1,485,605	57,320	-	1,542,925
Surgical instruments	122,273	2,516	-	124,789
Machinery and equipment	564,773	19,517	-	584,290
Buildings	827,109	843	15,296	843,248
Improvements in own buildings	328,716	-	6,388	335,104
Leasehold improvements	2,071,940	63,538	62,860	2,198,338
Furniture and fixtures	227,323	3,301	-	230,624
Vehicles	5,162	-	-	5,162
Facilities	138,789	2,752	-	141,541
Land	150,699	-	-	150,699
Construction in progress	1,091,391	229,782	(84,544)	1,236,629
Other	14,228	170	•	14,398
	7,028,008	379,739	-	7,407,747
Depreciation				
Hospital machinery and equipment	(1,152,009)	(43,579)	-	(1,195,588)
Surgical instruments	(53,419)	(4,486)	-	(57,905)
Machinery and equipment	(453,248)	(18,054)	-	(471,302)
Buildings	(215,725)	(8,663)	-	(224,388)
Improvements in own buildings	(145,846)	(3,277)	-	(149,123)
Leasehold improvements	(550,296)	(20,865)	-	(571,161)
Furniture and fixtures	(156,051)	(5,834)	-	(161,885)
Vehicles	(4,200)	(45)	-	(4,245)
Facilities	(78,009)	(2,825)	-	(80,834)
Other	(6,398)	(117)	-	(6,515)
	(2,815,201)	(107,745)	-	(2,922,946)
Property and equipment, net	4,212,807	271,994	-	4,484,801

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 9. Property and equipment (Continued)

# Changes - Individual (Continued)

	12/31/2021	Additions	Transfers	03/31/2022
Cost				
Hospital machinery and equipment	1,252,068	38,137	-	1,290,205
Surgical instruments	85,004	9,107	-	94,111
Machinery and equipment	509,370	1,551	-	510,921
Buildings	638,834	-	-	638,834
Improvements in own buildings	321,254	-	2,817	324,071
Leasehold improvements	1,787,733	869	49,881	1,838,483
Furniture and fixtures	204,339	3,168	-	207,507
Vehicles	4,530	-	-	4,530
Facilities	128,148	3,920	-	132,068
Land	150,699	-	-	150,699
Construction in progress	754,901	213,554	(52,698)	915,757
Other	13,784	-	-	13,784
	5,850,664	270,306	-	6,120,970
Depreciation				
Hospital machinery and equipment	(911,058)	(48,985)	-	(960,043)
Surgical instruments	(41,688)	(1,829)	-	(43,517)
Machinery and equipment	(354,741)	(16,353)	-	(371,094)
Buildings	(177,551)	(6,811)	-	(184,362)
Improvements in own buildings	(122,710)	(8,116)	-	(130,826)
Leasehold improvements	(470,412)	(17,876)	-	(488,288)
Furniture and fixtures	(128,399)	(5,198)	-	(133,597)
Vehicles	(3,776)	(50)	-	(3,826)
Facilities	(67,225)	(2,563)	-	(69,788)
Other	(5,956)	(103)	-	(6,059)
	(2,283,516)	(107,884)	-	(2,391,400)
Property and equipment, net	3,567,148	162,422	-	3,729,570

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 9. Property and equipment (Continued)

### Changes - Consolidated

				Business	
	12/31/2022	Additions	Transfers	combination	03/31/2023
Cost					
Hospital machinery and equipment	2,793,325	100,254	-	2,083	2,895,662
Surgical instruments	286,300	4,818	-	-	291,118
Machinery and equipment	1,047,738	27,391	-	3	1,075,132
Buildings	3,184,273	18,185	15,296	-	3,217,754
Improvements in own buildings	577,485	622	6,947	-	585,054
Leasehold improvements	3,145,996	148,415	111,351	-	3,405,762
Furniture and fixtures	463,911	5,876	-	12	469,799
Vehicles	28,512	330	-	-	28,842
Facilities	273,788	14,012	-	13	287,813
Land	1,168,390	9,600	-	10	1,178,000
Construction in progress	2,742,104	447,482	(133,594)	-	3,055,992
Other	59,627	362	-	-	59,989
	15,771,449	777,347	-	2,121	16,550,917
Depreciation					
Hospital machinery and equipment	(1,796,052)	(106,114)	-	(1,030)	(1,903,196)
Surgical instruments	(124,560)	(9,059)	-	-	(133,619)
Machinery and equipment	(737,044)	(35,187)	-	-	(772,231)
Buildings	(547,761)	(33,449)	-	-	(581,210)
Improvements in own buildings	(204,682)	(6,677)	-	-	(211,359)
Leasehold improvements	(803,341)	(15,299)	-	-	(818,640)
Furniture and fixtures	(279,331)	(12,013)	-	(8)	(291,352)
Vehicles	(24,350)	(845)	-	-	(25,195)
Facilities	(139,451)	(5,584)	-	(4)	(145,039)
Other	(8,591)	(157)	-	-	(8,748)
	(4,665,163)	(224,384)	-	(1,042)	(4,890,589)
Property and equipment, net	11,106,286	552,963	-	1,079	11,660,328

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### **9. Property and equipment** (Continued)

<u>Changes - Consolidated</u> (Continued)

				Business	
	12/31/2021	Additions	Transfers	combination	03/31/2022
Cost					
Hospital machinery and equipment	2,357,872	72,907	-	34,735	2,465,514
Surgical instruments	218,932	11,309	-	11,200	241,441
Machinery and equipment	875,457	22,046	-	4,860	902,363
Buildings	2,594,919	3,269	-	41,618	2,639,806
Improvements in own buildings	555,606	1,238	10,776	164	567,784
Leasehold improvements	2,571,492	18,443	94,554	-	2,684,489
Furniture and fixtures	386,554	7,786	-	9,844	404,184
Vehicles	19,454	168	-	558	20,180
Facilities	217,396	4,941	-	1,156	223,493
Land	1,019,026	22,114	-	1,548	1,042,688
Construction in progress	1,809,763	538,362	(105,330)	1,163	2,243,958
Other	58,156	28	-	-	58,184
	12,684,627	702,611	-	106,846	13,494,084
Depreciation					
Hospital machinery and equipment	(1,346,762)	(99,646)	-	(24,527)	(1,470,935)
Surgical instruments	(89,720)	(5,023)	-	(7,812)	(102,555)
Machinery and equipment	(566,903)	(27,658)	-	(3,064)	(597,625)
Buildings	(395,047)	(26,438)	-	(35,879)	(457,364)
Improvements in own buildings	(165,574)	(12,583)	-	(81)	(178,238)
Leasehold improvements	(662,654)	(29,625)	-	-	(692,279)
Furniture and fixtures	(215,397)	(10,339)	_	(7,038)	(232,774)
Vehicles	(18,650)	(634)	-	(144)	(19,428)
Facilities	(118,928)	(4,576)	-	(576)	(124,080)
Other	(7,942)	(138)	-	` -	(8,080)
	(3,587,577)	(216,660)	-	(79,121)	(3,883,358)
Property and equipment, net	9,097,050	485,951	-	27,725	9,610,726

Significant changes for the periods ended March 31, 2023 and 2022 were as follows:

### 2023

- (i) Purchases of hospital machinery and equipment for the beginning of operation of Hospital São Luiz Campinas and reformulation and remodeling of Hospital Aliança and Hospital Aviccena.
- (ii) Expenses with improvements in the real properties of Hospital e Maternidade São Luiz Anália Franco and Hospital e Maternidade Itaim.
- (iii) Construction costs of hospitals Novo Barra and Memorial Star, and expansion and renovation works of Hospital São Luiz Itaim, Hospital Aliança and Hospital São Lucas.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### **9. Property and equipment** (Continued)

#### 2022

- (i) Additions relating to property and equipment from business combinations for the period, especially of Hospital Memorial Arthur Ramos and Hospital Aeroporto.
- (ii) Purchase of hospital machinery and equipment as part of the Company's operational routine, and reformulation and remodeling of Hospital São Luiz Itaim, Hospital e Maternidade Anália Franco and Hospital Gloria D'Or.

#### Capitalized borrowing costs

The Company capitalizes borrowing costs attributable to qualifying assets. At March 31, 2023, R\$62,209 (R\$36,369 at March 31, 2022) in interest on loans and financing were capitalized in Property and equipment, net of finance income from fundraising.

#### Impairment testing of property and equipment

Management has assessed the existence of events or changes in economic, operational or technological circumstances and has not identified any evidence that could indicate deterioration or impairment of property and equipment.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

# 10. Intangible assets

Finite useful life	1/2022
Software (a)         20%         207,362         232,828         700,496         732           Customer portfolio - SASA (a)         8% to 33%         198,670         207,635         198,670         207           Exclusive agreements         20%         31,452         32,512         261,408         27           Other         108         71,774         78           Indefinite useful life           Godwill         80,058         80,058         80,058         80           Acquisition of HMSL         668,339         30,595         30,595         30,595         30,595         30,595         30,595         30	
Customer portfolio - SASA (a)         8% to 33%         199,670         207,635         198,670         207           Exclusive agreements         20%         31,452         32,512         261,408         270           Other         -         108         71,774         76           Indefinite useful life         Goodwill           Acquisition of Copa D'Or         80,058         80,058         80,058         80           Acquisition of HMSL         668,339         668         30,595         30,	-
Exclusive agreements	2,325
Other         -         108         71,774         76           Indefinite useful life         Coodwill         80,058         30,059         30,595         30,595         30,595         30,595         30,595         30,595<	,635
Indefinite useful life   Goodwill	,023
Goodwill   Acquisition of Copa D'Or   80,058   80,058   80,058   80	3,169
Acquisition of Copa D'Or         80,058         80,058         80,058         80,058           Acquisition of HMSL         668,339         30,595	
Acquisition of HMSL         668,339         121,398         121,494         136,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692         38,692	
Acquisition of Hospital Brasil       121,398       121,3739       136,022       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,595       30,692       38,692       38,692       38,692       38,692       38,692       38,692       38,692       38,692       38,692       30,692       30,692       30,692       30,692       30,692       30,892       30,892       30,892       30,892       30,892       30,89	,058
Acquisition of Hospital Prontolinda         30,595         38,692         38	3,339
Acquisition of Vivalle         38,692         36,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646         156,646	
Acquisition of São Marcos       -       -       10,807       10         Acquisition of Santa Luzia       199,333       199,333       199,333       199,333       199         Acquisition of Sinisgalli       156,646       156,442       156,442       166,442       166,442       166,444       166,442       166,444       166,442       166,444       166,442       166,444       166,442       166,444       166,442       166,444       166,444       166,444       166,444       166,444       166,442       166,444       166,442       166,442       166,442       166,442       166,442       166,442	),595
Acquisition of Santa Luzia       199,333       199,646       156       166       156,646       156	3,692
Acquisition of Sinisgalli       156,646	),807
Acquisition of Hospital Esperança       -       -       -       28,450       28         Acquisition of Norte D'Or       -       -       -       28,450       28         Acquisition of IFOR       85,724       86,724       136,074       136,274       155,474 <td></td>	
Acquisition of Norte D'Or       -       -       28,450       28         Acquisition of IFOR       85,724       85,724       85       241,947	
Acquisition of IFOR       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       85,724       82,724       241,947       241,948       105,584 <th< td=""><td>3,450</td></th<>	3,450
Acquisition of Sino Brasileiro       241,947       136,074       136,074       136,074       105,584       105,584       105,584       105,584       105,584       105,584       105,584       105,584       105,584       105,584       105,584       106,585	5,724
Acquisition of Villa-Lobos     136,074     136,074     136,074     136,074       Acquisition of Bartira     105,584     105,584     105,584     105,584     105       Acquisition of Onco ABC/Cardeal/JLD     -     -     52,174     52       Acquisition of Oncoholding     -     -     159,445     155       Acquisition of Hospital Fluminense     -     -     10,658     10       Acquisition of Hospital Santa Helena     125,802     125,802     125     125       Acquisition of Acreditar     -     -     -     155,720     155       Acquisition of Memorial São Jose     112,528     112,528     112,528     112,528     112,528       Acquisition of Alpha-Med     -     -     43,815     43       Acquisition of CEHON     -     -     68,757     68       Acquisition of Maximagem     46,742     46,742     46,742     46       Acquisition of Ribeirão Pires     129,739     129,739     129,739     129,739       Acquisition of NEOH     -     -     33,422     33	,947
Acquisition of Bartira       105,584       155,425       155,445       155,485       155,485       155,485       115,580       112,5802       125,802 <t< td=""><td>5.074</td></t<>	5.074
Acquisition of Onco ABC/Cardeal/JLD       -       -       52,174       52         Acquisition of Oncoholding       -       -       -       159,445       158         Acquisition of Hospital Fluminense       -       -       -       10,658       10         Acquisition of Hospital Santa Helena       125,802       125,802       125,802       125,802       125,802       125,802       155,720       155         Acquisition of Acreditar       -       -       -       155,720       155       155       125,802       125,	5,584
Acquisition of Oncoholding       -       -       -       159,445       159,445         Acquisition of Hospital Fluminense       -       -       -       10,658       10         Acquisition of Hospital Santa Helena       125,802	2,174
Acquisition of Hospital Fluminense     -     -     10,658     10       Acquisition of Hospital Santa Helena     125,802     125,802     125,802     125       Acquisition of Acreditar     -     -     -     155,720     155       Acquisition of Memorial São Jose     112,528     112,528     112,528     112,528       Acquisition of Alpha-Med     -     -     -     43,815     43       Acquisition of CEHON     -     -     -     68,757     68       Acquisition of Maximagem     46,742     46,742     46,742     46       Acquisition of Ribeirão Pires     129,739     129,739     129,739     129,739       Acquisition of NEOH     -     -     33,422     33	,445
Acquisition of Hospital Santa Helena     125,802     125,802     125,802     125,802       Acquisition of Acreditar     -     -     -     155,720     155       Acquisition of Memorial São Jose     112,528     <	,658
Acquisition of Memorial São Jose     112,528     112,528     112,528     112,528       Acquisition of Alpha-Med     -     -     -     43,815     43       Acquisition of CEHON     -     -     -     68,757     68       Acquisition of Maximagem     46,742     46,742     46,742     46,742       Acquisition of Ribeirão Pires     129,739     129,739     129,739     129,739       Acquisition of NEOH     -     -     33,422     33	,802
Acquisition of Alpha-Med       -       -       43,815       43         Acquisition of CEHON       -       -       -       68,757       68         Acquisition of Maximagem       46,742       46,742       46,742       46,742       46,742       42         Acquisition of Ribeirão Pires       129,739        129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739       129,739<	,720
Acquisition of CEHON       -       -       68,757       68         Acquisition of Maximagem       46,742       46,742       46,742       46         Acquisition of Ribeirão Pires       129,739       129,739       129,739       129,739         Acquisition of NEOH       -       -       33,422       33	,528
Acquisition of Maximagem       46,742       46,742       46,742       46         Acquisition of Ribeirão Pires       129,739       129,739       129,739       129,739         Acquisition of NEOH       -       -       33,422       33	3,815
Acquisition of Ribeirão Pires         129,739         129,739         129,739         129,739           Acquisition of NEOH         -         -         33,422         33	3,757
Acquisition of NEOH 33,422 33	,742
	,739
Acquisition of JTO 12.567 12	3,422
	2,567
	3,956
· · · · · · · · · · · · · · · · · · ·	5,220
	3,089
	,363
	,232
	5,883 0,939
	1,833 1,833
	3,079
	),476
	5,580
	,,300 I,198
	,583
	5,555
·	,475
·	,139
	5,673
	,786
	,894
	,555
	,751
	,782

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 10. Intangible assets (Continued)

	Annual	Individual		Conso	lidated
	amortization rate	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Indefinite useful life					
Acquisition of Balbino		-	-	77,500	77,500
Acquisition of América		-	-	456,511	456,511
Acquisition of Serra Mayor		-	-	68,981	68,981
Acquisition of Biocor		-	-	620,347	620,347
Acquisition of Proncor		-	-	202,929	202,929
Acquisition of Santa Emilia		-	-	121,991	121,991
Acquisition of Hospital Nossa Senhora					
das Neves		-	-	326,634	326,634
Acquisition of HNSN Empreendimentos		-	-	34,790	34,790
Acquisition of Orthoservice		-	-	33,705	33,705
Acquisition of HNA Emp. E Participações		-	-	12,401	12,401
Acquisition of Hospital Novo Atibaia		-	-	173,019	173,020
Acquisition of Hospital Arthur Ramos		-	-	272,686	272,686
Acquisition of Hospital Santa Isabel		-	-	243,287	243,287
Acquisition of Hospital Aeroporto		-	-	171,511	171,511
Acquisition of Paraná Clínicas		-	-	284,701	284,701
Acquisition of Sompo Saúde		-	-	192,430	192,430
Acquisition of Prodent		-	-	106,681	106,681
Acquisition of SASA		1,820,625	1,820,625	1,820,625	1,820,625
Other goodwill		48,650	48,650	600,821	600,899
Trademark - SASA		2,068,575	2,068,575	2,068,575	2,068,575
Trademarks and patents (b)		190,810	190,810	190,810	190,810
. , ,		6,845,345	6,880,944	16,421,748	16,477,631

<sup>(</sup>a) Restated (notes 2.1).

#### Software development costs and licenses

These refer mainly to expenditures incurred with the development of technological infrastructure, applications, improvements in the companies' website and in operations of Sul América S.A., development of own systems, and acquisition of software licenses used in operations.

#### **Impairment**

Goodwill is allocated to the Cash-Generating Units (CGU) identified by management, i.e. each hospital, as shown in the table above.

The recoverable amount of a CGU is determined based on the calculation of value in use. Value in use calculations use cash flow projections based on financial budgets approved by management covering a five-year period.

<sup>(</sup>b) This mainly refers to the Hospital São Luiz trademark registered upon its acquisition in 2010.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 10. Intangible assets (Continued)

<u>Impairment</u> (Continued)

Discount rates represent the current market assessment of the risks specific to each CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Company and is derived from its weighted average cost of capital (WACC). The WACC takes into consideration both debt and equity. The cost of equity is derived from the expected return on investment by the investors. The cost of debt is based on the interest-bearing financing the Company is obliged to service. Segment-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data.

There is no indication of impairment of intangible assets to date.

## 11. Right of use

#### Balance breakdown

	Individual								
		03/31/2023			12/31/2022				
Description	Cost	Amortization	Net	Cost	Amortization	Net			
Hospital machinery and									
equipment	32,286	(24,649)	7,637	32,473	(23,701)	8,772			
Properties	2,994,184	(755,759)	2,238,425	2,949,485	(694,803)	2,254,682			
	3,026,470	(780,408)	2,246,062	2,981,958	(718,504)	2,263,454			
						_			
			Conso	lidated					
		03/31/2023			12/31/2022				
Description	Cost	Amortization	Net	Cost	Amortization	Net			
Hospital machinery and									
equipment	59,569	(43,670)	15,899	64,520	(44,620)	19,900			
Properties	3,827,465	(1,090,164)	2,737,301	3,808,087	(994,642)	2,813,445			
Vehicles	3,794	(2,854)	940	3,764	(2,509)	1,255			
	3,890,828	(1,136,688)	2,754,140	3,876,371	(1,041,771)	2,834,600			
		•		-	•				

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **11. Right of use** (Continued)

## Changes - Individual

	12/31/2022	Additions (a)	Write-offs (b)	Amortization	03/31/2023
Cost					
Hospital machinery and equipment	32,473	-	(187)	-	32,286
Properties	2,949,485	44,699	` -	-	2,994,184
	2,981,958	44,699	(187)	-	3,026,470
Amortization					
Hospital machinery and equipment	(23,701)	187	-	(1,135)	(24,649)
Properties	(694,803)	-	-	(60,956)	(755,759)
	(718,504)	187	-	(62,091)	(780,408)
Rights of use, net	2,263,454	44,886	(187)	(62,091)	2,246,062
	12/31/2021	Additions (a)	Amortization	03/31/2022	
Cost	12/31/2021	Additions (a)	Amortization	03/31/2022	
Cost Hospital machinery and equipment	<b>12/31/2021</b> 29,725	Additions (a)	Amortization -	<b>03/31/2022</b> 29,965	
			Amortization - -		
Hospital machinery and equipment	29,725	240	Amortization	29,965	
Hospital machinery and equipment	29,725 2,217,921	240 61,993	Amortization	29,965 2,279,914	
Hospital machinery and equipment	29,725 2,217,921	240 61,993	Amortization	29,965 2,279,914	
Hospital machinery and equipment Properties	29,725 2,217,921	240 61,993	Amortization (1,370)	29,965 2,279,914	
Hospital machinery and equipment Properties  Amortization	29,725 2,217,921 2,247,646	240 61,993	-	29,965 2,279,914 2,309,879	
Hospital machinery and equipment Properties  Amortization Hospital machinery and equipment	29,725 2,217,921 2,247,646 (16,258)	240 61,993	- - - (1,370)	29,965 2,279,914 2,309,879 (17,628)	

## Changes - Consolidated

			Write-offs		
	12/31/2022	Additions (a)	(b)	Amortization	03/31/2023
Cost	·				_
Hospital machinery and equipment	64,520	-	(4,951)	-	59,569
Properties	3,808,087	19,378	-	-	3,827,465
Vehicles	3,764	30	-	-	3,794
	3,876,371	19,408	(4,951)	-	3,890,828
Amortization					
Hospital machinery and equipment	(44,620)	-	3,474	(2,524)	(43,670)
Properties	(994,642)	-	-	(95,522)	(1,090,164)
Vehicles	(2,509)	-	-	(345)	(2,854)
	(1,041,771)	-	3,474	(98,391)	(1,136,688)
Rights of use, net	2,834,600	19,408	(1,477)	(98,391)	2,754,140

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **11. Right of use** (Continued)

Changes - Consolidated (Continued)

	12/31/2021	Additions (a)	Write-offs (b)	Business combinations	Amortization	03/31/2022
Cost						
Hospital machinery and						
equipment	58,540	783	(1,386)	-	-	57,937
Properties	3,227,816	110,433	-	81,323	-	3,419,572
	3,286,356	111,216	(1,386)	81,323	-	3,447,509
Amortization						
Hospital machinery and						
equipment	(31,501)	-	1,386	-	(3,020)	(33,135)
Properties	(630,408)	-	-	-	(85,175)	(715,583)
	(661,909)	-	1,386	-	(88,195)	(748,718)
Rights of use, net	2,624,447	111,216	-	81,323	(88,195)	2,728,791

<sup>(</sup>a) Additions referring to new agreements and renewals due to maturity.

The rights of use are amortized during the lease contract term and take into consideration the expected renewal, when management intends to exercise this right, and in accordance with the terms of the contracts.

In view of the taxation regimes applicable to insurance entities and health plan entities, which do not allow allocation of the Contribution Tax on Gross Revenue for Social Integration Program (PIS) and for Social Security Financing (COFINS) credits to be calculated on the depreciation of the right to use of leased assets, in accordance with CVM/SNC/SEP Memorandum Circular No. 02/2019, the credits of other entities that can be used are immaterial for disclosure.

## 12. Insurance contract assets and liabilities (Restated in note 2)

_		03/3	31/2023	12/31/2022		
Insurance contracts	Assets	Liabilities	Assets	Liabilities		
Long-term contracts (BBA/VFA)		163	14,622,557	-	14,843,724	
Short-term contracts (PAA)		53,501	697,388	149,508	298,616	
	=	53,664	15,319,945	149,508	15,142,340	
	Current Noncurrent	25,130 28,534	4,566,088 10,753,857	70,012 79,496	3,913,312 11,229,028	

<sup>(</sup>b) Write-offs referring to contract termination.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities - (Restated in note 2) (Continued)

### 12.1. Changes in assets or liabilities for remaining coverage and claims incurred relating to insurance contracts

Short-term contracts (PAA)

			Individ	ual		
	-	Liabilities				
		(assets) for				
		remaining				
		coverage	Liabilities for clair	ms incurred		
	•				Assets for	
			Estimated future		insurance	
		Less loss	cash flows at	Risk	acquisition	
	-	component	present value	adjustment	costs	Total
Insurance contract liabilities at 01/01/2023		(683,679)	2,849,478	95,789	(1,962,972)	298,616
Insurance contract (assets) at 01/01/2023		(83,224)	28,003	298	(94,585)	(149,508)
Total insurance contracts at 01/01/2023	•	(766,903)	2,877,481	96,087	(2,057,557)	149,108
Insurance revenue;	Note 18.2	(5,618,848)	-	-	-	(5,618,848)
Insurance costs	Note 19.2	776,663	3,658,739	6,052	-	4,441,454
Income from (loss on) insurance services	•	(4,842,185)	3,658,739	6,052	-	(1,177,394)
Finance income (costs) from insurance operations	•	-	141,432	3,376	-	144,808
Changes in other comprehensive income	_	-	942	(39)	-	903
Total changes that impact P&L or other comprehensive income	-	(4,842,185)	3,801,113	9,389	-	(1,031,683)
Premiums and other cash flows received from policyholders	(a)	5,647,495	-	-	-	5,647,495
Claims and other benefits paid to policyholders or their beneficiaries		-	(3,418,640)	-	-	(3,418,640)
Acquisition cash flows paid	(b)	(349,362)	-	-	(105,588)	(454,950)
Other expenses allocable to the insurance service	(c)	(244,596)	-	-	-	(244,596)
Total cash flows	•	5,053,537	(3,418,640)	-	(105,588)	1,529,309
Other	(d)	(3,176)	329	-	-	(2,847)
Insurance contract at 03/31/2023	•	(558,727)	3,260,283	105,476	(2,163,145)	643,887
Insurance contract liabilities at 03/31/2023	•	(487,923)	3,232,465	105,180	(2,152,334)	697,388
Insurance contract (assets) at 03/31/2023	_	(70,804)	27,818	296	(10,811)	(53,501)
(a) Any promium reimburgements were included in this line	·-		· · · · · · · · · · · · · · · · · · ·			

<sup>(</sup>a) Any premium reimbursements were included in this line.

<sup>(</sup>b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

<sup>(</sup>c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocable to insurance contracts not directly related to claims (such as costs with issue and maintenance of contracts, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in Insurance Costs line.

<sup>(</sup>d) Refers to the elimination of transactions between group companies

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities - (Restated in note 2) (Continued)

# 12.1. Changes in assets or liabilities for remaining coverage and claims incurred relating to insurance contracts (Continued)

Long-term contracts (BBA/VFA)

				Consolidated		
		Liabilities (	(assets) for			<u>.</u>
		remaining	coverage	Liabilities for cla	aims incurred	
				Estimated future cash		
		Less loss	Loss	flows at	Risk	
		component	components	present value	adjustment	Total
Insurance contract liabilities at 01/01/2023		13,308,357	1,067,575	452,983	14,809	14,843,724
Insurance contract (assets) at 01/01/2023		-	-	-	-	-
Total insurance contracts at 01/01/2023		13,308,357	1,067,575	452,983	14,809	14,843,724
Insurance revenue	Note 18.2	(751,414)	-	-	-	(751,414)
Insurance costs	Note 19.2	(732,639)	(14,277)	1,306,619	(888)	558,815
Income from (loss on) insurance services		(1,484,053)	(14,277)	1,306,619	(888)	(192,599)
Finance income (costs) from insurance operations		258,693	25,701	21,978	519	306,891
Changes in other comprehensive income		(350,805)	(50,368)	5	(6)	(401,174)
Total changes that impact P&L or other comprehensive income		(1,576,165)	(38,944)	1,328,602	(375)	(286,882)
Premiums and other cash flows received from policyholders	(a)	1,426,798	-	-	-	1,426,798
Claims and other benefits paid to policyholders or their beneficiaries		-	-	(1,337,033)	-	(1,337,033)
Acquisition cash flows paid	(b)	(17,993)	-	-	-	(17,993)
Private pension redemption and investment		11,814	-	-	-	11,814
Other expenses allocable to the insurance service	(c)	(18,034)	-	-	-	(18,034)
Total cash flows	(d)	1,402,585	-	(1,337,033)	-	65,552
Insurance contract liabilities/(assets) at 03/31/2023		13,134,777	1,028,631	444,552	14,434	14,622,394
Insurance contract liabilities at 03/31/2023		13,138,075	1,028,631	441,450	14,401	14,622,557
Insurance contract (assets) at 03/31/2023		(3,298)	-	3,102	33	(163)

<sup>(</sup>a) Any premium reimbursements were included in this line.

<sup>(</sup>b) Insurance acquisition cash flows paid after initial recognition of the respective group are adjusted to the liability/asset for remaining coverage. Only these groups are recognized Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

<sup>(</sup>c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocable to insurance contracts not directly related to claims (such as costs with issue and maintenance of contracts, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in Insurance Costs line.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities - (Restated in note 2) (Continued)

#### 12.2. Expected recognition of contractual service margin (CSM) in coming years

	Consolidated							
	Long-t	Long-term contracts (BBA/VFA)						
	2024	2025 a 2029	Após 2029	31/03/2023				
Release of CSM	78.835	326.597	683.670	1.089.102				

#### 12.3. Expected recognition of acquisition cash flows in coming years

	Consolidated						
_	Short-term contracts (PAA)						
	2024	2025 a 2029	Após 2029	12/31/2023			
Release of acquisition cash flow assets	667.394	1.334.924	160.827	2.163.145			

## 12.4. Guarantee for technical reserves

The subsidiaries regulated by Brazil's Private Insurance Supervisory Office ("SUSEP") and the Brazilian Regulatory Agency for Private Health Insurance and Plans ("ANS"), based on the regulatory guidance established by these agencies, have to keep assets offered as guarantee for their technical reserves (liabilities representing the obligations of these companies to the policyholders/beneficiaries), measured based on accounting standards defined by such regulators, which differ materially from CPC 50/IFRS 17.

The assets offered as guarantee for such technical reserves are recorded in clearinghouses in the technical reserve account. SUSEP and ANS may authorize the free movement of assets offered as guarantee by the regulated companies, provided that all financial requirements regarding the coverage of technical reserves and sufficiency of capital, as well as all accounting obligations, are met.

As at March 31, 2023, the subsidiaries regulated by SUSEP and ANS were compliant with the requirements for coverage of technical reserves.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures

				Initial					Indiv	idual	Conso	lidated
Transaction/Instrument	Index	Spread	Curren cy	principal (R\$)	Beginni ng	Maturity	Amortizati on	Guarantees	03/31/2023	12/31/2022	03/31/2023	12/31/2022
												_
FINEP	TJLP/Fixed rate	0.5%/4.0%	R\$	170,252	Feb/15	Sept/24	Monthly	Surety bond	36,116	42,147	36,116	42,147
Citibank II (a)	LIBOR	0.46%	US\$	301,200	Nov/18	Nov/23	Bullet	n/a	410,012	417,697	410,012	417,697
BofA II (a)	Fixed rate	0.88%	EUR€	400,520	Jun/21	Jun/25	Bullet	n/a	337,102	342,386	337,102	342,386
JP Morgan II (a)	Fixed rate	1.58%	US\$	520,000	Jul/20	Jul/25	Bullet	n/a	458,294	472,668	458,294	472,668
CCB Bank of China	100% do DI	1.20%	R\$	85,000	May/20	May/26	Bullet	n/a	89,902	86,812	89,902	86,812
Other	CDI/PRE/IPCA	-	R\$	n/a	n/a	Mar/28	Monthly	Credit rights	-	-	46,965	62,430
Debentures – 3rd issue – Esperança	110.85% of DI	-	R\$	1,000,000	Aug/17	Aug/24	Semiannual	n/a	-	-	378,289	522,162
Debentures – 4th issue – Esperança	100% of DI	1.27%/1.50%	R\$	1,000,000	Feb/18	Dec/27	Annually	n/a	-	-	1,026,637	989,740
Debentures – 10th issue (a)	Fixed rate	11.82%	R\$	1,628,100	Jan/18	Jan/28	Bullet	n/a	1,528,778	1,547,929	32,470	33,397
Debentures – 13th issue (b)	100% of DI	1.02%	R\$	1,400,000	Sept/18	Sept/24	Annually	n/a	1,401,215	1,447,970	1,401,215	1,447,970
Debentures – 14th issue (b)	106% of DI	-	R\$		Oct/2018	Oct/26	Annually	Property	526,609	508,744	526,609	508,744
Debentures – 17th issue 3 <sup>rd</sup> series (b)	100% of DI	0.79%	R\$	1,000,000	Jun/19	Jun/29	Annually	n/a	1,031,398	996,359	1,031,398	996,359
Debentures – 17th issue 2 <sup>nd</sup> series	100% of DI	1.25%	R\$	2,500,000	Dec/19	Dec/26	Annually	n/a	2,581,804	2,491,258	2,581,804	2,491,258
Debentures – 17th issue 1st series (a)	Fixed rate	8.75%	R\$	3,198,350	Apr/20	Jan/30	Bullet	n/a	2,310,455	2,348,988	-	-
Debentures – 19th issue 2 <sup>nd</sup> series	100% of DI	1.90%	R\$	2,500,000	Aug/21	Aug/31	Annually	n/a	2,521,021	2,613,659	2,521,021	2,613,659
Debentures – 19th issue 3 <sup>rd</sup> series	100% of DI	1.90%	R\$	1,500,000	Sept/21	Aug/31	Annually	n/a	1,512,613	1,568,196	1,512,613	1,568,196
Debentures - 23rd issue 1st series	100% of DI	1.40%	R\$	900,000	May/22	May/28	Bullet	n/a	942,485	909,095	942,485	909,095
Debentures – 23rd issue 2 <sup>nd</sup> series	100% of DI	1.90%	R\$	850,000	May/22	May/32	Annually	n/a	891,776	859,126	891,776	859,126
Debentures - 23rd issue 3 <sup>rd</sup> series	100% of DI	1.90%	R\$	625,000	May/22	May/32	Annually	n/a	655,718	631,710	655,718	631,710
Debentures - 25th issue 1st series	100% of DI	2.00%	R\$	450,000	Oct/22	Oct/32	Bullet	n/a	477,303	459,714	477,303	459,714
Debentures - 25th issue 2 <sup>nd</sup> series	100% of DI	1.95%	R\$	150,000	Oct/22	Oct/32	Annually	n/a	159,066	153,223	159,066	153,223
Debentures – 27th issue (c)	100% of DI	1.70%	R\$	1,100,000	Feb/23	Feb/30	Annually	n/a	1,106,469	-	1,106,469	-
Debentures (SULA) -6th issue	111.5% of DI	-	R\$	700,000	Apr/19	Apr/24	Annually	n/a	500,959	483,094	500,959	483,094
Debentures (SULA) – 8th issue 1st series	100% of DI	1.50%	R\$	233,000	Feb/21	Feb/24	Bullet	n/a	238,170	248,542	238,170	248,542
Debentures (SULA) - 8th issue 2 <sup>nd</sup> series	100% of DI	1.80%	R\$	467,000	Feb/21	Feb/26	Annually	n/a	480,691	498,763	480,691	498,763
Debentures (SULA) - 9th issue 1st series	100% of DI	1.50%	R\$	750,000	Nov/21	Nov/26	Annually	n/a	798,321	769,817	798,321	769,817
Debentures (SULA) – 9th issue 2 <sup>nd</sup> series	100% of DI	1.70%	R\$	750,000	Nov/21	Nov/28	Annually	n/a	798,945	770,041	798,945	770,041
Debentures GGSH	100% of DI	2.80%	R\$	360,000	Apr/21	Apr/26	Semiannual	n/a	· -	· -	375,277	363,519
Debentures GGSH	100% of DI	2.20%	R\$	70,000	Sept/22	Sept/26	Semiannual	n/a	-	-	72,971	71,327
Senior Notes I (a)	Fixed rate	4.95%	US\$	1,596,400	Jan/18	Jan/28	Bullet	n/a	-	-	2,400,517	2,487,890
Senior Notes II (a)	Fixed rate	4.50%	US\$	5.062.504	Jan/20	Jan/30	Bullet	n/a	-	-	3.140.952	3.232.075
Promissory note - 3rd issue	112.5% of DI	-	R\$	1,000,000	Apr/18	Apr/23	Bullet	n/a	1,429,593	1,379,354	1,429,593	1,379,354
Mortgage-backed Securities (CRIs) – 1st issue	99% of DI	-	R\$	662,837	Mar/18	Mar/23	Bullet	n/a		670,988	-	670,988
Mortgage-backed Securities (CRIs) - 2 <sup>nd</sup> issue	IPCA	6.06%	R\$	300,000	Jul/18	Jul/25	Bullet	n/a	390.181	387,137	390.181	387,137
Mortgage-backed Securities (CRIs) - 3rd issue 1st series	96.5% of DI	-	R\$	227.051	Dec/18	Dec/23	Bullet	n/a	233,249	226,374	233,249	226,374
Mortgage-backed Securities (CRIs) - 3rd issue 2 <sup>nd</sup> series	IPCA	4.66%	R\$	372,949	Dec/18	Dec/25	Bullet	n/a	480,680	464,601	480,680	464,601
Mortgage-backed Securities (CRIs) – 4 <sup>th</sup> issue 1st series	95.75% of DI	-	R\$	269,900	Feb/19	Feb/23	Bullet	n/a	-	280,300	-	280,300
Mortgage-backed Securities (CRIs) – 4 <sup>th</sup> issue 2 <sup>nd</sup> series	IPCA	3.93%	R\$	30,100	Feb/19	Feb/26	Bullet	n/a	38,222	37,735	38,222	37,735
Mortgage-backed Securities (CRIs) – 5 <sup>th</sup> issue	IPCA	3.45%	R\$	538,328	Sept/19	Aug/29	Annually	n/a	669,755	660,440	669,755	660,440
Mortgage-backed Securities (CRIs) – 6th issue (a)	IPCA	4.93%	R\$	1,500,000	May/21	May/36	Annually	n/a	1,349,793	1,298,515	1,349,793	1,298,515
Mortgage-backed Securities (CRIs) – 7th issue 1st series (a)	IPCA	5.58%	R\$	400,000	Dec/21	Dec/31	Annually	n/a	408,902	390,833	408,902	390,833

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures (Continued)

				Initial					Indiv	idual	Consol	lidated
Transaction/Instrument	Index	Spread	Currency	principal (R\$)	Beginning	Maturity	Amortization	Guarantees	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Mortgage-backed Securities (CRIs) – 7th issue 2 <sup>nd</sup> series (a)	IPCA	6.10%	R\$	600,000	Dec/21	Dec/36	Annually	n/a	589,497	567,891	589,497	567,891
Mortgage-backed Securities (CRIs) – 8th issue 2 <sup>nd</sup> series (a)	IPCA	5.83%	R\$	798,634	Jun/22	Jun/29	Bullet	n/a	799,673	762,652	799,673	762,652
Mortgage-backed Securities (CRIs) - 8th issue 3 <sup>rd</sup> series (a)	IPCA	6.01%	R\$	341,867	Jun/22	Jun/32	Annually	n/a	340,402	325,600	340,402	325,600
Mortgage-backed Securities (CRIs) - 9th issue 1st series (a)	IPCA	6.38%	R\$	30,000	Aug/22	Jul/29	Bullet	n/a	30,694	30,119	30,694	30,119
Mortgage-backed Securities (CRIs) – 9th issue 2 <sup>nd</sup> series (a)	IPCA	6.54%	R\$	70,000	Aug/22	Jul/32	Bullet	n/a	71,705	70,603	71,705	70,603
Mortgage-backed Securities (CRIs) - 9th issue 3 <sup>rd</sup> series (a)	IPCA	6.77%	R\$	400,000	Aug/22	Jul/37	Bullet	n/a	407,467	405,255	407,467	405,255
Mortgage-backed Securities (CRIs) - 10th issue 1st series (a)	100% of DI	0.75%	R\$	86,186	Dec/22	Dec/27	Bullet	n/a	87,522	84,612	87,522	84,612
Mortgage-backed Securities (CRIs) – 10th issue 2 <sup>nd</sup> series (a)	100% of DI	1.00%	R\$	176,323	Dec/22	Dec/29	Bullet	n/a	179,330	173,130	179,330	173,130
Mortgage-backed Securities (CRIs) - 10 <sup>th</sup> issue 3 <sup>rd</sup> series (a)	IPCA	6.79%	R\$	82,487	Dec/22	Dec/29	Bullet	n/a	84,005	80,174	84,005	80,174
Mortgage-backed Securities (CRIs) - 10th issue 4 <sup>th</sup> series (a)	IPCA	6.94%	R\$	55,004	Dec/22	Dec/32	Annually	n/a	55,775	53,351	55,775	53,351
				39,708,992	- •				29,441,667	29,017,602	33,076,512	32,883,225
								Current Noncurrent	4,074,680 25,366,987	4,707,009 24,310,593	4,392,958 28,683,554	4,973,066 27,910,159

- (a) As mentioned in Note 25, the Group enters into derivative financial instruments to hedge foreign exchange differences and interest rate (Fixed rate, Libor and IPCA) and has adopted the fair value hedge accounting as accounting practice; therefore, these debts are recorded at fair value through profit or loss.
- (b) As mentioned in Note 25, the Group enters into derivative financial instruments to hedge interest rate (CDI) and has adopted the cash flow hedge accounting as accounting practice; therefore, these debts are recorded at amortized cost and derivatives at fair value; the effective portion of the debt is recorded at fair value through other comprehensive income and any ineffective portion and interest at fair value through profit or loss.
- (c) On February 28, 2023, Rede D'Or paid in the 27th issue of debentures in a single series, in the amount of R\$1.1 billion, maturing on February 20, 2030. This debenture issue is indexed to the CDI + 1.70% p.a., payable semiannually. There are no guarantees.
- (d) Citibank II and Citibank III On April 27, 2023, Rede D'Or settled the loan taken out from Citibank in the amount of US\$80 million, maturing in a lump-sum payment on November 21, 2023, at Libor + 0.46% p.a. paid quarterly. The Company settled the derivative financial instrument for currency and interest rate hedging purposes, which translated the debt into Brazilian reais plus interest equivalent to 109% of the CDI p.a. Concomitantly, Rede D'Or took out a loan from Citibank in the amount of US\$60 million, with repayments on April 27, 2026 and April 27, 2027, at SOFR + 0.99% p.a. paid semiannually. The Company also entered into a derivative financial instrument for currency and interest rate hedging purposes, which translated the debt into Brazilian reais plus interest equivalent to CDI + 1.63% p.a. There are no guarantees.
- (e) On June 5, 2023, Rede D'Or paid in the 28th issue of Debentures in a single series, in the amount of R\$490 million, maturing on May 25, 2028. This debenture issue is indexed to the CDI + 1.90% p.a., payable annually. There are no quarantees.
- (f) On August 4, 2023, Rede D'Or paid in the 29th issue of Debentures in a single series, in the total amount of R\$1.0 billion, maturing on July 25, 2031. This debenture issue is indexed to the CDI + 2.25% p.a., payable semiannually. There are no guarantees.
- (g) On August 24, 2023, Rede D'Or, through a securifization company, paid in the 11th issue of registered book-entry Mortgage-backed securities ("CRI"), in three series, in the amount of R\$1,510.8 billion, maturing on August 15, 2028, August 15, 2030 and August 15, 2033. The 1st series CRI is indexed to the CDI + 1.00% p.a.; the Lord to the IPCA + 6.20% p.a.; and the 3rd series CRI to the IPCA + 6.55% p.a., payable semiannually. Concomitantly, the Company entered into a derivative financial instrument for IPCA inflation rate hedging purposes, converting it into interest equivalent to 106.6% of the CDI and 109.3% of the CDI, respectively. There are no quarantees.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures (Continued)

Significant loans, financing and debentures were taken out for general corporate purposes, in order to acquire companies, expand hospitals and build new units.

Total costs related to the issues of loans, financing and debentures, in the amount of R\$286,736 at March 31, 2023 (R\$295,462 at December 31, 2022), were recorded as a reduction of the balances and have been amortized over the term of the agreements, as established by CPC 08 - Transactions Costs and Premiums on Issue of Marketable Securities.

Before the SASA business combination, the Company did not have covenants relating to debt ratios, nor corresponding ratios based on net debt, EBITDA and finance costs rather than the guarantees listed above. Since, as a result of the merger, the Company is the successor, there are covenants whose application is suspended (Note 13.1).

At March 31, 2023, the noncurrent maturity schedule is as follows:

03/31/2023									
Ind	ividual	Cons	olidated						
Year	Amount	Year	Amount						
2024	1,797,056	2024	2,061,827						
2025	3,380,056	2025	3,552,103						
2026	1,587,959	2026	2,188,492						
2027	1,005,755	2027	1,499,818						
2028	3,309,747	2028	4,236,492						
2029 to 2037	14,286,414	2029 to 2037	15,144,822						
	25,366,987		28,683,554						

#### 13.1. Covenants

The Company is exempt from the obligation to meet any financial ratios (financial covenants) until the quarters stated below, per transaction, as approved at the general meeting of debenture holders held on August 18, 2022.

Issue	Exempt until
Sixth issue of debentures of Sul América S.A.	3rd quarter of 2023
Eighth issue of debentures of Sul América S.A.	4 <sup>th</sup> quarter of 2023
Ninth issue of debentures of Sul América S.A.	3 <sup>rd</sup> quarter of 2025

The Company may settle in advance the respective issues before the covenants mentioned above become applicable.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures (Continued)

#### 13.1. Covenants (Continued)

From the quarters above, and in accordance with the early maturity clauses contained in the debenture indentures of the Sixth Issue of Debentures of Sul América S.A., Eighth Issue of Debentures of Sul América S.A., the Company will have to maintain certain financial ratios within the previously established thresholds (financial covenants). The table below presents the financial covenants to which the Company will be subject.

Covenant	Ratio
Covenant	Ratio

Financial ratio I - net financial debt/cash generation

Financial ratio II - cash generation/net finance income (cost) Financial ratio III - cash generation

Equal to or lower than 2 times the cash generation

Equal to or higher than 4 times the net finance income (cost)

Equal to or higher than zero

<u>Net financial debt:</u> financial obligations less cash, cash equivalents and short-term investments, net of technical reserves to be covered.

<u>Cash generation</u>: profit or loss before income taxes, less depreciation and amortization.

## 14. Provision for contingencies and judicial deposits

The Company and its subsidiaries are parties to various tax, civil and labor claims. The judicial deposits will only be released in the event of a decision favorable to the Company. Based on the opinion of its internal and external legal advisors, management recognized a provision for losses that is deemed sufficient to cover probable losses, as follows:

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 14. Provision for contingencies and judicial deposits (Continued)

		Individual				
	03/31/	/2023	12/31/2	2022		
	Provision for contingencies	Judicial deposits	Provision for contingencies	Judicial deposits		
Tax and social security Labor	832,302 125,145	(272,542) (24,951)	931,974 106,200	(264,620) (24,974)		
Civil	155,157 1,112,604	(3,994) (301,487)	170,768 1,208,942	(5,059) (294,653)		
		Cons	olidated			
	03/31/	/2023	12/31/2	2022		
	Provision for contingencies	Judicial deposits	Provision for contingencies	Judicial deposits		
Tax and social security Labor Civil (a)	2,011,738 311,064 1,166,737	(2,077,119) (136,509) (406,735)	2,379,022 267,772 1,145,378	(2,325,232) (133,763) (403,279)		
	3,489,539	(2,620,363)	3,792,172	(2,862,274)		

<sup>(</sup>a) Restated in notes 2.

## 14.1. Proceedings assessed as probable loss

Changes in provisions for contingencies for the periods ended March 31, 2023 and 2022 were as follows:

		Indiv	idual	
	Tax and social security	Labor	Civil	Total
Balances at December 31, 2021	617	82,412	52,191	135,220
Additions, net of reversals Payments	(435) (107)	(20,819) (88)	(126) (20)	(21,380) (215)
Balances at March 31, 2022	75	61,505	52,045	113,625
Balances at December 31, 2022	931,974	106,200	170,768	1,208,942
Additions, net of reversals Monetary restatement Payments	(99,442) 6 (236)	17,102 2,007 (164)	(17,062) 1,505 (54)	(99,402) 3,518 (454)
Balances at March 31, 2023	832,302	125,145	155,157	1,112,604

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 14. Provision for contingencies and judicial deposits (Continued)

#### 14.1. Proceedings assessed as probable loss (Continued)

		Conso	lidated	
	Tax and social security	Labor	Civil	Total
Balances at December 31, 2021	107,723	136,245	100,900	344,868
Additions, net of reversals Payments Additions from business combinations (a)	(7,372) (1,109) 500	(25,009) (772) 3,512	(412) (108) 99	(32,793) (1,989) 4,111
Balances at March 31, 2022	99,742	113,976	100,479	314,197
Balances at December 31, 2022 (c)	2,379,022	267,772	1,145,378	3,792,172
Additions, net of reversals Monetary restatement Changes in equity Payments (b)	(98,213) 17,173 - (286,244)	25,756 4,383 14,442 (1,289)	43,984 29,149 - (51,774)	(28,473) 50,705 14,442 (339,307)
Balances at March 31, 2023 (c)	2,011,738	311,064	1,166,737	3,489,539

<sup>(</sup>a) Additions related to business combinations conducted in the respective years, as described in Note 3.

#### 14.2. Proceedings assessed as possible loss

The proceedings assessed as possible loss by the Company and its legal advisors, for which no provisions have been recorded, are summarized below:

	Indiv	ridual	Consolidated	
Tax and social security (a)	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Tax and social security (a)	1,846,867	1,777,084	3,961,517	4,031,356
Labor (b)	263,773	217,646	404,445	353,753
Civil (c)	316,882	346,467	678,282	703,668
	2,427,522	2,341,197	5,044,244	5,088,777

<sup>(</sup>a) The significant challenges refer to administrative proceedings in the total amount of R\$1.2 billion, of which R\$875,4 million refer to notices served in 2016 and 2017, and R\$349.9 million to notice served in early 2018. These challenges are mostly derived from allegations of the Brazilian Internal Revenue Service (RFB) that certain doctors who render services in hospitals through legal entities would be effectively Company employees. As such, the Brazilian tax authorities assessed the Company demanding the payment of the Social Security Tax (INSS). The Company is currently challenging such allegations.

<sup>(</sup>b) Of the total payments made in the period, R\$288,103 refers to settlement of the proceedings with the transformation of the judicial deposit into definitive payment.

<sup>(</sup>c) Changes in civil and social security proceedings refer to: (i) the final and unappealable decision of RE No. 400.479, through which the Plenary session of the STF determined that finance income from the compulsory investments used to cover the technical reserves, held by Insurers, would not be subject to PIS and COFINS contributions; (ii) the success of the lawsuit related to the non-levy of ICMS on the sale of salvage vehicles; and (iii) the success of the final and unappealable decision in the tax dispute in which the levy of ISS on health insurance premiums in the municipality of Rio de Janeiro was challenged.

<sup>(</sup>d) Restated balance (Notes 2.1)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

#### 14. Provision for contingencies and judicial deposits (Continued)

### 14.2. Proceedings assessed as possible loss (Continued)

In addition, the Company is a party to various tax proceedings involving PIS, COFINS, ISS and Real Estate Tax (IPTU), such as: (i) assessment notices issued against subsidiaries CIA. SAUDE and TRADITIO, in which the deductibility of amortization of goodwill arising from the merger of parent companies SLT Participações S.A. and STA Participações S.A., respectively, in calendar years 2005, 2006 and 2007, was challenged; (ii) non-approval of tax offsetting at the administrative level; (iii) disallowance of income tax loss and social contribution loss carryforwards; and (iv) claim aimed at charging ISS debits arising from the alleged failure to pay tax on the services provided in the City of São Paulo, at the appellate phase, given the favorable decision in the Stay of Execution filed by Sul América S.A.

- (b) Proceedings largely derived from overtime payment, 13th monthly salary, 30-day resignation notice, vacation pay and Unemployment Compensation Fund (FGTS). There are no individually significant proceedings.
- (c) Proceedings related to compensation for alleged property and pain and suffering damages. There are no individually significant proceedings.

Considering the complexities of the lawsuits, as well as of the Brazilian legal system, the Company cannot estimate with reasonable accuracy a timeframe for the judgment to take place and whether any amounts will be disbursed in connection with these legal proceedings.

#### 15. Leases

	Indiv	idual
	03/31/2023	12/31/2022
	(Restated)	(Restated)
Nominal value of future payments	6,623,256	6,611,872
Present value adjustment	(4,030,428)	(4,018,544)
	2,592,828	2,593,328
Current	464,850	476,704
Noncurrent	2,127,978	2,116,624
	Conso	lidated
	03/31/2023	12/31/2022
	(Restated)	(Restated)
Nominal value of future payments	8,514,358	8,982,982
Present value adjustment	(5,227,400)	(5,650,580)
	3,286,958	3,332,402
Current	677,384	621,751
Noncurrent	2,609,574	2,710,651

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **15. Leases** (Continued)

The liabilities were measured at the present value of the remaining lease payments discounted at the average rate of 14.93% at March 31, 2023.

At March 31, 2023, the noncurrent maturity schedule is as follows:

Individua	al	Consolida	ted
Year	Amount	Year	Amount
2024	397,139	2024	482,374
2025	519,882	2025	609,379
2026	423,601	2026	516,120
2027	404,157	2027	482,789
2028 to 2055	4,337,011	2028 to 2082	5,647,048
Undiscounted amounts	6,081,790	Undiscounted amounts	7,737,710
Embedded interest	(3,953,812)	Embedded interest	(5,128,136)
Balance at 03/31/2023	2,127,978	Balance at 03/31/2023	2,609,574

## 16. Equity

#### a) Capital

The Company's capital is broken down as follows:

	31/03	/2023	31/12/2022		
Shareholders	Number of shares	Equity interest	Number of shares	Equity interest	
Controlling shareholders	1,043,023,526	45,56%	1,043,023,526	45,56%	
Outstanding share	1,211,615,657	52,93%	1,209,934,908	52,85%	
Treasury share	34,653,407	1,51%	36,334,156	1,59%	
Total common shares	2,289,292,590	100,00%	2,289,292,590	100,00%	

Subscribed and paid-in capital at March 31, 2023 amounts to R\$15,711,360 represented by 2,289,292,590 common registered no-par-value shares (same amount and number of shares at December 31, 2022). As approved in the Company's Articles of Incorporation, the limit of authorized capital is up to 8 billion shares (units).

Under the Company's Articles of Incorporation, each common share is entitled to a vote at the Company's general meetings.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

#### a) Capital (Continued)

The premium reserve on issue of shares derived substantially from capital contributions made (i) on March 31, 2015, by the former shareholder BTG Pactual Saúde Fundo de Investimento em Participações, in the amount of R\$600,000, of which R\$147,664 was recorded as capital increase and R\$452,336 as premium reserve on the subscription of shares; and (ii) on April 27, 2015, by HPT Participações S.A. (Carlyle Group investee), in the amount of R\$1,819,435, of which R\$181,943 for capital increase and R\$1,637,491 as premium reserve on the subscription of shares; and (iii) reduction of reserve through capitalization in the amount of R\$1,600,000.

#### b) Allocations of income

Changes in the balances of dividends and interest on equity payable in the periods ended March 31, 2023 and 2022 were as follows:

	2023	2022
Balance payable at beginning of period	145,085	64,551
Allocation of dividends and interest on equity	-	194,376
Dividends - noncontrolling interests	27,743	9,511
Payment of dividends and interest on equity	(136,438)	(41,927)
Withholding income tax	•	(21,990)
Balance payable at March 31	36,390	204,521

The distribution and payment of dividends and interest on equity were approved at the Annual General Meeting.

#### c) <u>Treasury shares</u>

Changes in treasury shares are as follows:

	03/31/2023				_	
	Number of shares	Share value (in reais)	Total	Number of shares	Share value (in reais)	Total
Opening balance	36,334,156	14.99	544,610	38,913,920	3.58	139,282
Disposals	(1,680,749)	14.99	(25,193)	(2,593,904)	3.58	(9,284)
Balance at March 31	34,653,407	14.99	519,417	36,320,016	3.58	129,998

Shares purchased and sold substantially refer to the share-based payment plan, as described below.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

#### d) Share-based payment (Restricted shares)

Restricted Stock Option Plan

The plan establishes the terms and conditions for the granting of common shares issued by the Company, subject to certain restrictions, to managing officers, employees and service providers of the Company, or of other companies under its control.

1<sup>st</sup> Restricted Stock Option Program

In 2020, the Company's Board of Directors approved the 1st Restricted Stock Option Program and established the conditions for the granting of the Company's common registered no-par-value shares to managing officers and employees.

The rights of beneficiaries in relation to restricted shares will only be fully vested if their contract with the Company or with any entity under its control, as the case may be, is not terminated for a certain period, subject to the conditions for the release of trading restrictions, as defined by the Board of Directors, with specific conditions in case of termination.

The total of restricted shares delivered through the Restricted Stock Option Plan cannot exceed the maximum limit of 5% (five percent) of shares issued by the Company, which at March 31, 2023 was equivalent to a total of 114,464,630 shares.

In the three-month period ended March 31, 2023, a total of 2,371,279 Restricted Shares was granted to the elected beneficiaries, referring exclusively to the 1st Restricted Stock Option Program, at the weighted average price of R\$17.88. All restricted shares granted in the three-month period ended March 31, 2023 were vested immediately on January 04, 2023, and there are no restricted shares already granted that have not been vested.

Of the total shares mentioned above, for purposes of measuring shareholder dilution, the total amount of shares effectively vested for the beneficiaries under the 1st Restricted Stock Option Program was 1,719,177 shares, referring exclusively to the Restricted Stock Option Plan, in accordance with item 33E of Accounting Pronouncement CPC 10 - Share-Based Payment (2020).

For the purpose of calculating the expenses to be allocated, a projected cancellation rate of 7.14% was used for 2023, based on the average historical cancellations of the Company's plans.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

d) Share-based payment (restricted shares) (Continued)

2<sup>nd</sup> Restricted Stock Option Program

Within the scope of the Restricted Stock Option Plan, the Company's Board of Directors approved the 2nd Restricted Stock Option Program, beginning January 2022, which established the specific conditions for receiving a certain amount of units of reference that will entitle to the settlement of awards provided for in the individual grant agreements, which can be settled with common registered no-par-value shares of the Company to its managing officers, employees and service providers, or in cash, at the Company's discretion, depending, in that case, on the appreciation of the RDOR3 share price in a certain period of time, under the terms of the individual agreements.

In the three-month period ended March 31, 2023, a total of 3,450,265 Restricted Shares was granted to and effectively vested for the elected beneficiaries, referring exclusively to the 2nd Restricted Stock Option Program, whose exercise rights had not been fully vested yet.

The 2<sup>nd</sup> Restricted Stock Option Program is measured and recognized at fair value, using the Company's valuation identification model (Market cap) and deducting the reference value agreed with each executive officer, duly restated by reference to the IPCA, according to Accounting Pronouncement CPC 10 - Share-Based Payment.

The rights of the beneficiaries in relation to the restricted shares will only be fully vested if their contract with the Company or any entity under its control, as the case may be, is not terminated for a certain period and if the result of the award arising from the exercise of their units of reference is positive in the specific settlement windows provided for in the individual agreements, which implies that the RDOR3 share price must have gone up at the time of the settlement window, for the Beneficiary to be entitled to receive it, with specific conditions in case of termination. The Company pays all taxes and charges levied on the award at the time of its settlement in shares, or in cash, at its sole discretion.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

d) Share-based payment (restricted shares) (Continued)

2<sup>nd</sup> Restricted Stock Option Program (Continued)

For the purpose of calculating the expenses to be allocated, a cancellation rate of 7.14% was used in 2023, based on the average historical cancellations of the Company's plans.

Like previous plans, the 1st Restricted Stock Option Program was measured and recognized at fair value using the Black, Scholes & Merton (1973) model, according to Accounting Pronouncement CPC 10 - Share-Based Payment, whose main assumptions are described below.

The 2nd Restricted Stock Option Program is measured and recognized at fair value, using the Company's valuation identification model (Market cap) and deducting the reference value agreed with each executive officer, duly restated by reference to the IPCA, according to Accounting Pronouncement CPC 10 - Share-Based Payment.

						Weighted average		
Program	Year	Grace period	Number of shares	Annual volatility	Risk-free rate	of fair value of shares (in reais)	Vesting status	Options canceled
1st program	2020	05/29/2020 to 05/29/2027	46,591,300	26.36%	4.66%	7.45	Partially vested	_
1st program	2021	04/01/2021 to 04/01/2028	5,361,026	28.81%	5.98%	25.50	Partially vested	-
1st program	2022	01/01/2022 to 01/01/2028	3,577,793	32.75%	11.55%	15.03	Partially vested	-
2 <sup>nd</sup> program	2022	01/01/2022 to 12/31/2028	1,972,735	-	-	29.16	Partially vested	-
1st program	2023	01/01/2023 to 12/31/2028	2,371,279	44.56%	11.64%	12.98	Partially vested	-
2 <sup>nd</sup> program	2023	01/01/2023 to 12/31/2029	3,450,265	-	-	17.39	Partially vested	-
							•	

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

### d) Share-based payment (restricted shares) (Continued)

2<sup>nd</sup> Restricted Stock Option Plan (Continued)

The effects of the share-based payment plans, covering all granted and outstanding options, on equity and profit or loss for the year, are as follows:

	Fair value of options per year	Effect on P&L for the year	Changes - RSU	Cumulative effect on liabilities/equity
2011	1,457	1,457	-	1,457
2012	16,234	16,234	-	17,691
2013	20,656	20,656	-	38,347
2014	27,363	27,363	-	65,710
2015	51,949	51,949	-	117,659
2016	30,864	30,864	-	148,523
2017	32,599	32,599	-	181,122
2018	40,662	40,662	-	221,784
2019	40,656	40,656	-	262,440
2020	80,071	80,071	(80,071)	· -
2021	120,427	120,427	(120,427)	-
2022	124,276	124,276	(70,623)	53,653
2023	20,363	20,363	(11,035)	9,328
2024	11,670		, , ,	
2025	11,670			
2026	11,670			
2027	11,670			
	654,257	<del>.</del>		

#### e) Other comprehensive income

In the three-month period ended March 31, 2023, the effects of the cash flow hedge taken out for debt hedging purposes were recognized as other comprehensive income, decreasing equity for the period by R\$29,844.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

### 17. Deferred taxes

Income and social contribution tax expenses for the three-month periods ended March 31, 2023 and 2022 are broken down as follows:

	Individual		Conso	lidated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
	(Restated)		(Restated)	
Deferred				
Corporate Income Tax (IRPJ)	(12,543)	38,738	92,078	53,852
Social Contribution Tax on Net Profit (CSLL)	(4,515)	13,946	54,778	19,362
	(17,058)	52,684	146,856	73,214
Current				
IRPJ	-	-	(123,795)	(59,920)
CSLL	-	-	(47,925)	(22,589)
	-	-	(171,720)	(82,509)
Income and social contribution tax expenses	(17,058)	52,684	24,864	(9,295)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 17. Deferred taxes (Continued)

Changes in deferred income and social contribution tax assets and liabilities for three-month period ended March 31, 2023 and 2022 were as follows:

	Individual				Consolidated			
	Additional benefits Other			Other				
		(expenses)	comprehensive			Additional benefits	comprehensive	
	12/31/2022	recorded	income	03/31/2023	12/31/2022	(expenses)	income	03/31/2023
Assets	(Restated)			(Restated)	(Restated)			(Restated)
Income tax losses	392,468	30,740	-	423,208	967,814	161,920	-	1,129,734
Social contribution tax losses	141,288	11,066	-	152,354	349,821	80,821	-	430,642
Allowance for expected credit losses and provision for disallowances	285,442	17,400	-	302,842	589,369	27,123	-	616,492
Provision for contingencies	50,848	1,042	-	51,890	786,169	(8,738)	-	777,431
Provision for bonuses	24,038	5,591	-	29,629	25,517	15,005	-	40,522
Deferred gain on property sales	23,242	-	-	23,242	17,871	2,119	-	19,990
Amortization of right of use (IFRS 16)	255,703	21,111	-	276,814	401,700	59,072	-	460,772
PVA allocation (IFRS 16)	428,916	31,361	-	460,277	591,927	55,475	-	647,402
D'Or Finance	53,103	1,260	-	54,363	53,103	1,260		54,363
Actuarial gain/loss on defined benefit pension plans			-		11,910			11,910
Impairment of tax credits	-	-	-	-	73,704	3,197	-	76,901
Insurance and private pension reserve	-	-	-	-	1,378,144	(55,766)	(160,088)	1,162,290
Other provisions	24,421	(3,530)	-	20,891	-	` ' -	` , ,	
Total deferred tax assets	1,679,469	116,041		1,795,510	5,247,049	341,488	(160,088)	5,428,449
Liabilities		(= ·						
Differences between accounting and tax bases of goodwill	(711,911)	(5,137)	-	(717,048)	(930,432)	(45,247)	•	(975,679)
Gain on acquisition in stages	(99,040)		•	(99,040)	(124,003)		-	(124,003)
Swap difference	(65,308)	(41,239)	-	(106,547)	(62,459)	(39,780)	-	(102,239)
Foreign exchange differences	30,105	(9,464)	•	20,641	30,105	(9,464)	-	20,641
Leases (IFRS 16)	(563,923)	(46,178)	-	(610,101)	(818,725)	(100,625)	-	(919,350)
Insurance and private pension reserves (SASA)	-	-	-	-	-	-		-
Cash flow hedge	(133,621)	-	14,069	(119,552)	(159,738)	-	15,374	(144,364)
Deferred revenue	(2,666)	(332)	-	(2,998)	(7,601)	-	-	(7,601)
Variable income investment	-	-	-	-	(6,812)	-	-	(6,812)
Revaluation surplus - business combinations	(440,364)	(30,749)	-	(471,113)	(440,364)	(30,749)	-	(471,113)
Gain/loss on adjustment to market value	-	-	-	-	57.700	(2,063)	(47,875)	7,762
Other provisions	-	-	-	-	(55,315)	33,296		(22,019)
Total deferred tax liabilities	(1,986,728)	(133,099)	14,069	(2,105,758)	(2,517,644)	(194,632)	(32,501)	(2,744,777)
	(173,638)							
Net effect - asset (liability)	(173,030)	(17,058)		(400 606)	2,889,143	146,856		3,035,999
Net effect - asset (liability) Net effect - deferred PIS/COFINS		(17,058)	•	(190,696)		140,830	•	
	(400.004)	•	44.000	(440 EES)	238,461	•	(400 E00)	254,437
Effect on equity	(133,621)	-	14,069	(119,552)	(159,738)	-	(192,589)	(352,327)
Assets as per statement of financial position	-			-	3,366,280			3,348,841
Liabilities as per the statement of financial position	(307,259)			(310,248)	(398,414)			(410,732)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 17. Deferred taxes (Continued)

	Individual				Consolidated				
	12/31/2021	Additional benefits (expenses) recorded	Other comprehensive income	03/31/2022	12/31/2021	Additional benefits (expenses)	Other comprehensive income	Additions from business combinations	03/31/2022
Assets									
Income tax losses	123,033	27,644	-	150,677	283,472	45,674	-	9,532	338,678
Social contribution tax losses	44,292	9,952	-	54,244	103,181	16,443	-	3,708	123,332
Allowance for expected credit losses and provision for									
disallowances	227,826	(2,304)	-	225,522	508,135	6,800	-	4,550	519,485
Provision for contingencies	45,975	(7,342)	-	38,633	124,427	(11,407)	-	239	113,259
Provision for bonuses	24,849	8,500	-	33,349	24,646	8,201	-	38	32,885
Foreign exchange differences	229,296	(76,144)	-	153,152	229,296	(76,144)	-	-	153,152
Deferred gain on property sales	23,242	-	-	23,242	20,502	-	-	-	20,502
Amortization of right of use (IFRS 16)	171,305	15,399	-	186,704	273,348	33,569	-	-	306,917
PVA allocation (IFRS 16)	274,918	25,652	-	300,570	411,691	39,947	-	1,027	452,665
Tax effects - D'Or Finance	45,737	5,818	-	51,555	45,737	5,818	-	-	51,555
Other provisions	14,349	1,020	-	15,369	(3,557)	1,037	-	4,203	1,683
Total deferred tax assets	1,224,822	8,195	-	1,233,017	2,020,878	69,938	-	23,297	2,114,113
Liabilities									
Differences between accounting and tax bases of									
goodwill	(686,562)	(4,912)	-	(691,474)	(830,356)	(18,846)	-	-	(849,202)
Gain on acquisition in stages	(99,040)	-	-	(99,040)	(124,003)	-	-	-	(124,003)
Swap difference	(102,775)	77,251	-	(25,524)	(105,953)	72,159	-	-	(33,794)
Leases (IFRS 16)	(362,478)	(39,441)	-	(401,919)	(554,110)	(64,806)	-	(3,955)	(622,871)
Variable income investment	-	11,924	_	11,924	(954)	11,924	_	-	10,970
Cash flow hedge	(133,644)		(12,129)	(145,773)	(164,985)		(10,823)	-	(175,808)
Deferred revenue	(1,333)	(333)	-	(1,666)	(6,268)	(333)	-	_	(6,601)
Other provisions	(.,,	()	_	(1,000)	(35,142)	3,178	_	2,831	(29,133)
Total deferred tax liabilities	(1,385,832)	44,489	(12,129)	(1,353,472)	(1,821,771)	3,276	(10,823)	(1,124)	(1,830,442)
Net effect - asset (liability)	(27,366)	52,684	-	25,318	364,092	73,214	-	22,173	459,479
Effect on equity	(133,644)	-	(12,129)	(145,773)	(164,985)	-	(10,823)	-	(175,808)
Assets as per statement of financial position	-			-	792,083				882,848
Liabilities as per the statement of financial position	(161,010)			(120,455)	(592,976)				(599,177)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 17. Deferred taxes (Continued)

The reconciliation of income and social contribution taxes to the amount determined at the statutory rate as at March 31, 2023 and 2022 is as follows:

	Indivi	dual	Consoli	dated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
	(Restated)		(Restated)	
Income before income and social contribution				
taxes	315,750	157,886	339,931	234,451
Income and social contribution tax expenses at				
statutory rates	107,355	53,681	115,577	79,713
Social contribution tax rate difference (a)	-	-	(3,548)	-
Equity pickup, net of any gains earned abroad	(89,341)	(34,900)	3,201	(3,087)
Interest on equity	-	(66,088)	-	(66,088)
Accrual (reversal) of tax credit on temporary				
differences	-	-	(72,979)	-
Restatement of judicial deposits	-	-	(11,444)	-
Unduly paid taxes computed	-	-	(5,345)	-
Other	(956)	(5,377)	(598)	(1,243)
Expenses recorded in the statement of profit or		•	•	•
loss	17,058	(52,684)	24,864	9,295

<sup>(</sup>a) Refers to the difference in the social contribution rate between financial and similar companies (15%) and non-financial subsidiaries (9%).

Accumulated income and social contribution tax losses may be carried indefinitely; however, offsetting is limited to 30% of taxable profit generated in each fiscal year.

The Company expects that deferred tax assets calculated on income and social contribution tax losses will be realized within 5 years. Management expects that other temporary differences will be realized between 1 and 5 years, except for deferred gain on property sales, the realization of which will take place during the lease agreement term.

#### 18. Net revenue

	Indivi	dual	Consolidated	
Note	03/31/2023	03/31/2022	03/31/2023	03/31/2022
			(Restated)	
18.1	3,208,976	2,667,682	4,914,555	5,373,283
18.2	-	-	6,335,417	-
	3,208,976	2,667,682	11,249,972	5,373,283
	18.1	Note 03/31/2023 18.1 3,208,976 18.2 -	Note 03/31/2023 03/31/2022 18.1 3,208,976 2,667,682 18.2 -	Note         03/31/2023         03/31/2022         03/31/2023           18.1         3,208,976         2,667,682         4,914,555           18.2         -         -         6,335,417

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 18. Net revenue (Continued)

#### 18.1. Hospital services

	Individ	dual	Conso	lidated	
	03/31/2023	03/31/2022	03/31/2023	03/31/2022	
Gross revenue (a) Deductions from revenue	3,578,148	2,940,397	5,564,633	5,979,788	
Cancellations and rebates (a)	(169,677)	(119,800)	(275,361)	(272,587)	
Taxes on revenues	(199,495)	(152,915)	(374,717)	(333,918)	
	3,208,976	2,667,682	4,914,555	5,373,283	

<sup>(</sup>a) Includes eliminations of Gross Revenue and Cancellations and rebates between the Group companies in the amount of R\$1,214,964.

#### 18.2. Insurance - Net Premiums

Breakdown of total insurance revenue recognized in the period per measurement model is as follows:

		Consolidated 03/31/2023 (Restated)
Amounts relating to changes in the liability/asset for remaining coverage		
Expected insurance expenses	(a)	723,186
Changes in non-financial risk adjustment	(b)	413
Recognition of CSM in P&L for the period	(c)	9,748
Allocation of portion of premiums relating to recovery of insurance acquisition cash		
flows	(d)	18,067
Insurance revenue - Long-term products (BBA/VFA)		751,414
Premium release due to provision of insurance services	(e)	5,618,848
Insurance revenue - Short-term products (PAA)		5,618,848
Gross insurance revenues		6,370,262
Taxes on insurance revenues		(34,845)
Net insurance revenues		6,335,417

- (a) Expected expenses for the period due to the provision of insurance services that comprise claims and other expenses that the Company expects to incur to cover insured events that occurred during the period.
- (b) The change in risk adjustment shows the amount of risk that expired during the period.
- (c) CSM is recognized in P&L during the coverage period of the corresponding group of contracts based on coverage units
- (d) Premiums relating to acquisition cash flows are systematically allocated, on a straight-line basis, based on the passage of time over the coverage period of the group of contracts or according to the portfolio's permanence curve.
- (e) Amount recognized as insurance revenue for services rendered in the period.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

#### 19. Cost of services

		Indiv	ridual	Consolidated		
Description	Note	03/31/2023	03/31/2022	03/31/2023	03/31/2022	
		(Restated)		(Restated)		
Hospital services	19.1	(2,231,956)	(1,893,409)	(4,657,138)	(4,275,921)	
Insurance cost	19.2	-	-	(5,000,269)	-	
	•	(2,231,956)	(1,893,409)	(9,657,407)	(4,275,921)	

#### 19.1. Hospital services

	Individ	ual	Consoli	idated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
	(Restated)		(Restated)	
Personnel	(784,555)	(709,989)	(1,639,041)	(1,596,070)
Materials and medicines	(701,990)	(546,468)	(1,451,918)	(1,260,151)
Third-party services	(520,982)	(438,972)	(1,120,076)	(980,532)
Utilities and services	(46,769)	(47,184)	(100,562)	(106,943)
Rent	(2,204)	(760)	(20,752)	(19,449)
Depreciation and amortization	(175,456)	(150,036)	(324,789)	(312,776)
	(2,231,956)	(1,893,409)	(4,657,138)	(4,275,921)

#### 19.2. Insurance cost

		Long-torm prod	Consolidated Long-term products (BBA/VFA) Short-term products (PAA)			
		Liability for remaining coverage	Liability for claims incurred	Liability for remaining coverage	Liability for claims incurred	03/31/2023
Claims incurred and other expenses allocated to insurance contracts	(a)	750.706	(1,305,731)	(244,596)	(3,664,791)	(4,464,412)
Amortization of acquisition cash flows  Amortization of allocation of consideration paid in business combinations to the short-term	(b)	(18,067)	-	(319,123)	-	(337,190)
insurance portfolios (PAA)	(c)	-	-	(212,944)	-	(212,944)
Losses or reversal of losses on onerous contracts		14.277	_	_	_	14.277
Insurance operating expenses		746,916	(1,305,731)	(776,663)	(3,664,791)	(5,000,269)

- (a) The most significant expenses are linked to claims incurred. This balance also includes expenses related to loss adjustments, issue, maintenance and collection of premiums, compliance with regulatory requirements, among other requirements necessary for the fulfillment of the Company's obligations linked to insurance contracts. Includes the elimination of direct Claims and variation in the reserve for claims and claims incurred and not reported between the Group companies in the amount of R\$1,216,567.
- (b) Acquisition cash flows are systematically allocated, on a straight-line basis, based on the passage of time over the coverage period of the group of contracts or according to the portfolio's permanence curve.
- (c) Amortization of the asset fair value computed by means of acquisition Purchase Price Allocation (PPA) allocated to the insurance contract portfolios, which was systematically and rationally allocated to the liability for remaining coverage, a portion of the contracts in force in 2023, and to the acquisition cash flow asset, portion of futures contracts (renewals).
- (d) Amortization of part of the liability fair value determined in the acquisition PPA allocated to the insurance contract portfolios as a loss component, experience adjustments, changes in estimated cash flows, and onerous contract group risk adjustment.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 20. General and administrative expenses

	Indiv	idual	Conso	lidated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
Personnel	(171,326)	(166,354)	(217,395)	(166,354)
Third-party services	(37,212)	(31,865)	(62,000)	(31,865)
Travel and lodging	(6,899)	(6,861)	(14,657)	(12,210)
Depreciation and amortization	(43,217)	(34,685)	(74,283)	(34,685)
Reversal of (provision for) contingencies	99,402	21,380	28,473	32,793
	(159,252)	(218,385)	(339,862)	(212,321)

## 21. Other operating expenses, net

	Individual		Conso	lidated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
			(Restated)	
Taxes, charges and penalties	(18,400)	(17,039)	(45,258)	(37,492)
Gain on property sales	980	980	980	980
Equipment lease	(3,353)	(2,455)	(9,935)	(9,105)
Freight expenses	(2,686)	(2,224)	(8,667)	(7,029)
Legal fees	(10,668)	(6,379)	(13,232)	(10,080)
Other income and expenses	19,672	(11,397)	(22,085)	(32,302)
	(14,455)	(38,514)	(98,197)	(95,028)

## 22. Finance income (costs), net

Finance income (costs) for the three-month periods ended March 31, 2023 and 2022 are as follows:

	Individual		Consc	olidated
	03/31/2023	03/31/2022	03/31/2023	03/31/2022
			(Restated)	
Short-term investment yield Valuation (devaluation) of investment fund shares,	355,429	251,474	422,865	279,584
government securities and corporate bonds	-	-	467,855	-
Net foreign exchange differences on financing	27,698	223,706	201,774	1,280,076
Fair value of debt	(63,198)	224,398	(73,634)	492,120
Fair value of derivatives (swaps)	(9,502)	(449,274)	(222,879)	(1,817,970)
Interest and monetary difference on financing and	• • •	, ,		,
debentures	(952,167)	(582,471)	(1,002,345)	(610,850)
Interest on lease liabilities	(92,239)	(75,448)	(117,625)	(105,602)
Taxes on finance income (costs)	(20,434)	(6,395)	(25,017)	(9,058)
Finance income (costs) from insurance and	, , ,	, ,	, , ,	, , ,
reinsurance contracts	-	-	(451,699)	-
Other income and expenses	8,916	(46,360)	<b>17,031</b>	(67,385)
·	(745,497)	(460,370)	(783,674)	(559,085)
Total finance income	798,355	631,183	2,071,766	1,740,010
Total finance costs	(1,543,852)	(1,091,553)	(2,855,440)	(2,299,095)
	(745,497)	(460,370)	(783,674)	(559,085)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 23. Earnings per share

#### a) Basic

Basic earnings per share are calculated by dividing the profit attributable to the Company's shareholders by the weighted average number of common shares issued over the period, excluding common shares purchased by the Company and held as treasury shares.

	03/31/2023	03/31/2022
	(Restated)	
Income attributable to the Company's controlling shareholders	298,692	210,570
Weighted average number of common shares issued (in thousands)	2,254,639	1,974,047
Basic earnings per share - in R\$	0.1325	0.1067

#### b) Diluted

Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares assuming the conversion of all the potentially dilutive common shares.

	03/31/2023	03/31/2022
	(Restated)	
Income attributable to the Company's controlling shareholders Weighted average number of common shares issued, including dilution	298,692	210,570
factors (in thousands)	2,254,639	1,974,047
Dilution instruments - weighted average number of shares (in thousands): Share-based payment (Restricted shares)	4,500	5,560
Diluted earnings per share - in R\$	0.1322	0.1064

## 24. Financial instruments and financial risk management (Continued)

#### **24.1. Financial instruments by category** (Continued)

#### Fair value hierarchy

The financial instruments recognized at fair value are measured at levels from 1 to 3, based on the fair value measurement, as follows:

Level 1: fair value measurement derives from quoted (unadjusted) prices in active markets for identical assets or liabilities;

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

### **24.1. Financial instruments by category** (Continued)

Fair value hierarchy (Continued)

Level 2: fair value measurement derives from other inputs included in Level 1, which are quoted through an asset or liability directly (i.e. as prices) or indirectly (i.e. derived from prices);

Level 3: fair value measurement derives from valuation techniques that include an asset or liability that is not included in an active market.

The tables below present breakdown of financial assets and liabilities at March 31, 2023 and December 31, 2022:

	Individual			
			Book b	alance
Financial assets	Classification by category	Fair value hierarchy	03/31/2023	12/31/2022
Cash and cash equivalents Marketable securities (shares and	Fair value through profit or loss	Level 2	109,032	96,360
government securities)	Fair value through profit or loss	Level 1	49,199	30,201
Marketable securities (corporate bonds and investment fund shares) Others	Fair value through profit or loss	Level 2	10,390,221	11,024,443 111.246
Accounts receivable	Amortized cost		4,198,675	3,966,046
Dividends receivable	Amortized cost		170,384	75,277
Judicial deposits	Amortized cost		301,487	294,653
Derivatives	Fair value through profit or loss and other comprehensive			
	income	Level 2	565,248	537,916
			15,784,246	16,136,142

			Book b	alance
Financial liabilities	Classification by category	Fair value hierarchy	03/31/2023	12/31/2022
Trade accounts payable	Amortized cost		675,777	532,476
Loans, financing and debentures	Amortized cost (a)	Level 2	29,441,667	29,017,602
Salaries, accruals and social charges	Amortized cost Fair value through profit or loss and		502,534	445,623
Derivatives	other comprehensive income	Level 2	1,684,894	1,813,933
		_	32,304,872	31,809,634

<sup>(</sup>a) The debt portion recorded as hedge accounting (fair value hedge) is measured at fair value through profit or loss, and at March 31, 2023 totaled R\$9,246,320 (R\$9,177,650 at December 31, 2022).

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.1. Financial instruments by category (Continued)

Fair value hierarchy (Continued)

Consolidated					
		_	Book bala	ince	
Financial assets	Classification by category	Fair value hierarchy	03/31/2023	12/31/2022	
Cash and cash equivalents Marketable securities (shares and	Fair value through profit or loss	Level 2	2,077,753	1,109,796	
government securities) Marketable securities (corporate bonds	Fair value through profit or loss	Level 1	6,118,903	5,954,989	
and investment fund shares) Marketable securities (government	Fair value through profit or loss Fair value through profit or loss and	Level 2	19,084,931	20,590,093	
securities)	other comprehensive income		1,691,857	1,370,998	
Marketable securities (government securities)	Fair value through profit or loss and other comprehensive income		1,274,739	1,269,354	
Marketable securities Accounts receivable	Amortized cost Amortized cost	Level 1	1,813,519 10,178,143	1,857,545 9,765,717	
Judicial deposits	Amortized cost Fair value through profit or loss and		2,620,363	2,862,274	
Derivatives	other comprehensive income	Level 2	2,638,149	2,739,505	
			47,498,357	47,520,271	

		Fair value	Book b	alance
Financial liabilities	Classification by category	hierarchy	03/31/2023	12/31/2022
Trade accounts payable	Amortized cost		1,397,012	1,256,601
Loans, financing and debentures	Amortized cost (a)	Level 2	33,076,512	32,883,225
Salaries, accruals and social charges	Amortized cost		1,108,816	982,150
	Fair value through profit or loss and			
Derivatives	other comprehensive income	Level 2	1,831,080	1,959,016
			37,413,420	37,080,992

<sup>(</sup>a) The debt portion recorded as hedge accounting (fair value hedge) is measured at fair value through profit or loss, and at March 31, 2023 totaled R\$11,001,445 (R\$11,054,711 at December 31, 2022). As mentioned in Note 13, the maturity of debentures of HSPE 14 - 4th issue of Debentures of Hospital Esperança was extended, with cost reduction, and such modifications were not reflected in the respective hedging instrument. Thus, the cash flow hedge no longer offsets changes in cash flows of the risk associated with the recognized liabilities of this debt and was then written down to profit or loss, deferred over the debt maturity.

Financial assets and liabilities accounted for at amortized cost approximate their respective fair values, as they are adjusted by provisions, present value and/or restated at floating market rates.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management

The Company's financial transactions are conducted by the financial function in accordance with the strategy previously approved by the executive board and shareholders. The Company's risk management strategies and the corresponding effects on the individual and consolidated interim financial information can be summarized as follows:

#### a) Capital management

The main purpose of capital management is to ensure the Company's ability to continue as a going concern and maximize return to shareholders.

The Company uses own and third-party capital to finance its activities, and the use of third-party capital seeks to optimize its capital structure. The Company monitors its capital structure and makes adjustments in light of changes in economic conditions. At March 31, 2023 and December 31, 2022, the Company presents the following capital structure:

	Individual		Consol	idated
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Cash and cash equivalents Marketable securities Technical reserves	109,032 10,439,420	96,360 11,165,890	2,077,753 29,983,949	1,109,796 31,042,979
Insurance Private pension	-	-	(4,565,242) (10,308,380)	(4,141,017) (10,111,054)
	10,548,452	11,262,250	17,188,080	17,900,704
Loans, financing and debentures	(29,441,667)	(29,017,602)	(33,076,512)	(32,883,225)
Derivatives	(1,119,646)	(1,276,017)	807,069	780,489
Cash flow hedge	(351,625)	(393,002)	(424,603)	(469,822)
Net debt (a)	(20,364,486)	(19,424,731)	(15,505,966)	(14,671,854)
Total equity (b)	21,911,898	21,442,803	23,185,259	22,707,734
Total net debt and equity (b)	1,547,412	2,018,432	7,679,293	8,035,880
Leverage ratio	0,93	0,91	0,67	0,65

<sup>(</sup>a) The net debt corresponds to the sum of the balances of loans, financing and debentures, derivative financial instruments, net (current and noncurrent) plus the cash flow hedge effect of other comprehensive income (the Company has swaps accounted for in accordance with the fair value and cash flow hedge accounting, for purposes of hedging the Company against fluctuations in foreign currency and interest rates, respectively) deducted of the balance of cash and cash equivalents and marketable securities.

#### (b) Restated 2.3

#### b) Interest rate risk

The Company has loans, financing and debentures in local currency subject particularly to the fluctuation of the CDI and IPCA rates. The risk inherent to these liabilities arises from the possibility of fluctuations in these rates that impact the Company's cash flows.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

#### b) Interest rate risk (Continued)

The sensitivity analysis of interest on loans, financing and debentures, net, considered as probable scenario (Scenario I) the reference rates obtained with BM&FBOVESPA at March 31, 2023, and Scenarios II and III take into consideration a rate increase by 25% and 50%, respectively. The results, in nominal values, are as follows:

Scenarios	Scenario I	Scenario II	Scenario III
	current	+ 25%	+ 50%
CDI rate (p.a.)	13.65%	17.06%	20.48%
IPCA rate (p.a.) Projected interest expenses (in millions)	4.65%	5.81%	6.98%
	(10,221)	(13,036)	(15,852)

#### c) Credit risk

Credit risk is the risk that a counterparty to a business arrangement will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade accounts receivable) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments. In the case of identification of imminent risk of non-realization of these assets, the Company records provisions to bring them to their probable realizable value.

#### d) Liquidity risk

This is the risk of shortage of funds and of the Company facing difficulties in paying its debts. The Company seeks to align the maturity of its debts with the cash generation period to avoid any mismatch and generate the need for greater leverage.

Liquidity risks arise from the possibility of lack of readily available resources to honor commitments made on a timely basis due to the mismatch between payment and receipt flows.

SulAmérica's Investment Policy provides for and describes minimum amounts that must be invested in highly liquid assets to mitigate the risk of non-payment of claims and benefits.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

### d) Liquidity risk (Continued)

Daily cash projections and stress tests are carried out to anticipate any abnormal situation, having a daily control over liquidity risk.

The following table presents the expected maturities and payments of the main financial insurance assets and liabilities, except for those related to the benefit accumulation phase of the PGBL and VGBL plans, whereby the exposure falls on the participant. The amounts disclosed below are projected considering inflation and interest through to maturity.

		Individual - 03/31/2023				
	within	From	From	Over	Total financial	
	1 year	1 to 2 years	2 to 5 years	5 years	liabilities	
Trade accounts payable	675,777	-	_	_	675,777	
Loans, financing and debentures Salaries, accruals and social	4,118,271	2,163.322	8,442,816	20,098,398	34,822,807	
charges	502,534	_	_	_	502,534	
Derivatives	(479.202)	(430,535)	(1,138,394)	3,624,365	1,576,234	
	4,817,380	1,732,787	7,304,422	23,722,763	37,577,352	
		0	-1:-1-41 00/	24/2022		
	itle lee		olidated – 03/3		Tatal financial	
	within	From	From	Over	Total financial	
	1 year	1 to 2 years	2 to 5 years	5 years	liabilities	
Trade accounts payable	1,397,012	_	-	-	1,397,012	
Loans, financing and debentures	4,442,673	2,463,314	10,986,098	21,167,925	39,060,010	
Liabilities of insurance contracts	6,758,477	1,571,788	3,641,205	7,306,096	19,277,566	
Salaries, accruals and social						
cararres, accreate and coolar					4 400 040	
charges	1,108,816	-	-	-	1,108,816	
,	1,108,816 (590,733)	- (550,026)	- 550,679	6,714,927	1,108,816 6,124,847	

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

#### d) Liquidity risk (Continued)

<del>-</del>		las al:		000				
<del>-</del>	Maria 1	Individual – 03/31/2022						
	Within	From	From	Over	Total financial			
<del>-</del>	1 year	1 to 2 years	2 to 5 years	5 years	liabilities			
Trade accounts payable Loans, financing and	532,476	-	-	-	532,476			
debentures	4,771,343	2,160,420	6,952,796	20,294,373	34,178,932			
Salaries, accruals and social								
charges	445,623	-	-	-	445,623			
Derivatives	(503,211)	(517,814)	(1,138,217)	3,368,241	1,208,999			
_	5,246,231	1,642,606	5,814,579	23,662,614	36,366,030			
_								
-		Cons	olidated - 03/31	/2022				
-	Within	From	From	Over	Total financial			
<u>-</u>	1 year	1 to 2 years	2 to 5 years	5 years	liabilities			
Trade accounts payable Loans, financing and	1,256,601	-	-	-	1,256,601			
debentures Liabilities of insurance	5,044,022	2,573,996	8,427,070	22,715,258	38,760,346			
contracts Salaries, accruals and social	6,648,209	1,459,066	3,403,215	7,587,689	19,098,179			
charges	982,150	-	-	_	982,150			
Derivatives	(606,403)	(623,434)	(1,365,493)	8,845,955	6,250,625			
-	13,324,579	3,409,628	10,464,792	39,148,902	66,347,901			

#### e) Foreign currency

The Company has loans and financing and trade accounts payable in foreign currency (mainly the US dollar). The risk related to these assets and liabilities arises from the possibility of incurring losses due to fluctuations in exchange rates. Liabilities in foreign currency represent 18.7% of total gross debt at March 31, 2023 (19.3% at December 31, 2022). The Company has derivative financial instruments to hedge loans and financing against foreign exchange rate fluctuation (see topic below). Management understands that the risk of exposure to foreign currency is not significant in relation to its financial position.

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

#### f) Derivatives

At March 31, 2023, the Company recorded swaps based on fair value and cash flow hedge accounting in order to hedge the Company against fluctuations in foreign currency and interest rate, respectively. The swaps exchange (i) the flow of interest and principal in foreign currency for Brazilian reais plus a percentage of CDI or CDI + spread; (ii) floating interest rate for fixed interest rate; and (iii) inflation rate IPCA + spread for CDI + spread.

The fair value of those instruments at the reporting date is as follows:

				Indiv	idual
	Maturity	Referer	nce value	03/31/2023	12/31/2022
Description	month/year	(notion	al value)	Fair value	
Swap (currency) Long position Short position	06/30/2025 EUR/BRL + 1.0366% CDI+1.35%	EUR R\$	67,433 372,524	(63,497)	(58,096)
Swap (currency) Long position Short position	11/21/2023 USD Libor + 0.46% 109% of CDI	US\$ R\$	80,441 408,671	104,556	112,285
Swap (currency) Long position Short position	07/01/2025 USD/BRL + 1.8588% CDI + 1.323%	US\$ R\$	100,386 510,002	(79,260)	(84,423)
Swap (index) Long position	01/18/2028 BRL Fixed rate (11.82%)	R\$	1,635,187		
Short position	CDI + 2.01%	R\$	1,635,187	(149,107)	(192,906)
Swap (index) Long position Short position	01/22/2030 BRL Fixed rate (8.80%) CDI + 2.125%	R\$ R\$	2,135,620 2,135,620	(636,265)	(693,035)
Swap (index) Long position Short position	22/01/2030 BRL Fixed rate (8.65%) CDI + 2.40%	R\$ R\$	1,116,361 1,116,361	(369,310)	(400,756)
Swap (index) Long position Short position	06/20/2029 CDI + 0.79% BRL Fixed rate (7.71%)	R\$ R\$	1,039,009 1,039,009	239,174	240,554
Swap (index) Long position	10/26/2026 106.0% of CDI BRL Fixed rate	R\$	530,495 530,495		
Short position	(6.765%)	R\$		66,762	68,264

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

				Indivi	dual
	Maturity	Reference value		03/31/2023	12/31/2022
Description	month/year	(no	otional)	Fair va	alue
Swap (index)	05/15/2036				
Long position	IPCA + 4.9347%	R\$	1,531,855		
Short position	CDI + 1.35%	R\$	1,531,855	(198,619)	(195,501)
Short position	CDI + 1.35%	ĽΦ	1,001,000	(190,019)	(195,501)
Swap (index)	12/15/2031				
Long position	IPCA + 5.5758%	R\$	406,997		
Short position	CDI + 0.56%	R\$	406,997	1,857	(2,703)
Swap (index)	12/15/2036				
Long position	IPCA + 6.1017%	R\$	611,464		
Short position	CDI + 1.403%	R\$	611,464	(22,581)	(22,631)
Swap (index)	06/15/2029				
Long position	IPCA + 5.83%	R\$	812,402		
Short position	102.7% of CDI	R\$	812,402	(12,512)	(23,003)
Short position	102.7% 01 CDI	КФ	012,402	(12,512)	(23,003)
Swap (index)	06/15/2032				
Long position	IPCA + 6.01%	R\$	347,939		
Short position	104.1% of CDI	R\$	347,939	(7,449)	(10,738)
Swap (index)	07/16/2029				
Long position	IPCA + 6.3828%	R\$	30,395		
Short position	103.65% of CDI	R\$	30,395	530	(892)
Swap (index)	07/15/2032				
Long position	IPCA + 6.5445%	R\$	70,945		
Short position	104.8% of CDI	R\$	70,945	1,301	(1,800)
Swap (index)	07/15/2037				
Long position	IPCA + 6.7692%	R\$	405,580		
Short position	107.9% of CDI	R\$	405,580	4,828	(9,161)
Swap (index)	12/17/2029				
Long position	IPCA + 6.7947%	R\$	84,043		
Short position	108.1% of CDI	R\$	84,043	135	(816)
Swap (index)	12/15/2032				
Long position	IPCA + 6.9354%	R\$	56,062		
Short position	110.1% of CDI	R\$	56,062	(191)	(659)
Current assets position				197,628	203,730
Noncurrent assets position				367,620	334,186
Current liabilities position				(647,473)	(682,825)
Noncurrent liabilities position				(1,037,421)	(1,131,108)
Effect on profit or loss for the year (fair				<b></b>	
value of derivatives - swaps) Effect on equity for the year (fair value of				(9,502)	(1,070,044)
derivatives - swaps)				(41,378)	(68)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

				Consol	idated
	Maturity	Reference value		03/31/2023	12/31/2022
Description	month/year	(no	tional)	Fair va	lue
Swap (currency)	06/30/2025				
Long position	EUR/BRL + 1.0366%	EUR	67,433		
Short position	CDI+1.35%	R\$	372,524	(63,497)	(58,096)
Short position	CDI+1.35%	KΦ	372,324	(63,497)	(56,096)
Swap (currency)	11/21/2023				
Long position	USD Libor + 0.46%	US\$	80,441		
Short position	109% of CDI	R\$	408,671	104,556	112,285
Swap (currency)	07/01/2025				
Long position	USD/BRL + 1.8588%	US\$	100,386		
Short position	CDI + 1.323%	R\$	510,002	(79,260)	(84,423)
Swap (currency)	01/18/2028				
Long position	USD Fixed rate (4.95%)	US\$	505,088		
Short position	BRL Fixed rate (11.82%)	R\$	2,566,047	915,283	984,627
Owen (in day)	04/40/2020				
Swap (index)	01/18/2028	DΦ	1,635,187		
Long position	BRL Fixed rate (11.82%) CDI + 2.01%	R\$ R\$	1,635,187	(140 107)	(102.006)
Short position	CDI + 2.01%	KΦ	1,033,187	(149,107)	(192,906)
Swap (index)	01/22/2030				
Long position	USD Fixed rate (4.525%)	US\$	504,313		
Short position	BRL Fixed rate (8.80%)	R\$	2,562,109	645,892	684,447
Swap (index)	01/22/2030				
Long position	BRL Fixed rate (8.80%)	R\$	2,135,620		
Short position	CDI + 2.125%	R\$	2,135,620	(636,265)	(693,035)
Swap (index)	01/22/2030				
Long position	USD Fixed rate (4.51%)	US\$	252,156		
Short position	BRL Fixed rate (8.65%)	R\$	1,281,055	280,905	298,507
Swap (index)	01/22/2030				
Long position	BRL Fixed rate (8.65%)	R\$	1,116,361		
Short position	CDI + 2.40%	R\$	1,116,361	(369,310)	(400,756)
Curan (in day)	42/20/2025				
Swap (index)	12/29/2025 CDI + 1.27%/1.75%	R\$	1,038,120		
Long position Short position	BRL Fixed rate (7.752%)	R\$	1,038,120	84,635	99.025
SHORE POSITION	DICE FIXED TALE (1.152%)	ĽΦ	1,030,120	04,033	88,925
Swap (index)	06/20/2029				
Long position	CDI + 0.79%	R\$	1,039,009		
Short position	BRL Fixed rate (7.71%)	R\$	1,039,009	239,174	240,554
Swap (index)	10/26/2026				
Long position	106.0% of CDI	R\$	530,495		
Short position	BRL Fixed rate (6.765%)	R\$	530,495	66,762	68,264

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

					olidated	
	Maturity	Refere	ence value	03/31/2023	12/31/2022	
Description	month/year	(no	otional)	Fair v	alue	
Swap (index)	05/15/2036					
Long position	IPCA + 4.9347%	R\$	1,531,855			
Short position	CDI + 1.35%	R\$	1,531,855	(198,619)	(195,501)	
Swap (index)	12/15/2031					
Long position	IPCA + 5.5758%	R\$	406,997			
Short position	CDI + 0.56%	R\$	406,997	1,857	(2,703)	
Swap (index)	12/15/2036					
Long position	IPCA + 6.1017%	R\$	611,464			
Short position	CDI + 1.403%	R\$	611,464	(22,581)	(22,631)	
Swap (index)	06/15/2029					
Long position	IPCA + 5.83%	R\$	812,402			
Short position	102.7% of CDI	R\$	812,402	(12,512)	(23,003)	
Swap (index)	06/15/2032					
Long position	IPCA + 6.01%	R\$	347,939			
Short position	104.1% of CDI	R\$	347,939	(7,449)	(10,738)	
Swap (index)	07/16/2029					
Long position	IPCA + 6.3828%	R\$	30,395			
Short position	103.65% of CDI	R\$	30,395	530	(892)	
Short position	103.65% 01 CD1	ĽΦ	30,393	550	(092)	
Swap (index)	07/15/2032					
Long position	IPCA + 6.5445%	R\$	70,945			
Short position	104.8% of CDI	R\$	70,945	1,301	(1,800)	
Swap (index)	07/15/2037					
Long position	IPCA + 6.7692%	R\$	405,580			
Short position	107.9% of CDI	R\$	405,580	4,828	(9,161)	
Swap (index)	12/17/2029					
Long position	IPCA + 6.7947%	R\$	84,043			
Short position	108.1% of CDI	R\$	84,043	135	(816)	
Swap (index)	12/15/2032					
Long position	IPCA + 6.9354%	R\$	56,062			
Short position	110.1% of CDI	R\$	56,062	(191)	(659)	
•				045.00	0-1-:-	
Current assets position				245,604	251,740	
Noncurrent assets position				2,392,545	2,487,765	
Current liabilities position				(793,659)	(827,908)	
Noncurrent liabilities position				(1,037,421)	(1,131,108)	
Effect on profit or loss for the year (fair value of derivatives - swaps)				(222,879)	(2,369,263)	
Effect on equity for the year (fair value of						
derivatives - swaps)				(45,218)	(15,432)	

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

#### f) <u>Derivatives</u> (Continued)

Given the changes in market rates, these amounts may suffer changes as well as early settlement or maturity of the transactions.

For derivative financial instruments, the Company considers as probable scenario +5% (Scenario I) future exchange rates of the Brazilian real in relation to the US dollar, euro, IPCA inflation rates, and DI futures interest rates, obtained from B3 for instrument maturity, calculated on the nominal amount of the agreement.

The Company adopted the scenarios corresponding to -25% (Scenario II), -50% (Scenario III), +25% (Scenario IV) and +50% (Scenario V) in relation to the exchange rates and DI rates used to determine the probable scenario.

Debt - Citibank and JP Morgan	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$)	5%	(25%) 4.0008	(50%) 2.6672	25%	50%
Appreciation of US\$ (rate in R\$)	5.3344	-	-	6.6680	8.0016
Effect on liabilities Loan 4131 - Citibank and JP Morgan	43,470	(217,350)	(434,700)	217,350	434,700
Effect on derivatives Swap	(43,470)	217,350	434,700	(217,350)	(434,700)
Net effect	-	-	-	-	-
Debt - Senior Notes I	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$)	5%	(25%) 4.0008	(50%) 2.6672	25%	50%
Appreciation of US\$ (rate in R\$)	5.3344	-	-	6.6680	8.0016
Effect on liabilities Senior Notes	120,587	(602,937)	(1,205,873)	602,937	1,205,873
Effect on derivatives			, ,	(	· · · · · · · · · · · · · · · · · · ·
Swap Net effect	(120,587)	602,937	1,205,873	(602,937)	(1,205,873)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

Debt - Senior Notes II	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$) Appreciation of US\$ (rate in R\$)	5% - 5.3344	(25%) 4.0008 -	(50%) 2.6672 -	25% - 6.6680	50% - 8.0016
Effect on liabilities in US\$ Senior Notes II	157,483	(787,416)	(1,574,833)	787,416	1,574,833
Effect on derivatives Swap Net effect	(157,483) -	787,416 -	1,574,833 -	(787,416) -	(1,574,833) -
Debt - Debentures	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Fluctuation in DI rate Depreciation of the DI rate Appreciation of the DI rate	5% - 14.3325%	(25%) 10.7494% -	(50%) 7.1663% -	25% - 17.9156%	50% - 21.4988%
Effect on liabilities Debentures	20,346	(86,469)	(193,284)	127,161	233,976
Effect on derivatives Swap Net effect	(20,346)	86,469 -	193,284 -	(127,161) -	(233,976) -
Debt - Debentures (CRI)	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Fluctuation of the IPCA rate Depreciation of the IPCA rate Appreciation of the IPCA rate	5% - 4.8825%	(25%) 3.6619% -	(50%) 2.4413% -	25% - 6.1031%	50% - 7.3238%
Effect on liabilities Debentures	9,843	(41,835)	(93,513)	61,522	113,200
Effect on derivatives Swap	(9,843)	41,835	93,513	(61,522)	(113,200)

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## **24.2. Risk management** (Continued)

Debt - BofA	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of EUR€ (rate in R\$) Appreciation of EUR€ (rate in R\$)	5% - 5.8006	(25%) 4.3505 -	(50%) 2.9003 -	25% - 7.2508	50% - 8.7009
Effect on liabilities Loan 4131 - BofA	16,885	(84,424)	(168,849)	84,424	168,849
Effect on derivatives Swap Net effect	(16,885) -	84,424 -	168,849 -	(84,424) -	(168,849) -

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.3. Changes in liabilities from financing activities

					Indiv	idual				
Individual	12/31/2022	Loans, financing and debentures raise	Interest, monetary variations and foreign exchange differences, net	Payment of acquisitions and principal	Payment of interest	Fair value of debt	Allocation of dividends and interest on equity	Payment of dividends and interest on equity	Other	03/31/2023
Loans, financing, debentures and leases Derivatives	31,610,932 1,813,933	1,100,000	1,076,458 64,952	(1,076,327) (193,991)	(802,720) -	63,198 -	-		62,954 -	32,034,495 1,684,894
Dividends and interest on equity payable	137,640	-	-	- (4.070.040)	- (000 700)	-	(113,758)	-	-	23,882
Current	33,562,505 6,004,178	1,100,000	1,141,410	(1,270,318)	(802,720)	63,198	(113,758)	-	62,954	33,743,271 5,210,885
Noncurrent	27,558,327									28,532,386
					Indiv	idual				
		Loans, financing and debentures	Interest, monetary variations vand foreign exchange differences,	Payment of acquisitions	Payment of	Fair value of	Allocation of dividends and interest on	Payment of dividends and interest on		
Individual	12/31/2021	financing and	monetary variations and foreign exchange				dividends and	dividends and	Other	03/31/2022
Loans, financing, debentures and leases Derivatives	12/31/2021 24,242,348 1,129,431	financing and debentures	monetary variations and foreign exchange differences,	acquisitions	Payment of	Fair value of	dividends and interest on	dividends and interest on	Other 83,960	03/31/2022 23,907,514 1,379,733
Loans, financing, debentures and leases	24,242,348	financing and debentures raise	monetary variations and foreign exchange differences, net	acquisitions and principal (418,993)	Payment of interest	Fair value of debt	dividends and interest on	dividends and interest on		23,907,514

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.3. Changes in liabilities from financing activities (Continued)

					Consc	olidated				
Consolidated	12/31/2022	Loans, financing and debentures raised and leases	Interest, monetary variations and foreign exchange differences, net	Payment of acquisitions and principal	Payment of interest	Fair value of debt	Allocation of dividends and interest on equity	Payment of dividends and interest on equity	Other	03/31/2023
Loans, financing, debentures and leases Derivatives Dividends and interest on	36,215,627 1,959,016	1,100,000 -	956,694 149,640	(1,256,937) (277,576)	(761,886) -	73,631 -	- -	- -	36,341 -	36,363,470 1,831,080
equity payable	145,085	-	-	-	-	-	27,743	(136,438)	-	36,390
	38,319,728	1,100,000	1,106,334	(1,534,513)	(761,886)	73,631	27,743	(136,438)	36,341	38,230,940
Current Noncurrent	6,159,748 32,159,980									5,900,391 32,330,549
					Cons	olidated				
Consolidated	12/31/2021	Loans, financing and debentures raised and leases	Interest, monetary variations and foreign exchange differences, net	Payment of acquisitions and principal	Conso	olidated Fair value of debt	Allocation of dividends and interest on equity	Payment of dividends and interest on equity	Other	03/31/2022
Loans, financing, debentures and leases Derivatives	12/31/2021 30,622,796 1,255,415	financing and debentures raised and	monetary variations and foreign exchange differences,	acquisitions	Payment of	Fair value of	dividends and interest on	dividends and interest on	Other 217,690	<b>03/31/2022</b> 28,874,869 1,528,158
Loans, financing, debentures and leases	30,622,796	financing and debentures raised and	monetary variations and foreign exchange differences, net	acquisitions and principal (433,651)	Payment of interest	Fair value of debt	dividends and interest on	dividends and interest on		28,874,869

Notes to interim financial statements (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 25. Assets, liabilities, revenues and expenses per segment

Assets, liabilities, revenues and expenses per segment are as follows:

				Consolidated 03/31/2023			
				(Restated)			
	Hospital	Health (a)	Life (b)	Corporate	Total – segments	Eliminations	Consolidated
Net revenues	•	```	` '	•			
Foreign customers	6,129,520	6,136,920	198,375	10,495	12,475,310	(1,225,338)	11,249,972
Intersegment	-	62	3,051	-	3,113	(3,113)	-
Other revenues and expenses							
Operating expenses	(4,657,139)	(6,011,368)	(212,934)	-	(10,881,441)	1,224,034	(9,657,407)
Administrative expenses	(166,206)	(155,502)	3,228	(22,464)	(340,944)	1,082	(339,862)
Finance income (costs)	(828,240)	(112,212)	90,092	66,686	(783,674)	-	(783,674)
Other amounts that have an impact on income	(162,868)	149,541	(30,285)	80,649	37,037	(190,999)	(153,962)
Net income	315,067	7,441	51,527	135,366	509,401	(194,334)	315,067
Assets Liabilities	46,123,454 38,691,583	19,507,806 11,236,014	11,528,238 10,664,589	18,684,465 3,528,530	95,843,963 64,120,716	(8,666,658) (128,670)	87,177,305 63,992,046

<sup>(</sup>a) The "Health" segment comprises administrative services only (ASO) plans, and health and dental insurance.

<sup>(</sup>b) The Life & pension segment is formed by life insurance and private pension.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

#### 26. Insurance coverage

At March 31, 2023, the Company maintains insurance coverage at amounts deemed sufficient by management to cover risks, if any, on its assets and/or liabilities.

Type of coverage	Amount insured
Property risk	5,465,656
Civil liability (D&O)	570,020
General civil liability	25,000
Engineering risks	4,235,658

## 27. Events after the reporting period

On April 25, 2023, Rede D'Or carried out the early settlement of the Loan 4131 Swap entered into with Citibank, and on April 27, 2023, it carried out the early settlement of Loan 4131 in the amount of US\$80 million.

On April 27, 2023, Rede D'Or paid the loan took out from Citibank in the amount of US\$60 million, in two annual installments maturing on April 27, 2026 and April 27, 2027, indexed to SOFR plus 0.99% per year, paid semiannually. Concomitantly, the Company entered into a derivative financial instrument for currency and interest rate hedging purposes, converting into Brazilian reais plus interest equivalent to 100% of the CDI plus 1.63% p.a. There are no guarantees.

On June 5, 2023, Rede D'Or paid in the 28th issue of Debentures in a single series, in the amount of R\$490 million, maturing on May 25, 2028. This debenture issue is indexed to the CDI + 1.90% p.a., payable annually. There are no guarantees.

On August 4, 2023, Rede D'Or paid in the 29th issue of Debentures in a single series, in the total amount of R\$1.0 billion, maturing on July 25, 2031. This debenture issue is indexed to the CDI + 2.25% p.a., payable semiannually. There are no guarantees.

As published on July 19, 2023, the Company is structuring the 11th issue of registered, bookentry Mortgage-Backed Securities (CRIs), in the initial amount of R\$2.0 billion. Initially, the operation will be distributed into three (3) series ("CRI DI", "CRI IPCA I" and "CRI IPCA II") with terms of 5, 7 and 10 years, respectively, and the number and final rate of each series will be defined within the scope of the Bookbuilding Procedure, according to the offering schedule. This transaction has no guarantees.

Notes to interim financial information (Continued) March 31, 2023 (In thousands of reais, unless otherwise stated)

## 27. Events after the reporting period (Continued)

On August 02, 2023, the Insurers of SulAmerica Group, brought together as co-plaintiffs, were successful in the Case Records No. 0005569-52.1996.4.02.5101/RJ, which challenged the illegality of PIS and promoted the withdrawal of judicial deposits made, in the total amount of R\$111,078 thousand, not generating an effect on P&L accounts, but representing changes in the statement of financial position accounts.

On October 13, 2023, Rede D'Or paid in the 31st issue of Debentures in a single series, in the total amount of R\$500.0 million, maturing on October 6, 2031. This issue is indexed to the CDI + 2.00% p.a., to be paid semiannually. There are no guarantees.

On October 27, 2023, the Company paid Interest on Equity based on the final shareholding structure on October 16, 2023, in the total gross amount of R\$416,288.

On November 3, 2023, Rede D'Or exercised the Optional Early Redemption in Full of the Sixth Issue of Debentures of Sul América S.A., which was succeeded by Rede D'Or due to merger, in the amount of R\$235 million. As of that date, there are no covenants related to the Sixth Issue of Debentures of Sul América S.A. (see Note 12.1.).

On October 2, 2023, Sul América Investimentos DTVM S.A. ("SAMI"), an indirect subsidiary of the Company, signed definitive documents regarding the sale of its 25% minority interest held in Órama Distribuidora de Títulos e Valores Mobiliários S.A. ("Órama DTVM"), in the context of the total disposal of Órama DTVM to BTG Pactual CTVM S.A. for the global firm amount of R\$500 million (for 100%), subject to certain adjustments ("Transaction"). The completion and closing of the Transaction are subject to certain conditions, including obtaining all necessary regulatory approvals, including from the Central Bank of Brazil.

On December 19, 2023, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the 1st private issue of nonconvertible, single-series, registered debentures amounting to R\$33,691,000.00, maturing on December 19, 2024. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.